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1 Introduction 
Cancer is the leading cause of death world wide where it accounts of approximately 13 % of 
all deaths. Amongst others lung, stomach, liver, colorectal and breast cancer cause the most 
cancer deaths world wide. Next to biological carcinogens like infectious agents, physical and 
chemical carcinogens are potent effectors of cellular transformation. Although most of these 
carcinogens like tobacco smoke could be avoided and education towards prevention of cancer 
increases yearly, 30% of all cancer death still occurs because of environmental factors and 
lifestyle influence. Therefore, the scientific understanding of the development of this disease 
is the most important basis in fighting cancer. 
1.1 Tumor suppressors  
Tumor suppressors either have a dampening or repressive effect on the regulation of the cell 
cycle or promote apoptosis, and sometimes do both. The functions of tumor suppressor 
proteins fall into several categories including the following (Sherr, 2004):  
 
1. Repression of genes that are essential for cell cycle progression. If these genes are 
not expressed, the cell cycle will not continue, effectively inhibiting cell division.  
2. Maintenance of genomic integrity. As long as there is damaged DNA in the cell, it 
should not divide. If the damage can be repaired, the cell cycle can continue.  
3. Initiation of cell death. If the damage cannot be repaired, the cell should initiate 
apoptosis (programmed cell death) to remove the threat it poses for the greater good of 
the organism.  
4. Repression of metastasis. Some proteins involved in cell adhesion prevent tumor 
cells from dispersing, block loss of contact inhibition, and inhibit metastasis. These 
proteins are known as metastasis suppressors (Hirohashi and Kanai, 2003; Yoshida et 
al., 2000).  
1.1.1 The Tumor Protein 53 (TP53) 
The p53 gene, first described in 1979, was the first tumor-suppressor gene to be identified. 
The heterozygous loss of p53 in humans causes the Li-Fraumeni syndrome with an early onset 
of cancers in diverse tissues. Similarily, the ablation of p53 in mice results in tumors of 
various tissues. P53 is primarily activated under conditions of cellular stress or DNA damage. 
Here, the activation of the network is dependent on the ATM kinase (for ataxia telangiectasia 
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mutated), which is stimulated by the DNA strand breaks and Chk2, which is in turn stimulated 
by ATM (Carr, 2000).  
Another route of p53 activation is triggered by aberrant growth signals, such as those resulting 
from the expression of oncogenes like Ras or Myc. In this case, activation of the p53 network 
in humans depends on the cell cycle inhibtor p14ARF (Lowe and Lin, 2000; Sherr and Weber, 
2000). The last known p53 pathway is induced by a wide range of chemotherapeutic drugs, 
ultraviolet light, and protein-kinase inhibitors and is not dependent on intact ATM, Chk2 or 
p14 ARF, and may instead involve kinases called ATR (ataxia telangiectasia related) and casein 
kinase (Meek, 1999). However, phosphorylated and thereby activated by these proteins, p53 
can be released from its negative regulator MDM2, which binds p53 and marks it for 
ubiquitination. Activated p53 can then act as a transcription factor of a multitude of genes 
involved in cell cycle arrest/senescence, apoptosis and prevention of blood vessel formation as 
seen in Figure 1.  
 
 
Figure 1: Network of p53; p53 gets activated via ATM, ATR or p14 in response to DNA-damage, cellular 
stress or oncogenes; released from its negative regulator MDM2 that marks p53 for degradation, p53 
activates the expression of its target genes to induce growth arrest, apoptosis or the prevention of new 
blood vessel formation (Vogelstein et al., 2000). 
 
All aforementioned processes shut down the multiplication of stressed cells, inhibiting 
progress through the cell cycle or cause apoptosis to defend the organism for a greater risk, 
that these cells become cancerous.  
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1.1.2 The retinoblastoma gene product (Rb) 
The retinoblastoma gene product (Rb) was the first tumor suppressor identified to be 
significantly lost in human cancer. This loss of heterozygosity in humans causes  
retinoblastoma (Friend et al., 1986). In the mouse, the germline knockout of Rb results in 
embryonic lethality at mid-gestation (Maandag et al., 1994). However, its primary function is 
to prevent the unscheduled entry into the mitotic cell cycle (Classon and Harlow, 2002; 
Cobrinik, 2005; Liu et al., 2004). In the absence of mitogens, Rb inhibits cell-cycle 
progression by preventing the transcription of multiple genes required for S-phase-entry 
(Blais and Dynlacht, 2004; Blais and Dynlacht, 2007; Diehl, 2002; Nevins, 2001; Sherr, 2000; 
Wang et al., 1994). The best studied targets are regulated through the E2F transcription factor 
family, the main target of Rb. Unbiased gene expression analyses revealed, that the Rb-E2F 
pathway regulates and controls approximately 150-200 genes (Figure 2) (Knudsen and 
Knudsen, 2008).  
 
 
Figure 2: Simplified scheme of Rb regulation; in cell cycle progression Rb gets inactivated via 
phosphorylation by CDK4/6; if the cell cycle is blocked by p16, Rb gets dephosphorylated and thereby 
activated to bind E2F. This binding inhibits E2F to activate the expression of its target genes to stimulate 
S-phase entry (Burkhart and Sage, 2008). 
 
For the cell cycle to progress, mitogens must counteract the action of Rb by activating cyclin-
dependent kinases, which attenuate the capacity of Rb to induce transcriptional repression by 
phosphorylation of Rb (Mittnacht, 1998). Through the cell cycle, Rb remains in this inactive 
stage, until passage through mitosis, at which point it is re-engaged through phosphatases 
(Vietri et al., 2006). 
Next to its main role in arresting cells in G1/S by inhibiting the transcription factor E2F (Riley 
et al., 1994; Weinberg, 1995),  Rb is also associated in various other physiological processes 
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like differentiation, regulation of cell death, maintenance of permanent cell cycle arrest 
(senescence) and preservation of genomic stability (Figure 3) (Dannenberg and te Riele, 2006; 
Zheng and Lee, 2001).  
 
 
Figure 3:  Model of physiological processes that are regulated by Rb; Rb is not only involved in cell cycle 
arrest, senescence or apoptosis, but also regulates differentiation, the integrity of the genome, angiogenesis 
and metastasis (Burkhart and Sage, 2008). 
 
1.1.3 Impact of p53 and Rb in human cancer 
It is well accepted that tumor cells invoke multiple mechanisms to bypass proliferative 
control. As crucial regulators of the cell cycle, p53 and Rb confer a proliferative advantage to 
tumor cells via their perturbations. 
Due to its frequent high expression in cancer the tumor suppressor p53 was originally 
believed to be an oncogene, but genetic and functional data obtained ten years after its 
discovery showed it to be a tumor suppressor. Moreover, it was found that the p53 protein 
does not function correctly in most human cancers (Table 1). In about half of these tumors, 
p53 is inactivated directly as a result of mutations in the p53 gene. In many others, it is 
inactivated indirectly through binding to viral proteins, or as a result of alterations in genes 
whose products interact with p53 or transmit information to or from p53. However, since 
1989, 10.000 tumor associated -mutations were discovered, highlighting the impact and the 
importance of p53 inactivation in human cancers (Hollstein et al., 1999; Hussain and Harris, 
1999). The importance of p53 in the inhibition of cellular transfornation is pointed out in p53-
restoration experiments in mice. Here, highly aggressive hepatocarcinoma, lymphoma and 
osteosarcoma start to regress if p53 is re-expressed (Xue et al., 2007)  
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Table 1: Status of the tumor suppressor p53 in various human cancers; next to genomic loss, p53 mostly 
gets inactivated via mutations or fractional deletions in human cancers. Furthermore, the deregulation of 
its negative regulator MDM2, viral infections or deletions of p53 target genes are found to dysregulate the 
p53-network. In breast or neuroblastomas p53 often gets mislocated to the cytoplasm and thereby lacks its 
function (Vogelstein et al., 2000). 
 
In the case of the retinoblastoma gene product several observations support the significant role 
of Rb –mediated cell cycle control and moreover the loss in human tumors. First, loss of 
heterozygosity of Rb results e.g. in tumor formation in the retina (retinoblastoma) (Cavenee et 
al., 1983). Second, mutations that are either inactivating or facilitate the phosphorylation of 
Rb are observed at high frequency like in small-cell lung cancer (Kaye, 2002) or moderate 
like in breast, bladder or prostate cancer (Diehl, 2002; Malumbres and Barbacid, 2001; 
Palmero and Peters, 1996; Sherr, 2000; Sherr and McCormick, 2002). Third, the inactivation 
of Rb is mediated by and cooperates with oncogenes that contribute to human cancers like 
HPV-E7 oncoprotein, that is involved in the aetiology of cervical cancer (Table 2) (Dyson et 
al., 1989; Munger, 2002; Munger et al., 2001). 
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Table 2: Inactivation of the RB gene in common human cancer types; Rb gets inactivated through genetic 
or epigenetic mechanism and its functional loss is a frequent event in human cancers. Via its inactivation 
cancers are either initiated or progressed early or to an invasive state (Burkhart and Sage, 2008). 
 
1.2 Cancer barriers and neoplastic transformation of cells 
In organisms every cell is embedded and organized in its characteristic tissue with its specific 
duties. To maintain this organisation of an organism, cells are strictly confined in their cell-
cell-interaction ability and behaviour. These restrictions are barriers to cancer and cells must 
overcome these barriers to escape the organized tissue and convert to a neoplastically 
transformed cell. 
1.2.1 Cancer barriers of cells:  limited life span, senescence and 
immortalisation 
Primary cells display a restricted life span in vitro. These cells enter  permanent growth arrest 
after a defined number of cell divisions, called replicative senescence (Harada et al., 2003; 
Hayflick, 1965). Senescent cells can be detected via different markers like the expression of 
β-galactosidase (Dimri et al., 1995), p16 and p21 or the activated of CHK1 and 2 (d'Adda di 
Fagagna et al., 2003; Suzuki et al., 2001). This permanent growth arrest is caused by different 
intrinsinc or extrinsinc stresses (Figure 4)(Prieur and Peeper, 2008).  
Formatiert: Englisch (USA)
Feldfunktion geändert
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Figure 4: Senescence in cultured cells; senescence can be triggered by different mechanisms including 
dysfunctional telomeres, DNA-damage, mitogenic signals or other stresses (Campisi and d'Adda di 
Fagagna, 2007). 
 
One of these stresses is the progressive shortening of telomeres. With each cell division 
telomeres are reduced by about 50-150 base pairs (bp) (Collado et al., 2007; Shay and Wright, 
2000). The achievement of a critical telomere length triggers a DNA-damage response which 
most of the times moves  the cells into  irreversible growth arrest (d'Adda di Fagagna et al., 
2003). This replicative senescence is finally driven by the activation of p53 and Rb (Campisi, 
2005). If these gatekeepers of tumor suppression are inactivated, loss of telomere function 
contributes to oncogenic transformation (Chin et al., 1999). 
Next to telomere-associated senescence, permanent growth arrest can be elicited by activation 
of oncogenes, a phenomenon that was firstly described in 1997 (Serrano et al., 1997). Here, 
the overexpression of the mutant H-Rasv12 induces cellular senescence in human and rodent 
cells. Activated mutants of RAF, MEK and BRAF were also shown to induce cell cycle arrest 
(Lin et al., 1998; Michaloglou et al., 2005; Zhu et al., 1998). These oncogenes trigger 
senescence by induction of a DNA-damage response, which contributes to cell cycle arrest 
(Bartkova et al., 2006; Di Micco et al., 2006).  
This permanent growth arrest is suggested as a tumor-suppressive mechanism and one of the 
main barriers to tumorigenesis (Reddel, 2000; Wright and Shay, 2001).  
The first step to a malignant phenotype of cells is the ability to bypass this senescence, a 
process called immortalisation where cells aquire an indefinite life span. As telomeres act as a 
“molecular clock” of the cellular life span, immortalized cells have to stabilize their telomeres 
to escape the definite growth capacity. Therefore pre-cancerous cells have to reactivate the 
expression of telomerase or maintain them through alternative telomere lengthening (ATL) 
(Counter et al., 1992; Kim et al., 1994). Further processes that contribute to immortalisation 
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are DNA-damage, inactivation of cell cycle regulatory genes like p53 and Rb, epigenetic gene 
silencing or the overexpression of oncogenic or viral proteins (Figure 5) (Berube et al., 1998; 
Bringold and Serrano, 2000; Itahana et al., 2003; Lundberg et al., 2000; Neumeister et al., 
2002).  
 
 
Figure 5: Implication of p53 and Rb in cellular senescence; as the cell triggers senescence signals, p53 gets 
released from HDM2 and induces senescence via p21; Rb governs the cell into permanent growth arrest 
through the permanent inhibition of E2F (Campisi and d'Adda di Fagagna, 2007). 
 
1.2.2 Cell transformation 
The basis of neoplastic cell transformation is the accumulation of genetic and epigenetic 
changes (Hanahan and Weinberg, 2000). These changes mainly apply to genes involved in the 
regulation of the cell cycle and proliferation such as proto-oncogenes and tumor suppressors. 
Large scale sequencing, transcriptonal profiling and gene expression analysis have implicated 
thousands of genetic modifications to be involved in neoplastic transformation of human cells 
(Baylin and Bestor, 2002; Golub et al., 1999; Perou et al., 2000). 
1.2.3 In vitro transformation systems 
Although studies on alterations in human cancer deliver a never ending number of genetic 
changes or combinations of alterations that are involved in distinct steps of neoplastic 
transformation, experimental models of in vitro transformation indicate, that just a few 
disruptions or amplifications of pathways seem to be sufficient to steer cells into a cancerous 
phenotype. In the early eighties the malignant transformation of bird and rodent cells via 
either viral or human oncogenes were the first described models of oncogenesis of primary 
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cells (Land et al., 1983; Ruley, 1983).  In human cells the introduction of viral oncoproteins 
like the papilloma simian virus 40 (SV 40) large T antigen (LT) or the human papilloma virus 
(HPV) E6 or E7 fail to induce immortalisation in cells although they extend their cellular 
lifespan via  inhibitory binding to p53 or Rb and thereby perturbating their signalling 
pathways. Only the introduction of both tumor suppressors allows pre-senescent cells to 
overcome the permanent growth arrest. By a successfull reactivation of telomerase or 
alternative mechanisms (ALT) to maintain stable telomere length, immortalisation and 
thereby the prerequisite of malignant transformation can be achieved. Further models develop 
immortalisation chemically, or with biological agents. Here, cells can be immortalized by 
addition of mutagens like aflatoxin B (Bond et al., 1999; Opitz et al., 2001; Shay et al., 1991).  
So far, some defined manipulations are necessary to completely transform cells. In normal 
human fibroblast the induction of the SV40 early region, expression of hTERT and oncogenic 
RAS cooperate to induce a malignant phenotype (Hahn et al., 2002; Yu et al., 2001). These  
genes are further sufficient to transform a wide range of primary cells like ephithelial cells of 
the breast or lung, mesothelial cells, melanocytes and neuroectodermal cells (Elenbaas et al., 
2001; Liu et al., 2004; Lundberg et al., 2002; Rich et al., 2001). Other combinations of 
introduced genes have shown to be successful without expression of hTERT. In keratinocytes, 
the coexpression of CDK4 and RAS appears to be sufficient for transformation. In fibroblasts 
the introduction of the adenoviral E1A oncoprotein, RAS and MDM2 transformed the cells 
without telomerase expression (Brookes et al., 2002; Seger et al., 2002).  
However, with few exceptions so far, the transformation of human cells requires the 
introduction of viral oncoproteins and thereby does not fully reflect the situation of malignant 
cell transformation in vivo. 
1.3 Receptor Tyrosine Kinases 
Protein tyrosine kinases are important regulators of intracellular signal transduction pathways 
mediating aspects of multicellular communication and development (Ullrich and Schlessinger, 
1990). Tyrosine kinases play an important role in the control of most fundamental cellular 
processes including cell cycle, migration, metabolism and survival, as well as proliferation 
and differentiation. There are currently more than 90 known tyrosine kinase genes in the 
human genome; 58 encode transmembrane receptor tyrosine kinases (RTKs). The epidermal 
growth factor receptor (EGFR) was the first RTK to be cloned and characterized by Ullrich 
and colleagues in 1984 (Ullrich et al., 1984). Since then, RTKs have been distributed into 20 
subfamilies based on their structural characteristics. RTKs are type I transmembrane proteins 
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and contain an extracellular ligand-binding domain that is usually glycosylated (Hubbard and 
Till, 2000). The structural diversity of RTK ectodomains is due to the presence of one or 
several copies of immunoglobulin-like domains, fibronectin type III-like domains, EGF-like 
domains, cysteine-rich domains, or other domains. The ligand binding domain is connected to 
the cytoplasmic domain by a single transmembrane helix. The cytoplasmic domain contains a 
highly conserved protein tyrosine kinase core and additional regulatory sequences that are 
subjected to autophosphorylation and phosphorylation by heterologous protein kinases 
(Blume-Jensen and Hunter, 2001). 
Beginning with the discovery that the EGFR and the oncogene v-erbB are directly related, 
RTKs were found to be frequently implicated in cancer development and progression by 
different mechanisms including activating mutations, gene fusions, overexpression or gene 
amplification (Ullrich et al., 1984). RTKs may also serve as excellent prognostic factors or 
targets of cancer therapy. The first and most prominent example for a RTK as an anticancer-
target is the human epidermal growth factor receptor 2 (HER2). In 1985, the HER2 EGFR-
like receptor gene was identified and its amplification in breast cancer was correlated with  
relapse and survival of breast cancer patients (Coussens et al., 1985; Slamon et al., 1987). 
Herceptin, the humanized monoclonal antibody that targets HER2 at the cell surface, is the 
first genomic-research based anti-cancer therapeutic. Herceptin is approved by the FDA for 
the treatment of locally advanced and metastatic breast cancer since 1998 (Fischer et al., 
2003). 
1.3.1 Fibroblast Growth Factor Receptors 
The fibroblast growth factor receptor (FGFR) family is composed of four receptors (FGFR1-
4) and more than 20 known ligands and has been implicated in the regulation of various 
physiological processes including angiogenesis, mitogenesis, differentiation and development  
(Burke et al., 1998; Jeffers et al., 2002). FGFRs consist of an extracellular ligand-binding 
domain, a single transmembrane domain and a cytoplasmic domain containing the catalytic 
protein tyrosine kinase core as well as additional regulatory sequences (Hunter, 2000; 
Schlessinger, 2000). The extracellular ligand-binding domain of FGFRs is composed of three 
immunoglobulin like domains, designated D1-D3; a stretch of seven to eight acidic residues in 
the linker connecting D1 and D2, designated the “acid box” and a conserved positively 
charged region in D2 that serves as a binding site for heparin (Eswarakumar et al., 2005; 
Schlessinger et al., 2000). 
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1.3.1.1 Signalling of Fibroblast Growth Factor Receptors and their implication in 
pathophysiological phenotypes 
Signalling via FGFRs is mediated via recruitment of several docking proteins after stimulation 
through FGFs. These docking-proteins, called FRS2α and FRS2β bind to the auto-
phosphorylation sites of the activated receptor (Dhalluin et al., 2000; Ong et al., 2000). 
Following recruitment of Grb-2 and Sos results in the activation of the Ras/MAP kinase 
signalling pathway (Kouhara et al., 1997). If Grb-2 recruits Gab-1, FGF stimulation results in 
the activation of the PI3-kinase leading to Akt dependent anti-apoptotis. Moreover, 
stimulation of FGFRs results in the expression of target genes that either trigger further 
cellular signals or result in a negative feedback loop of the respective FGFR (Figure 6). 
 
 
 
Figure 6: Signalling pathways of FGF Receptors; FGFRs get stimulated and thereby phosphorylated via 
binding of their cognate ligands. Upon autophosphorylation FRS2 proteins are able to bind FGFRs in 
order to build signalling platforms that stimulate either the Erk1/2 or the Akt pathway resulting in the 
expression of target genes that trigger a physiological output or activate negative feedback loops of FGFR 
signalling (Mason, 2007). 
 
FGFs and FGFRs are implicated in a variety of cellular processes with diverse 
pathophysiological phenotypes as a result of the loss of function of either FGFs or FGFRs. 
Table 3 and 4 display the functions of different FGFs and FGFRs investigated in knock-out 
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mice. Here, the disruption of either FGFs or FGFRs results in diverse phenotypes ranging 
from developmental disorders, which cause embryonic lethality to no obvious phenoypes. 
 
Table 3: Summary of phenotypes obtained from FGF knock-out mice; Phenotypes vary from 
developmental to regenerative to metabolic syndromes implicating the FGFs in variety of cellular 
processes (Eswarakumar et al., 2005). 
 
 
Table 4: Summary of phenotypes obtained from FGFR knock-out mice; Phenotypes vary from 
developmental to regenerative syndromes implicating the FGFRs in variety of cellular processes 
(Eswarakumar et al., 2005) 
 
In humans, the FGFR family is known to play a key role in skeletal development. Especially 
activating FGFR gene mutations are implicated in several skeletal disorders. Amongst others, 
an amino acid subsitution from Tyrosine to Cystein mostly results in a hyperactivated 
receptor. This amino acid substitution is present in the FGFR2 (Y375C) and the FGFR3 
(Y373C) and results in the Beare-Stevenson syndrome. Osteoglophomic dysplasia is linked to 
an Y372C mutation in the FGFR1. Furthermore, several other mutations in the FGFR1 and 
FGFR2 gene are linked to the Crouzon, Pfeiffer and Apert syndrome that all cause 
craniosynostosis. Dwarfing syndromes such as achondroplastic and hypochondroplastic 
dwarfism are associated with mutations in the FGFR3 gene. Table 5 summarizes the most 
frequent mutations in the FGFR 1-3 and the according syndromes (White et al., 2005; Wilkie 
et al., 2002).  
Introduction 
 13 
 
 
 
 
 
 
Gene AA-Substitution Syndrome Ref 
      
FGFR 1 Y372C Osteoglophonic dysplasia (White et al., 2005) 
  N330I    
 
     
 P252R Pfeiffer (Roscioli et al., 2000)  
  
     
FGFR 2 Y375C Beare-Stevenson (Krepelova et al., 1998) 
 
      
 N331I Crouzon (Rutland et al., 1995) 
 S252W    
 P253R    
       
 S252W Apert  
 P253R   
(Cohen and Kreiborg, 
1995) 
 
      
 C342R Pfeiffer  
 W290C   (Wilkie et al., 2002) 
 S351C    
  
      
FGFR 3 Y373C Beare-Stevenson (White et al., 2005) 
 
      
 P250R Muenke (White et al., 2005) 
 
      
 P250R Saethre-Chotzen (White et al., 2005) 
 
      
 N328I Crouzon (White et al., 2005) 
       
 G380R Achondroplastic dwarfism (White et al., 2005) 
 
      
 C1620A Hypochondorplasic dwarfism (Ramaswami et al., 1998) 
 
      
 K650M SADDAN (Bellus et al., 1999) 
 
Table 5: Summary of FGFR 1-3 gene mutations and the according phenotypes: FGFR1-3 are implicated 
in several skeletal disorders via gene mutations that result in amino acid substitutions. According 
phenotypes include the Peiffer, Apert or Crouzon syndrome. 
1.3.1.2 The Impact of the Fibroblast Growth Factor 4 and its variant Arg388 on 
human cancer 
In human cancer, the FGFRs are implicated either by overexpression like, pancreatic- or 
prostate carcinoma (Eswarakumar et al., 2005; Gowardhan et al., 2005; Morrison et al., 1994), 
or by activating mutations leading to abnormal fusion proteins or nucleotide substitutions 
(Cappellen et al., 1999; Fioretos et al., 2001; Jang et al., 2001; Macdonald et al., 1995) .  
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The human FGFR4 is known to be involved in the progression of diverse cancers. In 
hepatocellular carcinoma (HCC), FGFR4 promotes tumor growth by regulation cell 
proliferation and anti-apoptosis, suggesting that the FGFR4 may represent a potential target 
for HCC therapy development (Ho et al., 2009). Ablation of FGFR4 and the inhibition of 
FGF19, the specific ligand of FGFR4, in human colon cancer or liver cancer cell lines 
resulted in a reduced colony formation and tumor growth in nude mice by negatively affecting 
the β-catenin signalling pathway (Desnoyers et al., 2008; Pai et al., 2008; Xie et al., 1999).  In 
pituitary tumors, the FGFR4 promotes tumor progression as mutated truncated receptor. Here, 
the inactivation of the FGFR4 with an inhibitor reduces the tumor volume with an additional 
less invasive behaviour in nude mice (Ezzat et al., 2006). In addition, in prostate and 
medullary thyroid cancer the FGFR4 seems to promote tumor growth by its overexpression 
and is thought to be a valid target for prostate cancer therapy (Ezzat et al., 2005; Gowardhan 
et al., 2005; Shah et al., 2002). 
Beside somatic mutations, it has become increasingly clear, that germline alterations like 
single nucleotide polymorphisms (SNP) have clinical significance for the development and 
progression of diseases like cancer as well as for the definition of a patients individual 
response to therapeutic agents  (Ameyaw et al., 2002; Morimoto et al., 2003; Przybylowska et 
al., 2001).  
In the human FGFR4 gene a polymorphic nucleotide change in codon 388 converts Glycine 
(Gly) to Arginine (Arg)  in the transmembrane region of the receptor, a hot spot in receptor 
tyrosine kinases (RTKs) for disease-relevant sequence variations (Bange et al., 2002). This 
single nucleotide substitution in the FGFR4 was shown to be implicated in progression and 
poor prognosis of various types of human cancer (Bange et al., 2002; Spinola et al., 2005; 
Stadler et al., 2006; Streit et al., 2004; Streit et al., 2006; Wang et al., 2004). Here, Bange and 
colleagues could associate the FGFR4 Arg388 allele with tumor progression in breast and 
colon cancer patients (Bange et al., 2002). Similarly, soft tissue sarcoma patients, who carried 
the FGFR4 Arg388 allele had a poor clinical outcome (Morimoto et al., 2003). In melanoma 
the Arg388 allele is associated with increased tumor thickness, while in head and neck 
squamous cell carcinoma the FGFR4Arg388 allele correlates with reduced overall patient 
survival and advanced tumor stage. Furthermore, a recent study on prostate cancer patients 
strongly associated the FGFR4 Arg388 allele not only with tumor progression but also with 
prostate cancer initiation.  
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The main conclusion of these studies was that the presence of one or two Arg388 alleles in the 
genome of an individual does not initiate cancer development but predisposes the carrier to a 
more aggressive form if she or he is affected by the disease.  
Furthermore, some studies focused on the molecular mechanism of FGFR4 Arg388 allele. 
Studies on prostate cancer e.g. implicate the Arg388 allele in FGFR4 stability as the basis of 
its tumor promoting effect and further that the overexpression of Ehm-2 in the presence of the 
FGFR4 Arg388 isotype results in the higher invasive potential of Arg-carrying prostate cancer 
patients (Wang et al., 2006; Wang et al., 2008).   
In summary, the FGFR4 is implicated in various cancers and the disruption of its signaling via 
inhibitors or reduction of the receptor seems to be a valid approach in cancer therapy. 
Moreover, the single nucleotide polymorphism in the FGFR4, which substitutes Glycine with 
Arginine at  codon 388 is a promoter of aggressive cancer of various tissue origins and seems 
to be a more valid target and prognostic factor then the FGFR4 itself. 
1.4 Human breast cancer and modelling mammary carcinoma in vivo 
Breast Cancer is the most frequently diagnosed cancer in women in the United States and 
Europe and the fifth leading cause of cancer death. Breast cancers have a huge 
histopathological and genetic diversity, that all result in a variety of clinical phenotypes 
(Table 6). This diversity is confronted by just a few prognostic markers that turn breast cancer 
into a difficult disease to be cured with a standard therapeutic strategy.  
 
Table 6:  Histopathological type of invasive breast carcinoma its frequency and the estimated 10-year 
survival rate;  
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Due to the high diversity of breast cancer traditional prognostic markers can identify 
approximately 30% of patients to have a favourable or bad prognosis. Table 7 lists the few 
factors out of a large number that so far fulfill the requirements of being a prognostic marker. 
 
Table 7: Summary of prognostic factors of breast cancer metastasis and outcome; the best established 
factors include tumor size, lymph node status and histological grade;  
   
Therefore, there is still an urgent need of novel prognostic factors to improve existing 
therapies and the expansion of the current understanding to identify novel therapeutics.  
1.4.1 The impact of the FGFR4 and its Arg388 variant on breast cancer 
It is well known that the FGFR4 is frequently overexpressed in breast cancer and is therefore 
implicated in its progression (Jaakkola et al., 1993; Penault-Llorca et al., 1995). Further 
studies implicated the FGFR4 also in resistance to certain therapies. Here, breast cancer cell 
lines that were desensibilized to doxorubicin or cyclophosphamid, overexpress the FGFR4 
compared to the parental cell line. By specific knockdown of FGFR4, this apoptotic 
restistance can be rescued (Roidl et al., 2009). Besides that, overexpression of the FGFR4 
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ligand FGF8b promoted aggressiveness of MCF-7 breast cancer cells in vitro and in vivo 
(Ruohola et al., 2001). Moreover, high expression of the FGFR4 in patient mammary tumor 
samples is associated with a significantly higher rate of cancer relapse after usage of 
tamoxifen leading to a prognosis for breast cancer patients. These data involve the FGFR4 as 
a prediction marker of failure in tamoxifen treatment (Meijer et al., 2008). Above that, the 
single nucleotide polymorphism in the FGFR4 gene that substitutes Glycin by Arginin at 
codon 388 is strongly correlated to increased aggressiveness of breast cancer in vitro and in 
vivo. Here, the overexpression of the FGFR4 Arg388 variant accelerated motility in MDA-
MB-231 cells and altered gene expression towards a more aggressive phenotype (Bange et al., 
2002; Stadler et al., 2006). Above that, breast cancer studies correlate the FGFR4 Arg388 
allele not only with accelerated disease progression but also with higher resistance to adjuvant 
systemic- or chemotherapies in primary breast cancer leading to a significantly shorter 
disease-free and overall survival (Bange et al., 2002; Thussbas et al., 2006). Unfortunately, 
due to the highly complex and heterogeneous genetic background of the patients, statistical 
analysis yielded at times marginal results and because of differences in patient stratification 
and statistical evaluation diverging results led to controversies (Jezequel et al., 2004; Spinola 
et al., 2005). Because of that and in spite of the strong association of the FGFR4 SNP with 
disease progression, this genetic configuration is not yet established as progression marker for 
clinical outcome or as basis for individual patient treatment decisions. 
1.4.2 The TGFα–EGFR signalling cascade and its impact on human 
breast cancer 
The epidermal growth factor receptor (EGFR) plays an influential role in initiating the 
signaling that directs the behavior of epithelial cells and tumors of epithelial origin (Herbst, 
2004). Its overexpression is present in the majority of solid tumors, including breast cancer, 
head and neck cancer, non-small-cell lung cancer and colon cancer (Herbst and Langer, 
2002). For example in breast cancer the expression increases from 40.000 to 2x106 EGFR 
molecules per cell (Carpenter and Cohen, 1979; Ennis et al., 1991; Kondapaka et al., 1997). 
Multiple ligands can bind the EGFR, but among these the epidermal growth factor (EGF) and 
the transforming growth factor-α (TGFα) are the most important ligands among these 
(Salomon et al., 1995).  Upon ligand binding, the EGFR either forms a homo-or heterodimer, 
which subsequently gets autophosphorylated at the intracytoplasmatic tyrosine 
phosphorylation domain. These phosphorylated tyrosine residues serve as binding sites for 
diverse docking proteins (Franklin et al., 2002). The Ras-Raf mitogen-activated protein kinase 
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pathway and the phosphatidylinositol 3’ kinase and Akt pathway are the major signalling 
routes of the EGFR to regulate multiple processes including proliferation, or survival by target 
gene expression (Alroy and Yarden, 1997; Burgering and Coffer, 1995; Liu et al., 1999; 
Muthuswamy et al., 1999). In cancer, the EGFR additionally initiates the expression of target 
genes responsible for cell migration, adhesion and metastasis. In addition, angiogenesis, a 
process required for maintenance of tumor growth, can be regulated by the EGFR-signalling 
cascade by stimulation of the vascular endothelial growth factor (Figure 7) (Engebraaten et 
al., 1993; Goldman et al., 1993; Petit et al., 1997; Shibata et al., 1996). 
 
Figure 7: The TGFα-EGFR signaling cascade; Upon TGFα stimulation, the EGFR gets activated by 
dimerization and followed by autotyrosine-phosphorylation. After binding of diverse docking proteins, the 
EGFR can activate either the Akt or the Erk-pathway, which results in the transcription of target genes 
that are implicated in proliferation, survival, angiogenesis, migration, adhesion or invasion; Deregulation 
of this pathway and following dysregultated intracellular signaling results in various diseases like cancer. 
http://commons.wikimedia.org/wiki/Image:EGFR_signaling_pathway.png 
 
Valid models of carcinogensis in vivo are an important and necessary tool to investigate 
cancer progression and the participating components to elucidate not only mechanisms of 
tumorgenesis but also to find and test appropriate ways of therapy. In recent years more than a 
few mouse models of every possible cancer was developed to study the initiation and 
progression of this disease in the background and with the impact of a whole organism and to 
overcome the heterogeneity of patient cohorts (Frese and Tuveson, 2007). For breast cancer 
numerous mouse models are available to study the impact of diverse influences in different 
oncogenetic backgrounds that trigger mammary tumor initiation (Hennighausen, 2000). 
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As the EGFR has a role in a variety of cellular processes and is often overexpressed in human 
breast cancer, modelling of breast cancer in mice via  constitutive tissue-specific activation of 
the EGFR can be a very elegant and orthotopic model of mammary carcinogenesis. 
1.4.3 The WAP-TGFα mouse mammary carcinoma model 
The WAP-TGFα model is a routinely used mouse mammary tumor model (Pittius et al., 1988; 
Sandgren et al., 1995). In this model, TGFα overexpression is controlled by the whey acidic 
protein (WAP) promoter which specifically activates the transgene in mammary epithelial 
cells in mid-pregnancy. Thus, the process of mammary carcinogenesis is promoted by the 
constitutive overexpression of TGFα, a ligand of the epidermal growth factor receptor. 
Overexpression of TGFα in mammary epithelial cells results in accelerated alveolar 
development and impaired cell differentiation leading to failures in female lactation. 
Moreover, mammary involution is delayed and some alveolar structures fail to regress 
completely. As a consequence these hyperplasic alveolar nodules increase in number with 
successive pregnancies, and in some cases progress to tumors of variable histotype. These 
tumors have an onset of about 8 month and display well-differentiated carcinomas and 
adenocarcinomas (Sandgren et al., 1995). Whereas the C57BL/6 background requires 
continuous matings to get tumors established, mice transgenic for WAP-TGFα in the FVB 
background do not need be pregnant to establish mammary tumors.  
1.4.4 The MMTV-PymT model 
Since the Polyoma Virus was discovered to be an oncogene in vitro some 50 years ago, mice 
transgenic for the Polyoma Middle T (PymT) became a fast and efficient in vivo model to 
study cancer of various tissue origins. Two of the principal signalling pathways that are 
stimulated by the middle T antigen are the mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K) with the following activation of the respective 
downstream molecules. These pathways contribute to either activation of  proliferation, 
survival and transformation or inactivation of cell cycle arrest or apoptosis (Figure 8) 
(Dilworth, 2002). Under the transcriptional control of the mouse mammary tumor virus 
(MMTV) promoter, the PymT is exclusively expressed in the mammary gland. Here, the 
expression of Middle T results in synchronous appearance of multifocal tumors involving all 
mammary glands. This rapid conversion of the mammary ephithelium appears in several 
transgenic strains after 3 weeks of age. Moreover, mice transgenic for PymT develop multiple 
pulmonary metastases after 3 month (Guy et al., 1992).  
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Figure 8: Signalling pathways of the Polyoma Middle T Antigen; PyMT activates the mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) whereas SRC is the main target of 
PyMT. The following downstream targets result in enhanced proliferation or survival leading to 
transformation of cells rapidly and very efficiently (Dilworth, 2002). 
1.5 Liver Metabolism and Cancer  
The liver has a wide range of important functions including detoxification, protein synthesis, 
and production of biochemicals necessary for digestion. In addition, the liver plays a major 
role in metabolism and control processes like glycogen storage, decomposition of red blood 
cells and plasma protein synthesis (Maton, 1993). 
1.5.1 The impact of FGFR4 signalling on the hepatic bile acid synthesis, 
hyperlipidemia, insulin resistance and hypercholesterolemia 
One major function of the liver is the production of bile acids. This cholesterol metabolite is 
then stored in the gall bladder and is released postprandially in the small intestine for the 
emulsification of lipids (Chiang, 2004; Russell, 2003). The regulation of bile acid synthesis is 
tightly regulated by a negative feedback loop to prevent the damage of the enterohepatic 
tissue. Here, the cholesterol 7α-hydrolase, the catalyzer of bile acid expression, is repressed 
by circulating bile acids itself (Jelinek et al., 1990). Responsible for this feedback loop is the 
regulation of the FGFR4/FGF15/FGF19 pathway by bile acids (Inagaki et al., 2005). Here, the 
nuclear bile acid receptor FXR, a key regulator of bile acid homeostasis, is activated by the 
binding of bile acid together with cholic acid and chenodeoxy-cholic acid (Kok et al., 2003; 
Sinal et al., 2000). After heterodimerization with the retinoid X receptor (RXRs) this 
transcription factor induces the expression of several target genes (Edwards et al., 2002). 
Amongst others FGF19/15 is expressed via FXR/RXR in the small intestine (Inagaki et al., 
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2005). FGF19/15 binds selectively to the FGFR4 that is the primarily expressed FGF receptor 
in the liver (Kan et al., 1999; Nicholes et al., 2002; Stark et al., 1991). The activation of the 
FGFR4 results in repression of CYP7A and following reduction of bile acid synthesis via the 
suppression of c-Jun N-terminal kinase (Holt et al., 2003; Xie et al., 1999). Mice lacking the 
FGFR4 have an increased bile acid pool size, a reduced JNK activity and enhanced expression 
of CYP7A (Yu et al., 2000). Along these lines, transgenic mice expressing a constitutively 
active form of the FGFR4 display increased activity of JNK and decreased expression of 
CYP7A (Yu et al., 2005). Hence the FGF19/15-FGFR4 pathway is involved in gut-liver 
signalling to maintain bile acid homeostasis (Figure 9). 
 
 
 
Figure 9: Molecular action of the FGFR4 in gut-liver signalling; circulating bile acids in the intestine 
activate the expression of FGF15 via FXR/RXR signalling. FGF15 mediated activation of the FGFR4 in 
the liver results in JNK-dependent downregulation of CYP7A and following reduction in bile acid 
synthesis (Angelin, 2005). 
 
In maintaining homeostatsis, FGFR4 and the FGF19 subfamily members additionally play an 
important role in systemic lipid and glucose homeostasis. Here, the hepatic activity of  FGFR4 
serves to prevent systemic hyperlipidemia and -cholesterolemia under normal conditions as 
shown in mice deficient for FGFR4 display increased white adipose tissue as well as 
triglyceride levels, free fatty acids and cholesterol levels (Figure 10). Furthermore, mice 
lacking FGFR4 displayed increased levels of blood glucose and a decreased glucose and 
insulin tolerance. Contrarily, hepatic FGFR4 induces fatty liver after high-fat diet and obesity 
in mice. In summary, the hepatic FGFR4 seems to be a potential target for intervention in 
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systemic cholesterol/bile acid and lipid and glucose metabolism (Huang et al., 2007; Ishikawa 
and Fidge, 1979; Yu et al., 2002; Yu et al., 2000). 
 
 
Figure 10 : Mice lacking FGFR4 display an increase in white adipose tissue under normal conditions; the 
absence of the FGFR4 causes a 1.5-2-fold increase in reproductive white adipose tissue in males and 
females under normal conditions, whereas high fat diet fed mice display no difference in white adipose 
tissue regarding the phenotype (Huang et al., 2007). 
1.5.2 The impact of FGFR4 on hepatic carcinogenesis 
Next to the metabolic function of FGFR4 in controlling bile acid synthesis, insulin resistance, 
hyperlipidemia and –cholesterolemia, this FGF receptor seems to be implicated in the 
progression of hepatocellular carcinoma. Mice deficient in FGFR4 display an accelerated 
DEN-induced carcinogenesis and the restoration of FGFR4 increases apoptosis in tumor cells 
suggesting a tumor suppressive function in HCC (Huang et al., 2008). In contrast, the FGFR4 
was not suggested to regulate cellularity of normal or regenerating liver or cell proliferation 
during the response to liver injury (Hu et al., 1995; Yu et al., 2000). Interestingly, mice 
ectopically overexpressing FGF19 displayed hepatoma-like lesions and the inhibition of 
FGF19 by specific antibodies is reported to contribute to tumor reduction (Desnoyers et al., 
2008; Nicholes et al., 2002). Additionally, after injection of xenobiotics, FGFR4 deficieny 
accelerates liver injury and liver fibrosis (Yu et al., 2002). Taken together, these data 
demonstrate that the FGFR4 critically contributes to hepatic carcinogenesis. 
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2 Specific Aims 
Malignant transformation of cells is mostly based on specific alterations in the expression of 
oncogenes, tumor suppressors, tumor promotive and/or suppressive factors. The first aim of 
this study was to investigate the involvement of tumor suppressors and tumor promoting 
factors in oncogenesis in a human in vitro cell system. To this end, we intended to create a 
primary cell model in which the tumor suppressors p53 and Rb were downregulated. As the 
loss of p53 and Rb is a frequent and early event in carcinogenesis we hypothesized that the 
deletion of p53 and Rb would potentially initiate a process that mimics “natural” malignant 
transformation. Such a model system would offer the possibility to investigate the distinct and 
especially early steps of oncogenesis. This hypothesis is supported by Meuwissen et al. (2003) 
that could induce non-small cell lung cancer by the conditional loss of p53 and Rb in mice.  
Another approach towards the understanding of the influence of genetic factors in cancer 
progression focused on a single nucleotide polymorphism (SNP) in the human gene of the 
fibroblast growth factor receptor 4 (FGFR4) that substitutes a Glycin (Gly) with an Arginin 
(Arg) at codon 388 (FGFR4 Arg388). Since its discovery in 2002, the “abnormal” and 
frequent (50% of the human population) FGFR4 Arg388 allele was correlated with the 
progression and poor clinical outcome of various human cancers. Due to the heterogeneity of 
patient cohorts, the correlation of the FGFR4 Arg388 with cancer progression and poor 
clinical outcome sometimes led to controversial results. We therefore aimed to ultimately 
clarify the role of this SNP in breast cancer progression. Here, we hypothesized that a “knock 
in” (KI) FGFR4 Arg385 (corresponding to human codon 388) inbred mouse could 
unequivocally demonstrate the involvement of the Arg388 allele in breast cancer progression 
by intercrossing these FGFR4 Arg385 KI mice to mouse mammary tumor models. 
Furthermore we intended to use this mouse model to investigate the molecular mechanism 
that underlies the cancer progression accelerating effect of the FGFR4 Arg388 isoform and to 
possibly identify novel interaction partners of the FGFR4 and especially the FGFR4 
Arg385/388. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Laboratory Chemicals 
 
Acrylamide  Serva, Heidelberg 
Agar  Difco, USA 
Agarose  BRL, Eggenstein 
Ampicillin  Roche, Mannheim 
Aprotinin  Sigma, Taufkirchen 
APS (Ammonium peroxodisulfate)  Bio-Rad, München 
ATP (Adenosine triphosphate)  Amersham Pharmacia, Freiburg 
Basic FGF Peprotec 
Bisacrylamid Roth, Karlsruhe 
BSA (Bovine serum albumin)  Sigma, Taufkirchen 
Chloroquine Sigma, Taufkirchen 
Coomassie G250  Serva, Heidelberg 
Crystal Violet  Sigma, Taufkirchen 
Deoxynucleotides (dG/A/T/CTP)  Roche, Mannheim 
DTT (Dithiothreitol)  Sigma, Taufkirchen 
EGF  Sigma, Taufkirchen 
Ethidium bromide  Sigma, Taufkirchen 
FGF19 Peprotech 
Formaldehyde  PolySciences, Eppenstein 
Geneticin (G418, GibCo)  Invitrogen, Eggenstein 
Hemalaun Fluka, Schweiz 
Hemalaun-Eosin Fluka, Schweiz 
HEPES (N-(2-Hydroxyethyl)piperazine-N`-  Serva, Heidelberg 
(2-ethanesulfonic acid))  
Hoechst33324 dye Hoechst, Frankfurt am Main 
Humaninsulin® Normal 40  Lilly, Giessen  
Hydrogenperoxide Aldrich, Steinheim 
Kanamycin Gibco, Eggenstein  
L-Glutamine (GibCo)  Invitrogen, Eggenstein 
Leupeptin  Sigma, Taufkirchen 
Lipofectamine® (GibCo)  Invitrogen, Eggenstein 
Lysozyme  Sigma, Taufkirchen 
MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-
tetrazolium bromide) 
Sigma, Taufkirchen 
Oligofectamine®        Invitrogen, Eggenstein 
Paraformaldehyde Sigma, Taufkirchen 
Penicillin/Streptomycin  Gibco, Eggenstein  
Phenol  Roth, Karlsruhe  
PMSF (Phenylmethanesulfonyl fluoride)  Sigma, Taufkirchen 
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Polybren Sigma, Taufkirchen 
Ponceau S  Sigma, Taufkirchen 
SDS (Sodium dodecyl sulfate)  Roth, Karlsruhe 
Sodium azide  Serva, Heidelberg 
Sodium orthovanadate  Sigma, Taufkirchen 
TEMED (N,N,N',N'-Tetramethylethylenediamine)  Serva, Heidelberg 
TPA (Tetradecanoyl-phorbol-13-acetate)  Sigma, Taufkirchen 
Triton X-100  Serva, Heidelberg 
Tween 20  Sigma, Taufkirchen 
Xylol  Merck, Darmstadt  
 
All other chemicals were purchased in analytical grade from Merck (Darmstadt). 
3.1.2 Radiochemicals 
 
[γ-32P]-dATP PerkinElmer, France 
[α-33P]-dATP PerkinElmer, France 
 
3.1.3 Enzymes 
 
Calf Intestine Alkaline Phosphatase  MBI Fermentas, St. Leon-Rot 
DNAse I, RNAse free  Roche, Mannheim 
LysC Woka chemical, Hong Kong 
Proteinase K Sigma, Taufkirchen  
Restriction Endonucleases  NEB, Frankfurt/ Main 
 MBI Fermentas, St. Leon-Rot 
 Boehringer, Mannheim  
 Biolabs, New England  
RNase A  Sigma, Taufkirchen  
T4-DNA Ligase  Roche, Mannheim 
Taq DNA Polymerase MBI Fermentas, St. Leon-Rot  
Trypsin/EDTA Invitrogen, Eggenstein 
 
3.1.4  “Kits“and Other Materials 
 
BigDye® Terminator v1.1 Cycle Sequencing Kit                Applied Biosystems /Foster City 
Cell culture materials  Greiner, Solingen 
 Nunclon, Dänemark 
 Falcon, UK 
 Corning Incorporated, USA  
Cellulose nitrate 0.45 µm  Schleicher & Schüll, Dassel 
DNA-Ladder Eurogentec, Belgien 
Enhanced Chemi Luminscent (ECL) Kit  PerkinElmer/NEN, Köln 
Glutathion-Sepharose Amersham Pharmacia, Freiburg 
Hyperfilm MP      Amersham Pharmacia, Freiburg 
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Matrigel  BD Biosciences, Pharmingen  
Micro BCA Protein Assay Kit  Pierce, Sankt Augustin 
Parafilm  Dynatech, Denkendorf 
Poly Prep® Chromatography columns  Bio-Rad, München 
Protein A-Sepharose  Amersham Pharmacia, Freiburg 
Protein G-Sepharose  Amersham Pharmacia, Freiburg 
QIAGEN Dneasy Qiagen, Hilden 
QIAquick Gel Extraction Kit (50)  Qiagen, Hilden 
QIAquick PCR Purification Kit (50)  Qiagen, Hilden 
QIAGEN Plasmid Mini Kit  Qiagen, Hilden 
QIAGEN Plasmid Maxi Kit Qiagen, Hilden 
QIAGEN RNeasy Mini Kit  Qiagen, Hilden 
Ready-to.go PCR beads Amersham Pharmacia, Freiburg 
slides and cover slips Menzel 
Sterile filter 0.22 µm, cellulose acetate  Nalge Company, USA 
Sterile filter 0.45 µm, cellulose acetate  Nalge Company, USA 
Vectastain Elite ABC Kit Vector Laboratories (USA) 
Whatman 3MM  Whatman, Rotenburg/Fulda 
 
3.1.5 Growth factors and ligands 
 
EGF (murine) Toyoba, Japan 
EGF(human) Peprotech 
TGFα Peprotech 
Basic FGF Peprotech 
 
3.2 Media  
3.2.1 Bacterial media 
 
LB or 2xYT media were used for cultivation of all Escherichia coli strains. If and as required 
100µg/ml Ampicillin, 70µg/ml Kanamycin or 100µg/ml Chloramphenicol were added to the 
media after autoclavation. For the preparation of LB-plates 1.5% Agar was added. 
 
LB-Medium  1.0% Trypton 
 0.5% Yeast Extract 
 1.0% NaCl  
 pH 7.2 
  
2x YT-Medium  1.6% Tryptone 
 1.0% Yeast Extract 
 1.0% NaCl 
 pH 7.2 
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3.2.2 Cell culture media 
 
Cell culture media and additives were obtained from Invitrogen (Eggenstein). Media were 
supplemented to the requirements of each cell line. Freeze medium contained 90% cell media 
and 10% DMSO. 
 
Dulbecco’s Modified Eagle Medium (DMEM) with 4,5 mg/ml Glucose, 10% FCS, 2 mM L-
Glutamine, 1 mM sodiumpyruvate, 1% Penicillin/Streptomycin  
 
RPMI 1640, 10% FCS, 2 mM L-Glutamine, 1% Penicillin/Streptomycin  
 
The media for normal dermal fibroblasts (NHDF) were obtained from PromoCell 
(Heidelberg) and supplemented with 4% FCS, 1% Penicillin/Streptomycin, basicFibroblast 
Growth Factor 1ng/ml and human Insulin 5µg/ml 
3.3 Stock solutions and commonly used buffers 
 
Acrylamide solution (30/0.8%)  30.0% (w/v) Acrylamid  
 0.8% (w/v) Bisacrylamid  
  
Citratbuffer 100mM Citronensäuremonohydrat, pH 
6,0 
  
HBS (2x) 46mM HEPES, pH 7,5 
 274mM NaCl 
 1,5mM Na2HPO4, pH 7,0 
HNTG  20mM HEPES, pH 7.5 
 150mM NaCl 
            0.1% TritonX-100 
            10% Glycerol 
           10mM Na4P2O7 
  
DNA loading buffer (6x)  0.05% Bromphenol blue 
                                     0.05% Xylencyanol 
                                     30% Glycerol 
                                     100mM EDTA pH 8.0 
  
Laemmli buffer (2x)  65mM Tris/HCl pH 6.8 
           2% SDS 
           30% Glycerol 
                               0.01% Bromphenol blue 
                               5% ß-Mercaptoethanol 
  
Laemmli buffer (3x)  100mM Tris/HCl pH 6.8 
                               3% SDS 
                               45% Glycerol 
                               0.01% Bromphenol blue 
                               7.5% ß-Mercaptoethanol 
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MOPS (10x) 200mM Morphoinopropansulfunsäure 
 80mM Natriumacetat 
 10mM EDTA, pH 7,0 
  
NET  50mM Tris/HCl pH 7.4 
         5mM EDTA 
         0.05% Triton X-100 
         150mM NaCl 
  
PBS  137mM NaCl 
       27mM KCl 
        80mM Na2HPO4 
        1.5mM KH2PO4 pH 7.4 
  
RIPA Lysis Buffer 50mM Tris/HCl, PH8,0 
 150mM Nacl 
 1% Nonidet-P40 
 0.5% Desoxycholat 
 0.1% SDS 
  
SD-Transblot  50mM Tris/HCl pH 7.5 
                     40mM Glycine 
                     20% Methanol 
                     0.004% SDS 
  
SSC (20x) 3,0M NaCl 
 0.3M Sodiumcitrate 
  
“Strip” buffer  62.5mM Tris/HCl pH 6.8 
                      2% SDS 
                      100mM β-Mercaptoethanol 
  
TAE  40mM Tris/Acetate pH 8.0 
 1mM EDTA 
  
TE10/0.1  10mM Tris/HCl pH 8.0 
 0.1mM EDTA pH 8.0 
  
Tris-Glycine-SDS  25mM Tris/HCl pH 7.5 
                           200mM Glycine 
                           0.1% SDS 
  
Triton X-100 lysis buffer  50mM HEPES, pH 7.5  
 150mM NaCl  
 1mM EDTA  
 10% Glycerin  
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 1% Triton X-100  
 10mM Na4P2O7  
 2mM VaO5 
 10mM NaF  
 1mM PMSF  
 100µg/l Aprotinin  
 
3.4 Cells 
3.4.1 Eukaryotic cell lines 
 
Cell Line  Description Origin Reference 
   
Cos-7 Kidney fibroblasts Cercopithecus 
aethiops  
ATCC,USA 
   
MCF10A human mammary epithelial cells ATCC, USA  
   
HaCat human lung keartinocytes ATCC, USA  
   
HEK293 human embryonic kidney fibroblasts ATCC, USA  
   
Phoenix A HEK293,packaging cell line ampotrophic ATCC, USA  
   
Phoenix E HEK293,packaging cell line ecotrophic ATCC, USA  
   
NHDF normal human dermal fibroblasts PromoCell, Germany 
   
HMEC human mammary epithelial cells Lonza, Germany 
   
Kg-1a human acute myelobastic leukemia ATCC, USA  
   
MDA-MB-231 
(expressing empty 
pLXSN vector) 
Human mammary carcinoma ATCC, modified by 
Johannes Bange 
   
MDA-MB-231 
(expressing pLXSN 
vector-FGFR4 Gly388) 
Human mammary carcinoma ATCC, modified by 
Johannes Bange 
   
MDA-MB-231 
(expressing empty 
pLXSN vector 
FGFR4Arg388) 
Human mammary carcinoma ATCC, modified by 
Johannes Bange 
   
MDA-MB435 S human mammary carcinoma ATCC, USA  
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All cell lines used in this study were grown as recommended by the supplier.  
 
3.4.2 E. coli strains 
 
E. Coli strain              Genotype   Reference 
   
DH5αF’ F’ endA1 hsd17 (rk-mk+) supE44 recA1 gyrA 
(Nal) thi-1 ∆(lacZYA-argF196) 
Genentech, USA 
   
XL1-Blue relA1 lac [F'proAB lacIqZ∆M15 Tn10 (Tetr)] 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
Stratagene, NL 
   
DH10bpir116 DH10βUmcC::pir116-Frt Open Biosystems, USA 
 
3.5 Antibodies 
3.5.1 Primary Antibodies 
 
Antibody Immunogen Origin  Reference  
   
Akt1/2  Rabbit, polyclonal; AA 345-480 of human 
Akt1  
Santa Cruz, USA 
p-Akt/PKB  Rabbit, polyclonal; phospho-Akt (Ser-473); 
recognizes p-Akt of human, rabbit and rat 
origin  
NEB, Frankurt/M. 
ß-actin Rabbit, polyclonal; directed against a C-
terminal peptide 
Sigma, Taufkirchen 
CD34 Mouse, monoclonal, FITC labelled against 
human, CD34 
Abcam,USA 
CD44 Mouse monoclonal, FITC labelled against 
human CD44 
Abcam, USA 
Cyclin A Rabbit, polyclonal; recognizes the full length 
human Cyclin A protein 
Santa Cruz, USA 
Cyclin B1 Mouse, monoclonal; peptide of murine Cyclin 
B1  
Cell Signalling, MA 
Cyclin D1 Mouse, monoclonal; protein fragment 
corresponding to AA 1-200 of human 
Transduction Labs 
EGFR (1005) Rabbit, polyclonal against mouse, rat and 
human EGFR 
Santa Cruz, USA 
EGFR                                Sheep, polyclonal; part of cytoplasmic domain 
of the human EGFR 
UBI, Lake Placid 
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EGFR (108.1)  Mouse, monoclonal/ ectodomain of the human 
EGFR 
(Daub et al., 1997) 
p-EGFR  
(Y-1173) 
Rabbit, monoclonal; recognizes endogenous 
EGFR phosphorylated at Y1173 
Cell Signalling, MA 
ERK2 (C-14)  Rabbit, polyclonal; peptide at C-terminus of 
rat ERK2 
Santa Cruz, USA 
p-ERK  Rabbit, polyclonal; recognizes phospho-
p44/p42  
NEB, Frankurt/M. 
KI-67 Mouse, monoclonal; peptide between AA 
1547-1742 of human KI-67 
Transduction Labs 
p-Rb Rabbit, polyclonal; recognizes phospho-S780 
of human Rb 
Cell Signalling, MA 
Tubulin Mouse, monoclonal; ascites Sigma, Taufkirchen 
p-Tyr (4G10)  Mouse, monoclonal; recognizes phospho- (3)-
tyrosine residues 
UBI, Lake Placid 
Rb Mouse, monoclonal, against human residues 
701-928 of human Rb 
Cell Signalling, MA 
p53 (FL-393) Rabbit, polyclonal, against human full length 
p53 (1-393) 
Santa Cruz, USA 
actin Rabbit, polyclonal, against N-terminus of actin Sigma, Taufkirchen 
Bcl-xl (clone 44) Mouse, monoclonal, against human Bcl-xl as 
18-233 
Transduction Labs 
Src (N-16) Rabbit, polyclonal, against N-terminus of 
human src 
Santa Cruz, USA 
Bad  Rabbit, polyclonal, against human Bad 
phosphorylated on S-139 
Stressgen, Canada 
FGFR4 (C16) Rabbit, polyclonal, against cytoplasmic 
domain of FGFR4 (25-145) 
 
FGFR4 (H-121) Rabbit, polyclonal, against extracellular 
domain of FGFR4 (25-145) 
Santa Cruz, USA 
hTERT (H-231) Rabbit, polyclonal, against as 900-1130 of 
human TERT 
Santa Cruz, USA 
Ras (259) Mouse, monoclonal,  Santa Cruz, USA 
Bcl-2 (clone 4D7) Mouse, monoclonal, against human Bcl-2 as 
61-76 
Transduction Labs 
FGFR4 GST(Ex) Rabbit, polyclonal, FGFR4 (Ex)GST, 
expressed in HEK293 
Homemade, Christiane 
Stadler 
γH2AX (phospho Rabbit, polyclonal, against human H2AX Abcam, USA 
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S139) phosphorylated on S-139 
 
3.5.2 Secondary Antibodies 
 
For immunoblot analysis corresponding secondary antibodies conjugated with horseradish 
peroxidase (HRP) were used. 
 
Antibody  Dilution  Origin 
   
Goat anti-mouse-HRP  1:10000  Sigma, Taufkirchen 
Goat anti-rabbit-HRP  1:25000  BioRad, München 
Goat anti-sheep-HRP  1:10000  Jackson ImmunoResearch 
Labs, USA 
Sheep anti-goat-HRP 1:10000  Jackson ImmunoResearch 
Labs, USA 
 
3.6 Plasmids and oligonucleotides  
3.6.1 Primary Vectors and Constructs  
 
Vector  Origin     Reference  
   
pcDNA3  Mammalian expression vector, 
Ampr, CMV promoter, BGH 
pA,high copy number plasmid  
Invitrogen, USA  
    
pSuper Mammalian expression vector for 
short interfering RNA 
OligoEngine,USA 
   
pRETRO Super Mammalian expression vector for 
short interfering RNA for retroviral 
infection 
OligoEngine,USA 
   
pSM2c Mammalian expression vector for 
short hairpin RNA for retroviral 
infection 
Open Biosystems, USA 
   
pLXSN Mammalian expression vector for 
retroviral infection 
Clontech,USA 
 
3.6.2 Oligonucleotides 
 
RT-PCR Primers (mouse specific) 
 
Gene  Primer Sequence 
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GAPDH fwd 5’- CCAATATGATTCCACCCATGG -3’ 
GAPDH rev 5’- CCTTCTCCATGGTGGTGAAGA -3’ 
HPRT-LC fwd 5’- ATAAGCCAGACTTTGTTGGA-3’ 
HPRT-LC rev 5’- ATAAGCCAGACTTTGTTGGA-3’ 
FGFR4-LC fwd  5’- GCTTATGGATGACTCCTTACCCT -3’ 
FGFR4-LC rev 5’- AATGCCTCCAATACGATTCTC -3’ 
Cyclophilin fw 5’- GACGCCACTGTCGCTTTTCG -3’ 
Cyclophilin rev 5’- CTTGCCATCCAGCCATTCAGTC -3’ 
FGFR4 fwd  5’- CGTGGACAACAGCAACCCCTG -3’ 
FGFR4 rev 5’- GCTGGCGAGAGTAGTGGCCACG -3’ 
E-Cadherin fw 5’- GCTGGACCGAGAGAGTTA -3’ 
E-Cadherin rev 5’- TCGTTCTCCACTCTCACAT -3’ 
MMP13 fw 5’- TCCCTGGAATTGGCAACAAAG -3 
MMP13  rev 5’- GGAATTTGTTGGCATGACTCTCAC -3’ 
MMP9 fw 5’- CCCTGGAACTCACACGACA -3’ 
MMP9  rev 5’- GGAAACTCACACGCCAGAAG -3’ 
CD44 fw 5’- TTGAATGTAACCTGCCGCTACGCA -3 
CD44  rev 5’- TCGGATCCATGAGTCACAGTGCG -3’ 
flk-1 fw 5’- TCGTGCGTGACATCAAAGAG -3’ 
flk-1  rev 5’- TGGACAGTGAGGCCAGGATG -3’ 
Cox-2 fw 5’- CTGGTGCCTGGTCTGATGATG -3’ 
Cox-2  rev 5’- GGCAATGCGGTTCTGATCTG -3’ 
CDK4 fw 5’- TGGCTGCCACTCGATATGAAC -3’ 
CDK4 rev 5’- CCTCAGGTCCTGGTCTATATG -3’ 
p21 fw 5’- CGTTTTCGGCCCTGAGATGTT -3’ 
p21 rev 5’- ACCCGGGTCCTTCTTGTGTTTC-3’ 
cyclin D1 fw 5’- TCCCGCTGGCCATGAACTACC -3’ 
cyclin D1 rev 5’- GGCGCAGGCTTGACTCCAGAA -3’ 
CDK1 fw 5’- CCATGAACTGCCCAGGAG -3’ 
CDK1 rev 5’- CGGTGTGGTGTATAAGGGTAGA-3’ 
CDK2 fw 5’- CGATAACAAGCTCCGTCCAT -3’ 
CDK2 rev 5’- AGAAGTGGCTGCATCACAAG -3’ 
p53 fwd 5’- AACCGCCGACCTATCCTTACCATC -3’ 
p53 rev 5’- AGGCCCCACTTTCTTGACCATTGT -3’ 
N-Cadherin fw 5’- CCACAGACATGGAAGGCAATCC -3’ 
N-Cadherin  rev 5’- CACTGATTCTGTATGCCG CATTC-3’ 
Rb fwd 5’- CATCTAATGGACTTCCAGAG -3’ 
Rb rev 5’- CATAACAGTCCTAACTGGAG -3’ 
MMP14 fw 5’- CGTTCGCTGCTGGACAAGG -3’ 
MMP14  rev 5’- GACTGAGAAGGGAGGCTGGAG -3’ 
LC: primer for RT-PCR analysis via Light Cycler© 
 
RT-PCR Primers (human specific) 
 
Gene  Primer Sequence 
36B4 fwd 5’- CCCATTCTATCATCAACGGGTACAA -3’ 
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36B4 rev 5’- CAGCAAGTGGGAAGGTGTAATCC-3’ 
Telo fw 5’- GGTTTT(TGAGGG)5T-3’ 
Telo rev 5’- TCCCGA(CTATCC)4CTACTA-3’ 
MMP9 fw 5’- GACGCAGACATCGTCATCCAGTTT -3’ 
MMP9 rev 5’- GCCGCGCCATCTGCGTTT -3’ 
MMP2 fw 5’- ATGGCAAGGAGTACAACAGC -3’ 
MMP2 rev 5’- GCTGGTGCAGCTCTCATATT -3’ 
MMP 14 fw 5’- CGCTACGCCATCCAGGGTCTCAAA -3’ 
MMP 14 rev 5’- CGGTCATCATCGGGCAGCACAAAA -3’ 
AuroraKinaseA fw 5’- GAGAAAGCCGGAGTGGAGCATCAG -3’ 
AuroraKinaseA rev 5’- CATTTCAGGGGGCAGGTAGTCCAG -3’ 
AuroraKinaseB fw 5’- GGCGGCCGGGAGAGTAGCA -3’ 
AuroraKinaseB rev 5’- ACCTTGAGCGCCACGATGAAATG -3’ 
Mad1 fw 5’- TGTGAGCGACTCTGACGA-3’ 
Mad1 rev 5’- GTGGGACACTGAAGTTACG-3’ 
Mad2 fw 5’- CTCTTCCTGTTCCCGTCCTT-3’ 
Mad2 rev 5’- CACCTTTAGCTGGCTGT-3’ 
GAPDH fwd 5’- CCAATATGATTCCACCCATGG-3’ 
GAPDH rev 5’- CCTTCTCCATGGTGGTGAAGA-3’ 
p16 fwd 5’- AGCATGGAGCCTTCGGCTGACT-3’ 
p16rev 5’- CTGTAGGACCTTCGGTGACTGA-3’ 
p21 fwd 5’- AGTGGACAGCGAGCAGCTGA-3’ 
p21rev 5’- TAGAAATCTGTCATGCTGGTCTG-3’ 
p27 fwd 5’- AAACGTGCGAGTGTCTAACGCGA -3’ 
p27rev 5’- CGCTTCCTTATTCCTGGGCATTG-3’ 
p53 fwd 5’- CCGCAGTCAGATCCTAGCG-3’ 
p53 rev 5’- AATCATCCATTGCTTGGGACG-3’ 
Rb fwd 5’- TGGCGTGCGCTCTTGAGGTTGTAA-3’ 
Rb rev 5’- CTGGGTCTGGAAGGCTGAGGTTGC-3’ 
Rb –LC fwd 5’- GAATCATTCGGGACTTCTGAG-3’ 
Rb-LC  rev 5’- TTCCTTGTTTGAGGTATCCA-3’ 
p53-LC fwd 5’- TGCAGCTGTGGGTTGATTCC-3’ 
p53-LC rev 5’- AAACACGCACCTCAAAGCTGTTC-3’ 
 
Genotyping Primers (FGFR4 KI mice) 
 
Gene Primer Sequence 
FGFR4_1  5’-CGTGGACAACAGCAACCCCTG-3’ 
FGFR4_2  5’-GCTGGCGAGAGTAGTGGCCACG-3’ 
neoR-1 5’-AGGATCTCCTGTCATCTCACCTTCCTCCTG-3’ 
neoR-2 5’-AGAACTCGTCAAGAAGGCGATAGAAGGCG-3’ 
PymT_3  5’-TCGCCGCCTAAGACTGC-3’ 
PymT_3  5’- CCGCCCTGGGAATGATAG -3’ 
TGFα fw 5'-TGTCAGGCTCTGGAGAACAGC-3'  
TGFα rv 5'-CACAGCGAACACCCACGTACC-3'  
Cre-1 5’-AACATGCTTCATCGTCGG-3’ 
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Cre-2 5’-TTAGGATCATCAGCTACACC-3’ 
 
3.7 Methods of Molecular Cloning 
3.7.1 Plasmid preparation 
Small amounts of plasmid DNA were prepared using the Qiagen Plasmid Mini Kit, larger 
amounts of DNA were obtained with the Qiagen Plasmid Maxi Kit following the 
manufacturer’s recommendations. 
3.7.2 Enzymatic manipulation of DNA 
3.7.2.1 Specific digestion of DNA samples by restriction endonucleases 
The ratio of Enzyme/DNA, the temperature, the buffer and the time of incubation were 
adjusted according to manufacturer’s recommendations. Usually, incubations for 2 hours at 
37°C with a calculated 5-fold overdigestion and the buffers as supplied by the manufacturer 
were chosen. 
3.7.2.2 Dephosphorylation of 5'-termini with calf intestine alkaline phosphatase 
(CIAP)  
For dephosphorylation, 1µg of cut vector DNA was incubated with 5 units CIAP in adequate 
reaction buffer (e.g. 50mM Tris/HCl pH 8, 0.1mM EDTA pH 8.5) at 37°C for 10 minutes. 
Either reactions were stopped by heat inactivation at 85°C for 10 minutes or DNA was 
directly purified using the QIAquick PCR Purification Kit. 
3.7.2.3 Ligation of vector and insert DNA 
Purified, digested and dephosphorylated vector DNA (40ng), the designated insert DNA, 1µl 
10x T4 DNA Ligase buffer (0.66M Tris/HCl pH 7.5, 50mM MgCl2, 50mM DTT, 10mM 
ATP) and 1 unit T4 DNA Ligase were combined. A molar ratio between insert and vector of 3 
to 1 was usually chosen. Reactions were either left on 16°C overnight or at 37°C for 2 hours 
and subsequently transformed into competent bacteria. 
3.7.2.4 Agarose gel electrophoresis 
Depending on the size of the fragments of interest 0.7-2% agarose gels were prepared in 
horizontal chambers. TAE buffer was used for the electrophoresis. Voltage was usually set to 
4-10 V per cm width of the gel. After separation DNA fragments were stained by gently 
agitating gels in TAE containing 0.5µg/ml ethidium bromide and were subsequently viewed 
under UV light. 
3.7.2.5 Isolation of DNA fragments from agarose gels 
Following gel electrophoresis gel slices bearing DNA fragments of interest were cut out of the 
gel. Agarose was dissolved and DNA was purified using the QIAquick Gel Extraction Kit 
according to manufacturer’s recommendations. 
3.7.3 Introduction of plasmid DNA into E.coli 
3.7.3.1 Preparation of competent cells 
The preparation of competent cells was according to the procedure described by Chung and 
Miller (Chung and Miller, 1988). Competent cells were shock frozen in liquid nitrogen and 
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stored for up to one year at –70°C. Transformation frequency ranged between 105 and 
107colonies/µg DNA. 
3.7.3.2 Transformation of competent bacteria 
A 50µl aliquot of competent bacteria was added to a 50µl mixture of DNA usually ligation 
cocktails, 10µl 5x KCM solution (500mM KCl, 150mM CaCl2, 250mM MgCl2) and water. 
After thoroughly mixing, samples were incubated on ice for 20 minutes, 10 minutes at room 
temperature and after addition of 300µl LB broth at 37°C for 1 hour while constantly shaking. 
Bacteria were streaked out on appropriate agar plates containing ampicillin for the selection of 
the transformants. 
3.7.4 Enzymatic amplification of DNA by polymerase chain reaction 
(PCR) 
Amplification of DNA was done via Ready-to-go beads (GE Healthcare). Following has to be 
added to the beads 
1-5µl template cDNA or genomic DNA, 1-10ng 
1µl "forward" oligonucleotide, 10pmol/µl 
1µl "reverse" oligonucleotide, 10pmol/µl 
Ad 25µl H2O 
 
PCR reactions were carried out using an automated thermal cycler (Eppendorf).  
 
The following standard protocol was adjusted to each specific application: 
 
3 min    95°C (initial denaturation) 
 
30 cycles: 
1 min    95°C (denaturation) 
1 min      x°C    (appropriate annealing temperature) 
1-3 min 72°C (extension) 
 
5 min    72°C (final extension) 
    4°C hold  
 
PCR products were either separated by agarose gel electrophoresis, excised and subsequently 
purified or directly purified with QIAquick Gel Extraction or PCR Purification Kit, 
respectively. 
3.7.5 DNA sequencing 
Sequencing of DNA was performed following the “Big Dye Terminator Cycle Sequencing 
Protocol” (ABI). Pellets were dissolved in 20µl template suppression reagent, briefly boiled 
and analysed on a 310-Genetic Analyzer (ABI Prism). 
3.8 Methods of mammalian cell culture 
3.8.1 Calcium-Phosphate transfection  
Cells were maintained in appropriate culture media at 7.5% CO2 and 37°C. Transfections 
were carried out using a modified calcium phosphate method. Briefly, 2x106 cells were 
incubated overnight in 3ml of growth medium. 2µg of plasmid DNA was mixed with water 
and 0.25M CaCl2 solution in a final volume of 500µl. The mixture was added to the same 
volume of 2x transfection buffer (HBS) and incubated for 15 minutes at room temperature 
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before it was added dropwise to the cells. After incubation for 12 hours at 37°C, the medium 
was replaced. 
3.8.2 Transfection of plasmid DNA using lipofectamine®  
Target cells were transiently transfected using Lipofectamine® (Gibco-BRL) as described 
previously (Daub et al., 1997). Briefly, cells were seeded in 6cm plates. 350µl of serum-free 
medium containing 7µl of Lipofectamine and 2µg of total plasmid DNA per well were used. 
After 4 hours the transfection mixture was supplemented with an equal volume of medium 
containing 10% FCS. Then, cells were either stimulated or left untreated, lysed and subjected 
to Western Blot analysis. 
3.8.3 Transfection of siRNAs using oligofectamine® 
SiRNAs were transiently transfected in cells using Oligofectamine® (Gibco-BRL) according 
to the manufacturer’s recommendations. Briefly, 20pmol siRNA was mixed with the 
appropriate amount of OPTI-MEM medium, mixed with the oligofectamine reagent and 
incubated for 20 minutes at room temperature. The cells were washed once in OPTI-MEM 
containing 0% FCS. The mixture was put on the cells for 4 hours and thereafter the medium 
was changed to normal growth medium containing 10% FCS. Silencing efficiency was tested 
at different time-points after transfection by Western blot analysis. 
3.8.4 Infection of cells 
In order to generate cell lines with a stable expression of a target gene cells were infected as 
previously described (Pear et al., 1993). Briefly, 2x106 cells of the packaging cell line Phoenix 
E or A were seeded in 6-well dishes and transfected with Calcium-Transfection Method on 
the next day. Target cells were further seeded in 6-well dishes on the day of Calcium-
Transfection. After 24 hours target cells were infected with the viral supernatant of the 
packaging cell lines 
3.8.5 Stimulation of cells 
Cells were seeded in cell culture dishes of appropriate size and grown overnight to about 80% 
confluence. After serum-starvation for 24 to 48 hours cells were stimulated with appropriate 
growth factors, washed with cold PBS and then lysed for 10 minutes on ice.  
 
3.9 Methods of Biochemistry and Cell Biology  
3.9.1 Lysis of cells with Triton X-100 lysis buffer 
Cells were washed with cold PBS and then lysed for 10 minutes on ice, tissue was directly 
lysed for 30 minutes on ice in buffer containing 50 mM HEPES, pH 7.5, 150mM NaCl, 1% 
Triton X-100. 1mM EDTA, 10% glycerol, 10mM sodium pyrophosphate, 2mM sodium 
orthovanadate, 10mM sodium fluoride, 1mM phenylmethylsulfonyl fluoride, and 10µg/mL 
aprotinin. Lysates were precleared by centrifugation at 13000 rpm for 10 minutes at 4°C.  
3.9.2 Lysis of cells with RIPA lysis buffer 
Cells were washed with cold PBS and then lysed for 10 minutes on ice, tissue was directly 
lysed for 30 minutes on ice in buffer containing 50mM Tris/HCl, pH 8.0, 150mM NaCl 1%, 
Nonidet-P400 5%, Desoxycholat 0.1% SDS, 2mM sodium orthovanadate, 10mM sodium 
fluoride, 1mM phenylmethylsulfonyl fluoride, and 10µg/mL aprotinin. Lysates were 
precleared by centrifugation at 13000 rpm for 10 minutes at 4°C.  
Materials and Methods 
 38 
 
3.9.3 Determination of total protein concentration in lysates 
The overall protein concentration was determined using the Micro BCA Protein Assay Kit 
(Pierce, Sankt Augustin) according to the supplied standard protocol. 
3.9.4 Immunoprecipitation  
An equal volume of HNTG buffer was added to the precleared cell lysates that had been 
adjusted for equal protein concentration. Proteins of interest were immunoprecipitated using 
the respective antibodies and 20-40µL of protein A- or G-Sepharose over night at 4°C.  
Precipitates were washed three times with 0.5ml of HNTG buffer, suspended in 3x SDS 
sample buffer, boiled for 5 minutes, and subjected to Western Blot analysis. 
3.9.5 SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) 
SDS-PAGE was conducted as described previously (Maniatis, 1989). The following proteins 
were used as molecular weight standards: 
 
Protein MW (kD) 
Myosin                 205.0  
ß-Galactosidase    116.25  
Phosphorylase b      97.4  
BSA                       66.2  
Ovalbumin               42.7 
Carboanhydrase       29.0 
Trypsin-Inhibitor     21.7 
Lysozym                  14.4 
 
3.9.6 Transfer of proteins on nitrocellulose membranes 
For immunoblot analysis proteins were transferred to nitrocellulose membranes (Gershoni and 
Palade, 1982) for 3 hours at 0.8mA/cm2 using a "Semidry”-Blot device in the presence of 
Transblot-SD buffer. Following transfer proteins were stained with Ponceau S (2g/l in 2% 
TCA) in order to visualize and mark standard protein bands. The membrane was destained in 
water. 
 
3.9.7 Immunoblot detection 
After electroblotting the transferred proteins are bound to the surface of the nitrocellulose 
membrane, providing access for reaction with immunodetection reagents. Remaining binding 
sites were blocked by immersing the membrane in 1x NET, 0.25% gelatine or 5% milk, TBS-
T for at least 4 hours. The membrane was then probed with the primary antibody overnight at 
4°C. Antibodies were diluted 1:500 to 1:2000 in NET, 0.25% gelatine or 1% BSA, TBS-T. 
The membrane was washed 3x 20 minutes in 1x NET, 0.25% gelatine or TBS-T, incubated 
for 1 hour with secondary antibody and washed again as before. 
Antibody-antigen complexes were identified using horseradish peroxidase coupled to the 
secondary anti-IgG antibody. Luminescent substrates were used to visualize peroxidase 
activity. Signals were detected with X-ray films. Membranes were stripped of bound antibody 
by shaking in strip-buffer for 1 hour at 50°C. Stripped membranes were blocked and reprobed. 
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3.9.8 RNA isolation and RT-PCR analysis  
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden) and reverse transcribed 
using AMV Reverse Transcriptase (Roche, Mannheim). 2-10µg of RNA and 1µl of random 
primer in a volume of 10µl were incubated for 2 minutes at 68°C, followed by 10 minutes 
incubation at room temperature. After addition of 0.5µl RNase inhibitor, 4µl 5x AMV RT 
buffer, 4µl dNTPs (2.5 mM each) and 1µl AMV RT the volume was adjusted to 20µl. The 
reaction mix was incubated at 42°C for 1 hour and thereafter cDNA was purified using the 
Qiagen PCR purification kit (Qiagen, Hilden). For PCR amplification Light Cycler 
Technology© or PuReTaq Ready-To-Go PCR Beads (Amersham Biosciences, Piscataway, 
NJ) were used. Here 1µl RT-PCR products were used for PCR amplification according to the 
manufacturer’s recommendations. PCR products were subjected to electrophoresis on 1.5-2% 
agarose gels and DNA was visualized by ethidium bromide staining.  
3.9.9 Southern Blot analysis  
For analysis of the telomere length in p53/Rb double knockdown cells genomic DNA was 
subjected to standard protocol of southern blotting, after PCR amplification of the 
telomeres(Southern, 1974). Loading of DNA samples was verified by the single copy gene 
36B4. 
3.9.10 Proliferation assay 
5.000 or 15.000 cells were seeded in 6cm plates. The cells were grown in the presence of 
medium containing 10% FCS or. The cell number was counted (Coulter counter, Beckton 
Dickinson) at the indicated time points and the population doubling rate was calculated. 
Furthermore, cell proliferation in response to the inhibitors Gefitinib and Cetuximab was 
measured by MTT assay. Briefly, 5.000 cells were seeded in 48 well plates. The cells were 
allowed to grow for 72 hours and at that time point, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolimbromide; thizolyl blue, Sigma, Taufkirchen) was added to each well at a 
final concentration of 1mg/ml. The plates were incubated for 2 hours. The yellow MTT dye is 
reduced by mitochondrial dehydrogenase activity to a purple formazan, which was then 
solubilized (SDS, 2-Butanol and HCl) and absorbance was measured at 570nm on a micro-plate 
reader. All data are shown as mean ± SDM. 
3.9.11 Migration assay 
15.000-20.000 cells seeded on to a membrane with 8µM pores of a modified Boyden chamber 
(Schubert and Weiss) containing 400µl serum-free or 0.1% FCS medium with or without 
inhibitors. The lower chamber was filled with 600µl medium containing 4-10% fetal calf 
serum. The cells were allowed to migrate for 16-24 hours through the pores and were then 
stained by crystal violet. Stained cells were washed in PBS and pictures were taken on a Zeiss 
Axiovert 300 microscope (Carl Zeiss, Jena). For spectrophotometric measurement of stained 
cells the membranes were incubated for 1 hour in 5% Acetic acid to dissolve the crystal violet 
and thereafter measured in an ELISA reader (BioRad) at 570 nm.  
3.9.12 Anchorage independent growth 
50.000 cells were seeded in uncoated culture dishes to prevent adherens of the cells. After 
72hours cells were analysed under the microscope for occurrence of cell-clusters that indicate 
anchorage independent growth of the cells. Furthermore, anchorage independent growth was 
calculated by Soft Agar Assays. Here, cells (1x105) were added to 3 ml of DMEM 
supplemented with 10% FBS and 0.3% agar and layered onto 6ml of 0.5% agar beds in 60mm 
dishes. After 24-96hours anchorage independent growth of cells was calculated and quantified 
microscopically. 
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3.9.13 Focus formation assay 
The Focus Formation Assay was performed by infection of mouse embryonic fibroblast 
(MEFs) with pLXSN (Clontech, Palo Alto, USA) based retroviruses containing the oncogenes 
v-scr (positive control) HER2, EGFR or v-Kit. 24hours after infection cells were starved in 
medium containing 4% FCS and maintained for 21 days. Afterwards cells were stained with 
crystal violet and foci were counted macroscopically. 
3.9.14 Karyotyping 
5.000-15.000 cells were seeded on cover slips in 24-well plates. On the next day, cells were 
treated with 10nM Nocodazol to arrest cells in mitoses. After 24hours cells were washed with 
prewarmed PBS and swollen with 0.075M KCl for 30minutes on 37°C. After the treatment 
with 0.075 M KCl cells burst and the released chromosomes were fixed with acetate/methanol 
(1:3) 3x5minutes. Afterwards cover slips were dried over night and then stained with 
mounting media containing DAPI. Mitotic spreads were analysed for karyotypical 
abnormalities microscopically. 
3.9.15 Cell branching assay 
For cell branching assays 96-well plates were coated for at least 3 hours with 50µl Matrigel 
(contains laminin, collagen type IV, heparan sulfate proteoglycan and entactin; BD 
Biosciences) diluted in according cell medium. Then 10.000 cells were seeded in triplicates on 
to the Matrigel in medium containing 0-10% FCS with or without inhibitors.  The cells were 
allowed to invade the matrix for one week. The medium was changed every second day 
during the assay. Bright field pictures were taken on a Zeiss Axiovert 300 microscope (Carl 
Zeiss, Jena).  
3.9.16 Apoptosis assay and cell cycle analysis by propidium Iodide staining  
5.000-15.000 cells were seeded into 12-well plates (Nunc). 24 hours later apoptosis was 
induced by adding chemotherapeutic drugs or inhibitors in DMSO to the medium. After 48 
hours the supernatant of each reaction was collected and the cells were trypsinized. After 
centrifugation the cells were incubated for 2 hours in a Propidium-Iodide buffer (0.1% Na-
Citrate, 0.1% Triton X-100, 20µM Propidium-Iodide) and thereafter subjected to flow 
cytometric analysis (Beckton-Dickinson Biosciences) as described previously (Nicoletti et al., 
1991). Cell cycle profiles and apoptosis were determined using the Cell Quest Pro software 
(Beckton Dickinson Biosciences).  
3.9.17 Senescence assay 
Senescence assays (Cell Signalling, USA) were performed on 1x 105 cells seeded in 6cm 
dishes. After 24hours cells were stained for β-galactosidase expression according to 
manufactures recommendation and analysed under a light microscope (Visitron Systems, 
Zeiss). 
3.9.18 Indirect flow cytometry 
Cells in the logarithmic growth phase were collected using 10mM EDTA and dissolved in 
1ml 3% FCS in PBS. The cell number was adjusted to 250.000 cells per reaction and cells 
were incubated for 30 minutes with 10µg/ml of each FITC-labeled primary antibody at 4°C. 
The cells were washed 3 times and resuspended in 3% FCS/PBS and fluorescence intensity 
was measured in a flow cytometer (Beckton Dickinson Biosciences) and analyzed using the 
Cell Quest Pro software. 
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3.9.19 Stable isotope labelling by amino acids in vivo and in vitro (SILAC) 
and mass spectrometry  
Livers from all FGFR4 genotypes, FGFR4 knockout (kindly provided by Wallace L. 
McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute of Biosciences and 
Technology, Texas, Houston, USA) or SILAC mice were preparated and washed in 0.9% 
NaCl to get rid of the excess blood. Then every liver was snap frozen in liquid nitrogen and 
stored at -80°C until use.  Here, the liver was grinded in liquid nitrogen and lysed for 30 
minutes in Triton-X 100 Lysis buffer containing proteinase and phosphatase inhibitors. The 
lysate was centrifuged for 10min 3000rpm and the supernatant was filtered using a sterile 
45µm filter to preclear the lysate. MDA-MB-231 cells expressing empty pLXSN, 
pLXSNG388 or R388 were subcultured in RPMI media containing 10% dialyzed FCS, 1%L-
Glutamine and 1%Penicillin/Streptomycin. To incorporate appropriate isotope labeled amino 
acids cells were grown in the corresponding media for at least six cell doublings. MDA-MB-
231 cells expressing empty pLXSN vector were grown in RPMI containing [13C6] arginine an 
[4,4,5,5-D4]lysine (=Arg6/Lys4). MDA-MB-231 cells expressing pLXSN G388 or R388 were 
either in native amino acids (=Arg0/Lys0) or [13C6, 15N4] arginine an [13C6, 15N2] lysine 
(=Arg10/Lys8) to perform a “lable switch”. Labeled arginine and lysine was added in 
62.8µg/µl and 105.3µg/µl, respectively. Cells were washed witch pre-chilled PBS and lysed 
in Triton-X 100 Lysis buffer containing proteinase and phosphatase inhibitors. The lysate was 
then centrifuged for 10min 3000rpm. 
Next, FGFR4 from liver or cell lysates was immunoprecipitated (80-100mg) using a 
homemade α-FGFR4 antibody. Next to the FGFR4 KO livers, specific blocking peptides were 
used as a further control to identify proteins that bind unspecifically to the beads or the 
antibody. The samples were pooled and prepared for mass spectrometry as described 
previously (Selbach and Mann, 2006). The samples were analyzed by online liquid 
chromatography–tandem mass spectrometry (LC-MS/MS) on a LTQ-Orbitrap mass 
spectrometer (Thermo Electron). The identified peptides were assigned to proteins using 
Mascot (Matrix Science) and quantified with MSQuant. 
3.10  Methods of mouse genetics 
3.10.1 Mice and gene targeting 
The animals used in this study were kept in a barrier facility at the Max Planck Institutes in 
Martinsried, Germany. The FGFR4 Arg385 KI mice were generated using standard ES cell 
homologous recombination and blastocyst injection techniques as described previously 
(Seitzer et al., 2009).  
3.10.2 Genotyping and intercrosses to oncomice 
Genotyping was done by PCR of genomic tail-DNA isolated using the Qiagen Blood & 
Tissue DNeasy Kit according to manufacture’s recommendation. The removal of the selection 
cassette was detected using neoR-specific primers. Removal of the Cre transgene was 
determined by Cre-specific primers. Primer for detecting the genotype of the FGFR4 allele 
were specific for amplifying a 168bp band spanning the FGFR4-SNP with subsequent 
restriction of the amplification product via MvaI restriction enzyme to distinguish the different 
FGFR4 alleles. The presence of the TGFα and PymT transgene was confirmed by performing 
PCR analysis with TGFα Primers as mentioned above. 
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3.10.3 Isolation of mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts were isolated from E13.5 embryos as described previously 
(Conner, 2001). The cells were cultured in DMEM high glucose containing 10% fetal calf 
serum, 1% L-Glutamine and 1% Penicillin/Streptomycin (Todaro and Green, 1963).  
3.10.4 Tumor analysis 
To analyse the occurring tumors, mice were sacrificed by cervical dislocation and opened 
ventrally. All mammary glands were excised for tumor-measurement. Tumor size and mass 
were analysed by metrical measurement and weighing of the tumor tissue and the mammary 
gland tissue independently. Raw-data were normalised to bodyweight. All data are shown as 
mean ± SDM. All p-values were calculated using the students T-Test and values < 0.03 were 
considered statistically significant. 
3.10.5 Analysis of lung metastases 
For pathological analysis and quantitation of metastases, preparated lungs were sectioned and 
analysed at 800 to 1000µm intervals. Sections were stained with hematoxilin and eosin (H&E, 
Fluka, Switzerland) to identify lung metastases under the light microscope. Metastatic burden 
was calculated based on number and size of metastatic lesions. 
3.10.6 Immunohistochemistry on murine organs and tumor sections 
Tumor samples and tissues were fixed in 70 % Ethanol at 4°C overnight. On the next day 
samples were embedded in paraffin and sections of 4-8µM were cut on a microtome 
(HM355S, microm). The sections were subjected to deparaffinisation in xylene and 
rehydrated in a graded series of ethanol. Antigen retrieval was achieved by cooking in citrate 
buffer (pH 6) in a microwave. Immunohistochemical staining was done with the Vectastain 
Staining Kit (Vector Laboratories, Burlingame) following the manufacture’s protocol.  After 
blocking with 10% horse serum in PBS buffer containing 3% Triton-X for one hour, the 
sections were incubated with the primary antibody (αFGFR4 Hs121, Santa Cruz) at 4°C 
overnight. The secondary antibody (α-rabbit, VectorLabs, USA) was incubated for one hour 
in PBS buffer containing 3% Triton-X. Mayer’s Hematoxylin (Fluka, Switzerland) was used 
as counterstain. 
3.10.7  Injection of nude mice  
For injection 6-8 week old female Balb/C Nu/Nu mice were used. Here 7x106 NHDF cells 
(p53/Rb double knockdown or mock transfected) or 2x106 MDA-MB-435S (as a positive 
control) cells were injected subcutaneously in the flank of the mice. The state of health of the 
injected mice was controlled repeatedly per week. If there was a visible tumor growth mice 
were sacrificed by cervical dislocation and the tumor growth was monitored. 
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4 Results 
4.1 Establishment of an in vitro transformation system 
4.1.1 Knockdown strategy of p53 and Rb; physiological output on 
proliferation and G2 Arrest upon p53 and Rb reduction in non-
cancerous human primary cells 
 
In order to establish an in vitro transformation system, two strategies were tested to efficiently 
knockdown the tumor suppressors p53 and Rb. On the one hand, several siRNAs against p53 
and Rb were tested for their knockdown capacity. The most efficient ones were then cloned in 
the pRETRO Super vector and transfected in HEK293 cells to obtain stable knockdown cells. 
Unfortunately, these constructs had a low or no knockdown efficacy due to a possibly 
ineffective structure of the siRNAs. 
On the other hand plasmids containing shRNAs against p53 and Rb that were available at the 
core facility of the MPI of Biochemistry in Martinsried were tested. As shown in Figure 11 
both contructs displayed a sufficient knockdown after transfection into HEK293 cells. Hence, 
these contructs were further used to generate a stable knockdown of p53 and Rb in non-
cancerous immortalized cell lines HEK293, HaCaT and MCF10A. As a negative control 
HEK293, HaCaT and MCF10A cells were stably transfected with a construct expressing a 
non-silencing shRNA. 
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Figure 11: Knockdown strategy of the tumor suppressors p53 and Rb; The knockdown strategy on the left 
hand displays the use of the siRNA approach; after analyzing the knockdown efficacy of several siRNAs 
the most efficient siRNAs were cloned into pRETROSuper for stable transfection. Transient transfection 
of the constructs displayed an insufficient knockdown of the target genes; on the right hand p53 and Rb 
were downregulated by a miRNA approach in HEK293, HaCaT and MCF10A cells; transient knockdown 
displayed sufficient efficacy, so that stable double-knockdown clones were established.   
 
As p53 and Rb are key regulators of the cell cycle and the main guardians of the integrity of 
the genome (Classon and Harlow, 2002; Vogelstein et al., 2000), the impact of a stable 
knockdown of these two tumor suppressors was assayed by a proliferation and cell cycle 
arrest assay via FACS analysis. As seen in Figure 12 A the knockdown of p53 and Rb resulted 
in an accelerated proliferation of all tested cell lines. Accordingly, the cell lines displayed a 
decreased growth arrest after treatment with doxorubicin for 24 hours, a chemotherapeutic 
drug that causes DNA damage which guides cells into growth arrest or apopotosis (Figure 12 
B). Hence the knockdown of p53 and Rb in HEK293, HaCaT and MCF10A cell lines 
displayed the expected cell biological output to manipulate cells into uncontrolled cell growth 
by loss of cell cycle control even in the presence of a DNA-damaging agent. 
 
Results 
 45 
 
 
 
Figure 12: Increased cell proliferation and decreased G2-Arrest in p53/Rb knockdown cell lines A) The 
knockdown of p53 and Rb facilitates proliferation in HEK293, HaCat and MCF10 A cells (n=3); B) The 
knockdown of p53 and Rb decreases the number of cells arresting in G2 after 24 hours of doxorubicin-
treatment (0.5 µM) in HEK293, HaCat and MCF10 A cells (n=3); 
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4.1.2 Reduction of p53 and Rb in primary normal human dermal 
fibroblasts (NHDF) 
 
Routinely used non-cancerous cell lines are artificially immortalized and thereby released 
from senescence and primed for the establishment of a neoplastic phenotype. Furthermore, the 
perpetual subculturing of these cells enables the accumulation of mutations. For that reason, 
typical non-cancerous cell lines do not reflect the status of real primary cells. Therefore, the 
stable knockdown of the tumor suppressors p53 and Rb was established in normal human 
dermal fibroblasts as seen in Figure 13 (further referred as NHDFdk). As a negative control 
NHDF cells were stably transfected with a construct expressing a non-silencing shRNA 
(further referred NHDFscr). 
 
 
Figure 13: Stable knockdown of p53 and Rb in normal human dermal fibroblasts (NHDF); NHDFscr cells 
were stably transfected with a non-silencing shRNA construct; knockdown verification via Western Blot 
Analysis; tubulin served as a loading control 
 
4.1.2.1 Increased proliferation, morphological changes and decreased senescence 
in NHDF cells deficient for p53 and Rb 
 
As a proliferative advantage should be also observed in NHDF deficient for p53 and Rb the 
population doubling rate (PDR) was monitored in comparison to mock transfected NHDFscr. 
Moreover, the calculation of population doubling rates displays a possible prolonged life span 
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and immortalisation of the manipulated cells. These processes are necessary to take place and 
are one of the first anti-cancer barriers to be overcome in the process of oncogenesis (Ha et 
al., 2008; Prieur and Peeper, 2008). As shown in Figure 14A NHDFdk cells display an 
increased PDR compared to mock transfected cells indicating a loss of cell cycle control 
induced by the knockdown of p53 and Rb.  Furthermore, after 15 population doublings (PDs) 
NHDFs normally enter replicative senescence, a process activated by diverse intrinsic and 
extrinsic stresses e.g. telomere shortening (Prieur and Peeper, 2008). In contrast NHDFdk 
overcome this permanent growth arrest and display a normal growth rate even after 30 
calculated population doublings. Therefore, NHDFdk seem to be immortalized as the 
doubling of a normal growth rate is expected to occur only in immortalized cell lines (Gray-
Schopfer et al., 2006).  
Under the microscope, NHDFdk cells display a more vital phenotype than NHDFscr cells and 
show a smaller cell volume. This phenotype is similar to transformed NIH 3T3. As the 
knockdown cells exhibited accelerated proliferation, the expression of typical cell cycle 
progressors, like Cyclin A or D were analyzed in NHDFdk cells (Figure 14B). Whereas 
NHDFscr show downregulation of Cyclin A and D and thereby decelerate their proliferation 
over time, at least Cyclin D gets upregulated in NHDFdk indicating increased proliferation. 
Furthermore, the mRNA expression level of the two cell cycle promoting kinases Aurora 
Kinase A and B were analyzed as shown in Fugure 14C. Similar to Cyclin A and D, NHDFscr 
cells display a decrease in Aurora Kinase A and B over time indicating a deceleration of the 
cell cycle. In contrast, NHDFdk cells exhibit an increase of both Aurora Kinase A and B over 
time. Along these lines, the overexpression of these two cell cycle kinases is an common 
event in transformed cells (Keen and Taylor, 2004).  
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Figure 14: Increased proliferation and morphological changes in NHDFdk cells A) NHDF deficient for 
p53 and Rb display an increased proliferation, prolonged life span and seem to be immortalized. Further 
NHDFdk display a smaller and more viable phenotype (n=2); B) NHDFdk cells maintain the expression of 
the cell cycle promotor Cyclin A and increase the expression of Cyclin D indicating a progressed cell cycle; 
(n=2); C) NHDFdk cells overexpress Aurora Kinase A and B indicating an increased proliferation (n=2); 
PD=population doubling 
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Next to the analysis of cell cycle progression in NHDFdk cells, the occurrence of senescence 
was analyzed via staining of β-galactosidase, an enzyme which is predominantly expressed in 
senescent cells (Bandyopadhyay et al., 2005). As seen in Figure 15A senescence in NHDFscr 
cells occurs after 9 PDs whereas NHDFdk cells display no senescence even after 15 PDs. The 
occurrence of senescence was further quantified.  Hence, the NHDFdk display increased 
proliferation with a decreased onset of senescent cells, a prolonged life span and seem to 
overcome senescence and enter an immortalized phenotype. To further analyze the occurrence 
of permanent growth arrest the expression pattern of NHDFdk regarding the senescence 
inducing and thereby tumor suppressive proteins p27, p21 and p16 were monitored (Figure 
15B). On mRNA level all investigated tumor suppressors displayed a clear downregulation or 
no upregulation in high population doubling rates compared to NHDFscr cells. Here the 
expression of tumor suppressors is accelerated indicating the induction of senescence 
visualized by the β-galactosidase staining (Herbig et al., 2004).  
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Figure 15: Decreased senescent phenotype in NHDFdk cells and downregulation of tumor suprressors A) 
β-galactosidase staining of senescent cells; Senescence in NHDFscr occurs after 9PDs, NHDFkd cells 
display only a slight positive β-galactosidase staining even after 15 PDs; the percentage of positively 
stained cells was quantified (n=3); B) tumor suppressors p27, p16 and p21 are downregulated in NHDFdk 
cells compared to NHDFscr cells  indicating the absence of senescence (n=2); expression were quantified 
on GAPDH expression level; PD= population doubling 
 
4.1.2.2 Reduction of contact inhibition, anchorage independence and invasion in 
NHDF deficient for p53 and Rb 
 
Transformed cells acquire or loose specific characteristics associated with a malignant 
phenotype of cancer cells. An important property of cells of the multicellular organism is their 
ability to stop proliferating when the space allotted to them has been filled. Also in vitro, 
normal cells fill the surface of the culture dish but stop in the G1/G0 phase of the cell cycle, 
when a dense monolayer has been formed. For tumor formation in vivo or focus formation in 
vitro it is essential for a single cell to overcome such a contact inhibition (Herrlich et al., 
2000). For that reason, NHDFdk cells and NHDFscr cells were seeded on subconfluency and 
grown for 72 hours. As seen in Figure 16A, NHDFdk cells clearly continue proliferating in a 
confluent culture compared to NHDFscr controls indicating the reduction of contact 
inhibition. If this confluent cell culture was stained with crystal violet, NHDFdk cells display 
a disordered cell layer compared to the typical fibroblastic layer of NHDFscr cells. A further 
characteristic of a malignant cell is the ability to grow anchorage independently. By 
acquisition of anchorage independence, cancer cells are able to disseminate from the primary 
tumor and enter the lymphatic or blood stream for the invasion of distant organs. For that 
purpose, NHDFdk and scr cells were seeded in non-coated culture dishes to prevent adherence 
of the cells. The prevention of adherence should induce anoikis in the NHDFscr cells, a form 
of apoptosis induced by the loss of cell-cell or cell-matrix interactions. As seen in Figure 16B 
NHDFdk cells are able to build cell clusters by proliferating over 72 hours. In contrast, 
NHDFscr cells display a reduced number of cells after 72 hours indicating apoptosis by 
anoikis. Hence, NHDFdk cells acquired the ability to grow without adherence (Chiarugi and 
Giannoni, 2008; Simpson et al., 2008). To further characterize the malignant phenotype of the 
NHDFdk cells the expression of known oncogenes was analyzed. As seen Figure 16C the 
oncogene H-RAS is not expressed in NHDFdk cells. In contrast, the oncogenic kinase SRC is 
overexpressed in NHDFdk over time. That overexpression possibly contributes to the pre-
malignant phenotype of NHDFdk cells namely the loss of contact inhibition and the ability to 
grow anchorage independently. 
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Figure 16: NHDFdk display loss of contact inhibition and increased anchorage independent growth; A) 
NHDFdk cells display cell proliferation in confluent subculture indicating the loss of contact inhibition; 
NHDFdk cells stained with crystal violet display a disordered cell layer compared to NHDFscr (n=3); B) 
NHDFdk display anchorage independent growth in non-coated cell culture dishes and form typical cell 
clusters compared to NHDFscr cells (n=3); expression analysis of kown oncogenes shows an 
overexpression of SRC in NHDFdk cells over time; H-RAS is not expressed (n=2); PD= population 
doubling 
 
A further indication for a cancerous and invasive potential is the branching in Matrigel by 
deconstructing the pseudo-extracellular matrix by upregulation of Matrix-Metalloproteinasen 
(Stahtea et al., 2008). As seen in Figure 17A NHDFdk cells display cell clusters when grown 
for 10 days on Matrigel. In contrast, NHDFscr cells were not able to grow under these 
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conditions. This proliferation is the first hint for an invasive potential of cells. Furthermore, as 
seen in the magnification of Figure 17A NHDFdk cells display a slight branching ability 
compared to mock transfected cells. Hence, the NHDFdk cells seem to be able to degrade the 
Matrigel. To further analyze the invasive potential the m-RNA expression of the Matrix-
Metalloproteases (MMP) 14, 9 and 2 was analyzed as the activation of MMPs is essential for 
the decomposition of Matrigel. As seen in Figure 17B MMP 14 is not upregulated in NHDFdk 
cells. In contrast, MMP9 and 2 are clearly upregulated in NHDFdk cells when compared to 
NHDFscr cells. Thus, MMP9- and 2-overexpression in NHDFdk cells may explain the 
observed slight invasive phenotype. 
Taken together, these results indicate that the knockdown of p53 and Rb in NHDF enables the 
acquisition of typical properties of cancer cells and display distinct hallmarks of progressing 
oncogenesis in NHDFdk cells. 
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Figure 17: Invasion in NHDFdk cells and expression of MMPs; A) NHDFdk display focus formation in 
Matrigel with a slight branching activity,  indicating a certain invasiveness when compared to NHDFscr 
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(n=3); B) NHDFdk cells overexpress MMP2 and 9 over time; MMP14 is not overexpressed when 
compared to NHDFscr cells (n=2) 
 
4.1.2.3 NHDFdk cells display karyotypic abnormalities and tolerate extended 
telomere shortening 
 
The acquisition of typical properties of cancer cells depends on aberrations of the destabilized 
genome. Uncontrolled cell division cycles can result in chromosomal aberrations and 
progressing genomic instability. Once the genome is altered through aberrant fusions, 
translocations or deletions, malignant cells can change their gene expression pattern and their 
physiological behaviour. Hence, genomic instability and DNA-damage are one of the most 
prominent processes in cellular transformation (Cheung and Deng, 2008; Hanahan and 
Weinberg, 2000; Jeggo, 2005; Li and Li, 2006; Lingle et al., 2005). 
To analyze NHDFdk cells for the occurrence of genomic instability, the expression of several 
markers for DNA-damage and uncontrolled cell division were monitored over time. As seen 
in Figure 18A NHDFdk cells upregulate the active form of H2AX, the so called γH2AX, 
which gets activated by damaged DNA, thereby initiating a signalling cascade that results in 
either growth arrest and DNA-repair or apoptosis (Fillingham et al., 2006; Halicka et al., 
2005). The upregulation of this Histone in its active form occurs at high population doubling 
rates, indicating that the DNA damage takes place as a result of the prolonged life span and  
uncontrolled cell proliferation induced by the loss of p53 and Rb. Furthermore, the m-RNA 
expression of Mad (mitotic- arrest-deficient-like) 1 and Mad 2 were analyzed. These two cell 
cycle checkpoint proteins prevent cells of entering in anaphase if the chromosomes are not 
properly organized for cell division. Several studies showed that the loss of Mad1 and 2 in 
cancer cells results in chromosomal instability. The overexpression of Mad1 and 2 results in 
suppression of proliferation or the malignant phenotype of cancer cells (Chen et al., 1995; 
Vastrik et al., 1995; Zou et al., 2006). As seen in Figure 18A the expression of Mad2 is 
comparable between NHDFdk and NHDFscr cells. In contrast, Mad1 is lost in NHDFdk cells 
over time and gets clearly upregulated in NHDFscr cells. These data indicate an elevated cell 
cycle rate in NHDFdk cells and possible chromosomal instability as a result of a defective 
checkpoint control.  
Because of these results, the number of chromosomes in NHDFscr and NHDFdk was 
analyzed over time to investigate if there are accelerated chromosomal alterations with 
increasing population doublings. Accordingly, the number of chromosomes in NHDFscr cells 
was kept stable till senescence occurs. In comparison, NHDFdk cells lost their integrity of the 
genome after about 25 PDs with an increasing number of aneuploid cells displaying more or 
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less than 46 chromosomes. These results indicate that one of the most prominent hallmarks of 
cancer, the genomic instability and the accumulation of chromosomal aberrations, takes place 
after the loss of p53 and Rb in normal human dermal fibroblasts. 
As telomere shortening is a barrier of tumorigenesis by initiating permanent growth arrest, 
reactivation of telomerase is a common event in cancer progression. As seen in Figure 18C 
NHDFdk cells do not reactivate telomerase expression as analyzed by Western Blotting. 
These data indicate the possibility of another mechanism of telomere-stabilizing, so called 
ATL (alternative telomere lengthening) that should prevent cells from entering a mitotic crisis 
(Cesare and Reddel, 2008; Shay and Wright, 2005). As NHDFdk cells do not reexpress 
telomerase it was important to analyze the length of telomeres in these cells as another mark 
of chromosomal aberration. For that purpose, a telomeric PCR was performed as seen in 
Figure 18C. The single copy gene 36B4 served as loading control. Here, NHDFdk cells 
display an augmented telomere shortening compared to NHDFscr cells. Human embryonic 
lung cells (HEL), Melanocytes and mammary epithelial Ac745 cells served as a control 
regarding the telomere length of primary cells. MDA-MB435S and MDA-MB-231 cells 
served as a positive control regarding telomere lengthening via telomerase reactivation. This 
result indicates that the loss of p53 and Rb enables the cell to tolerate an extended telomere 
shortening that may result in the aforementioned instability of the genome. 
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Figure 18: NHDFdk cells show accelerated DNA damage and chromosomal aberrations and tolerate an 
extended telomere shortening; A) γH2AX gets upregulated in NHDFdk cells as an indicator of DNA 
damage; wheras the expression of Mad2 display no difference the expression of Mad1 is lost in NHDF dk 
cells over time compared to NHDFscr cells (n=2); B) karyotypical analysis of NHDFscr cells display a 
normal genome whereas NHDFdk cells accumulate aneuploid cells over time; C) NHDFdk cells display no 
reactivation of telomerase expression; NHDFdk cells tolerate extended telomere shortening compared to 
NHDFscr cells (n=10); PD= population doubling 
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4.1.2.4 NHDFdk cells do not establish a stem cell-like cancer cell subpopulation 
 
In recent years, more and more attention has been drawn to stem cells and their implication in 
tumor progression. Cancer-stem cells seem to be involved in tumor initiation and progression 
and seem to be responsible for  resistance  certain therapies (Bjerkvig et al., 2005; Dean et al., 
2005; O'Brien et al., 2007). Further, recent publications show, that a lot of routinely used 
cancer cell lines and tumors contain a subpopulation of cancer stem cells that display a highly 
aggressive malignant phenotype when isolated from their original culture (Ho et al., 2007; 
Huang et al., 2008; Sung et al., 2008). For this reason, two experiments were performed to 
analyze, if NHDFdk cells developed a cancer stem cell subpopulation. As stem cells 
upregulate the ABCG2 transporter, a Hoechst 33324 dye assay was performed (Scharenberg 
et al., 2002). If the ABCG2 transporter is upregulated the dye should be transported out of the 
cell. As seen in Figure 19A there is no difference between NHDFscr or NHDFdk cells 
demonstrating that this stem cell marker is not present to accelerate the efflux of Hoechst 
33324. Furthermore, there was no stem cell-like subpopulation detectable microscopically, as 
stem cells display a roundish, barely attached phenotype. 
Next, a surface expression assay of stem cell markers was performed via FACS analysis. 
Here, the expression of CD34 and CD44 were analyzed. Cos7 cells and KG1a cells served as 
negative and positive control, respectively. As shown in Figure 19B CD34 is not expressed in 
NHDFdk cells. In contrast, CD44 is upregulated in NHDFdk cells. However, this elevated 
surface expression of CD44 seems to be rather a result of the loss of p53 than an indication for 
the presence of a stem cell subpopulation (Godar et al., 2008). 
In summary, NHDFdk cells neither overexpress ABCG2 nor express typical stem cell surface 
markers. Hence, NHDFdk cells seem not to develop a cancer stem cell subpopulation as a 
result of p53 and Rb deficiency. 
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Figure 19: NHDFdk cells do not develop a stem-cell like cancer cell subpopulation; A) NHDFdk do not 
express the Hoechst 33324 efflux pump and stem cell marker ABCG2 (n=3); B) NHDFdk cells do not 
express the stem cell surface marker CD34, but do express CD44 (n=3); PD= population doubling 
 
4.1.2.5 The malignancy of NHDF cells deficient for p53 and Rb is not potent 
enough to induce tumor growth in nude mice 
All aforementioned experiments display a distinct hint for the succesful malignant 
transformation of NHDF cells deficient for p53 and Rb. Nevertheless, it is essential to 
investigate the malignancy of cells in a so called “animal culture” that examines subcutaneous 
tumor growth in nude mice. For that purpose, NHDFdk and NHDFscr cells were injected 
subdermally in the flanks of female Balb/C Nu/Nu mice to monitor tumor growth in vivo. The 
injection of the highly aggressive MDA-MB-435S cells served as a positive control for tumor 
growth. As seen in Figure 20A only the MDA-MB-435S cells display visible tumor growth 
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after 3 month. In contrast, even after 9 month, no visible tumors could be detected in mice 
injected with NHDFdk cells (Figure 20 A/B). As expected, mice injected with the negative 
control NHDFscr cells displayed no tumor growth after 9 month. These data suggest that the 
knockdown of p53 and Rb just partially transforms NHDF cells, but this level of malignancy 
is not potent enough to promote tumor growth in vivo. Furthermore, the used Balb/C nude 
mice just partially lack their immunesystem, which may explain the relatively poor tumor 
growth. The use of other nude mice strains possibly could overcome this limitation and may 
result in tumor growth of the NHDFdk cells.  
 
Figure 20: NHDF cells deficient for p53 and Rb display no tumor growth in vivo (NHDFdk); A) injected 
NHDFdk cells display no tumor growth in vivo; NHDFscr cells served as negative control, MDA-MB-435S 
cells served as positive control and display obvious tumor growth indicated by the white arrow; B) nine 
month after cell injection wether NHDFdk (0/5) nor NDHDscr (0/3) cells display visible tumor growth; 
MDA-MB-435S cells display visible tumor growth after 3 month (2/2)   
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4.2 The impact of the FGFR4 and its variant Arg385 on tumor progression  
 
Since an impact of the human FGFR4 Arg388 allele on tumor progression was only shown in 
correlative studies on patient populations with an otherwise heterogeneous genetic 
background, there was an urgent need to ultimately prove the influence of this single 
nucleotide polymorphism (SNP) on tumor progression in vivo. Here, the defined genetic 
background of a mouse model overcomes the problem of genetic heterogeneity of patient 
cohorts and thus the cause of diverging conclusions. We generated a FGFR4 Arg385 
(corresponding to human codon 388) knock-in (KI) model in the genetic background of 
SV/129 mice, which represents the first directly targeted KI mouse model to investigate the 
impact of a single nucleotide polymorphism on the progression of cancer. In order to generate 
the FGFR4 Arg385 allele, the Glycine in exon 8 was changed to an Arginine by site-directed 
mutagenesis. A neomycin selection cassette flanked by loxP sites was cloned between exons 
10 and 11 (Figure 21A).  After gene targeting, neomycin-resistant ES-cell clones were 
analyzed by southern blotting and PCR-RFLP of the genomic DNA (Figure 21B 1-2) 
(Southern, 1974).  
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Figure 21: A) FGFR4 Arg385 KI gene-targeting construct: FGFR4 wt locus spanning exons 2 to 12 of the 
murine FGFR4 genomic sequence; targeted locus: exon 8 contains the SNP established via specific 
mutagenesis, selection-cassette flanked by loxP-sites for Cre-deletion is introduced between exon 10 and 
11;  
B) 1) Southern Blot analysis of ES-cell clones after gene targeting: positive clones display an additional 
10kb fragment detected by a 5’external probe 2) genotyping of ES-cell clones via PCR-restriction 
fragment length polymorphism (RFLP): positive clones contain an additional fragment of 93 bp after Mva 
I restriction enzyme (S. Streit, 2004) 
Gly385: Glycin at codon 385; Arg385: Arginin at codon 385; Neo: Neomycin-resistance; TK: thymidin-
kinase-cassette 
 
Next, positive clones were injected into blastocysts of pseudo-pregnant mice to generate 
chimeras. These mice were then backcrossed to C57BL/6 mice to raise the first generation of 
FGFR4 Arg385 KI mice. In order to delete the neomycin selection cassette, the FGFR4 
Arg385 mice were crossed to mice transgenic for the Cre-recombinase (Deleter-Cre). 
FGFR4 Arg385 KI Cre-deleted mice were analyzed by segregation analysis of a statistically 
significant number of mice for Mendelian inheritance of the FGFR4 allele (Table 8). In 
backcrosses to FGFR4 Gly/Gly385 mice, the offspring displayed the expected distribution of 
1:1 from FGFR4 Gly/Gly385 to FGFR4 Gly/Arg385. Heterozygote intercrosses displayed the 
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expected distribution of 1:2:1 from FGFR4 Gly/Gly385 to Gly/Arg385 to Arg/Arg385. Hence, 
the FGFR4 Arg385 allele is inherited in the correct Mendelian ratio.  
 
 
Table 8: Segregation analysis of FGFR4 Arg385 KI mice: The FGFR4 Arg385 allele is inherited in the 
correct Mendelian ratio; progeny of backcrosses (FGFR4 Gly/Gly385 x FGFR4 Gly/Arg385) is distributed 
1:1, progeny of intercrosses (FGFR4 Gly/Arg385 x FGFR4 Gly/Arg385) is distributed 1:2:1. 
 
4.2.1 Characterisation of the FGFR4 Arg385 KI mouse   
In humans, the FGFR4 Arg388 allele is expressed in various tissues without any differences  
compared to the FGFR4 Gly388 and has yet no known impact on the healthy organism itself 
(Bange et al., 2002). Similarly, the FGFR4 Arg385 KI mouse model displays no obvious 
phenotype that distinguishes it from FGFR4 Gly385 carrying mice (data not shown). To 
analyze if the generated FGFR4 Arg385 KI mice display a pathological phenotype matching 
human patients with the same SNP genotype and show similar characteristics of FGFR4 
expression, localization and distribution, we first analyzed FGFR4 mRNA- and protein- levels 
and analyzed the localization and distribution in various tissues of 3 month old female mice 
with different FGFR4 genotypes. 
As shown in Figure 22A and B FGFR4 is expressed in various tissues including mammary 
gland, lung, brain or liver. The investigated FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 mice displayed no altered expression of the FGFR4 neither on mRNA 
nor on the protein level in the presence of the FGFR4 Arg385 allele. Next, we analyzed the 
expression and localization of the FGFR4 in different tissues immunohistochemically. Figure 
22C displays the FGFR4 expression and localization in the lung and the mammary gland of 
FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 mice. Here, the lung tissue, displays a clear 
FGFR4 staining in smooth muscles, blood vessels and bronchial epithelial cells. In the 
mammary gland tissue, blood vessels and ductal epithelial cells show distinct FGFR4 
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expression. The magnification shown further indicates a membranous and cytoplasmatic 
localization of the FGFR4. Figure 22D summarizes the immunohistochemical analysis of 
FGFR4 expression and quantifies the levels of FGFR4 staining in the different compartments 
of the investigated tissue.  Similar to the observations on mRNA-level and protein-level 
neither localization, distribution nor the level of expression changes in the presence of the 
FGFR4 Arg385 allele. Here, FGFR4 is detectable in various tissues and, as with mRNA or 
protein expression levels; there is no difference between the different FGFR4 allele carriers. 
These results indicate that the FGFR4 Arg385 allele has not altered expression, localization or 
distribution in vivo. These conclusions match previously published data on human samples 
(Partanen et al., 1991). 
Hence the FGFR4 Arg385 KI mice display the same characteristics as their human 
counterparts in mRNA and protein expression levels, -localisation and -distribution. 
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Figure 22: Characterisation of the FGFR4 Arg385 KI mice; A) mRNA expression levels in different tissues 
of 3 month old female mice carrying the FGFR4 Gly/Gly385 (n=3), Gly/Arg385 (n=3) or Arg/Arg385 (n=3) 
locus quantified by LightCycler® analysis: Expression levels are normalized to HPRT gene expression 
and blotted relatively to the expression in FGFR4 Gly/Gly385 mice which was set to 1; FGFR4 is equally 
expressed in various tissues regarding the FGFR4 isotype; all data are shown as mean ± SDM.  
B) Protein-expression levels in different tissues of 3 month old female mice carrying the FGFR4 
Gly/Gly385 (n=3), Gly/Arg385 (n=3) or Arg/Arg385 (n=3) locus analysed by immunoprecipitation and 
Western Blotting of FGFR4: Actin served as a loading control and as normalization value of FGFR4 
expression levels; FGFR4 is equally expressed in various tissues regarding the FGFR4 isotype; all data are 
shown as mean  
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C) Lung and mammary gland tissue of 3 month old female mice carrying the FGFR4 Gly/Gly385 (n=3) or 
Arg/Arg385 (n=3) locus: FGFR4 expression was analyzed immunohistochemically and evaluated 
microscopically (20x); the higher magnification of the lung and mammary gland shows membranous and 
cytosolic localization of the FGFR4 as well as FGFR4 negative cells as a staining control; FGFR4 is 
equally expressed regarding the FGFR4 isotype. 
D) Table of FGFR4 expression pattern in different tissues of 3 month old female mice carrying the FGFR4 
Gly/Gly385 (n=3) or Arg/Arg385 (n=3) locus: FGFR4 was analyzed immunohistochemically and quantified 
for expression level and localization of the FGFR4 protein; FGFR4 is expressed in various tissues with a 
cytosolic and membranous localization; FGFR4 is equally expressed in various tissues regarding the 
FGFR4 isotype; cell types with negative FGFR4 staining are not listed. 
MG: mammary gland; SM=skeletal muscle 
 
4.2.2 The impact of the FGFR4 and its variant Arg385 in vitro 
4.2.2.1 The impact of the FGFR4 Arg385 on fibroblast transformation  
Mouse embryonic fibroblasts (MEFs) display an easily available in vitro system to investigate 
the impact of genetically altered loci in mice. Therefore, we analyzed the impact of the 
FGFR4 Arg385 allele on biological mechanisms in vitro using isolated E13.5 mouse 
embryonic fibroblasts. Previous reports of clinical studies do not implicate the FGFR4 
Arg388 allele in tumor initiation, but rather associate it with enhanced disease progression 
once cancer has been initiated (Bange et al., 2002; Streit et al., 2004). Thus, we firstly 
investigated the impact of this SNP on the transformation of MEFs by focus formation assays. 
Here some primary cells loose contact inhibition as a consequence of overexpression of proto-
oncogenes and grow in local multilayers that result in the formation of cell foci . In order to 
study the impact of the FGFR4 Arg385 allele on focus formation we initiated neoplastic 
transformation of FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and FGFR4 Arg/Arg385 MEFs 
via infection with viruses carrying overexpression modules for several oncogenes. We used 
the human proto-oncogenes HER2, EGFR and the feline viral oncogene v-kit to determine if 
either one of the FGFR4 alleles would influence the transformation capacity and the 
progression of MEFs in cooperation with different receptor tyrosine kinases acting as the 
initiating oncogenes. Infection of MEFs with viruses containing expression modules of the 
oncogene v-src served as a positive control as v-scr triggers cell transformation at very early 
time points. Infection of MEFs with viruses containing expression modules of the empty 
pLXSN-vector served as a negative control to calculate the spontaneous transformation rate of 
the infected MEFs. In Figure 23A the number of foci in FGFR4 Gly/Gly385, FGFR4 
Gly/Arg385 and FGFR4 Arg/Arg385 MEFs is plotted against the investigated oncogenes after 
21 days of focus formation. MEFs heterozygous for the FGFR4 Arg385 display a significantly 
increased focus formation in cooperation with the initiating oncogenes HER2 (p=0.00033) 
and EGFR (p=0.017). MEFs homozygous for the FGFR4 Arg385 show a significantly 
enhanced focus formation with all three investigated oncogenes (HER2-p=0.00016, EGFR-
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p=0.0000095, v-kit-p=0.00012). These results suggest that the FGFR4 Arg385 allele 
significantly promotes cell transformation in cooperation with classical oncogenes. 
Remarkably, cell transformation by the EGFR or v-kit, which are commonly regarded as weak 
oncogenes, led to an unusually high number of foci. These results indicate yet unknown 
crosstalk between FGFR4 Arg385 and other receptor tyrosine kinases similar to the known 
crosstalk between FGFR4 and HER2 (Koziczak and Hynes, 2004).  
Further, we wanted to monitor the progression of transformation in FGFR4 Gly/Gly385 and 
FGFR4 Arg/Arg385 MEFs over time. Therefore, we performed the focus formation by 
terminating the assay at different time points (7 days, 14 days and 21 days). As it is clearly 
shown in Figure 23B, FGFR4 Arg/Arg385 carrying MEFs not only transform considerably 
faster, but also generate an increased number of foci. These results indicate that the FGFR4 
Arg385 is clearly involved in the progression of transformed cells initiated by different 
oncogenes. Furthermore, the FGFR4 Arg385 allele seems to facilitate the transformation of 
MEFs resulting in a higher number of foci that form at earlier time points. 
 
 
Figure 23: The FGFR4 Arg385 allele promotes cell transformation in MEFs A) Focus Formation Assay in 
FGFR4 Gly/Gly385 (n=5), FGFR4 Gly/Arg385 (n=5) and FGFR4 Arg/Arg385 (n=5) carrying MEFs: MEFs 
transformed by the overexpression of HER2, EGFR or v-kit display a statistically significant increase in 
the formation of foci in the presence of the FGFR4 Arg385 allele after 21 days (HER2: Gly/Arg-p=0.00033, 
Arg/Arg-p=0.00016; EGFR: Gly/Arg-p=0.017, Arg/Arg-p=0.000095; v-kit: Arg/Arg-p=0.00012); 
overexpression of the empty vector served as negative control; transformation by v-scr served as positive 
control; all data are shown as mean ± SDM; all p-values were calculated using the students T-test and 
values ≤ 0.03 were considered statistically significant. 
B) Focus Formation Assay in FGFR4 Gly/Gly385 (n=3) and FGFR4 Arg/Arg385 (n=3) carrying MEFs 
monitored over time: Foci growth was determined after 7, 14 and 21 days; FGFR4 Arg/Arg385 MEFs 
show an earlier onset of transformation and a higher progression of foci growth over time; overexpression 
of the empty vector served as negative control; transformation by v-scr served as positive control. 
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4.2.2.2 Impact of FGFR4 Arg385 on proliferation, life span, migration and 
apoptosis of MEFs 
To support these observations by molecular analytical methods, we determined, whether the 
molecular action of the FGFR4 Arg385 itself is responsible for the accelerated transformation 
rate in FGFR4 Arg385 carrying MEFs. Therefore we analyzed the expression and the 
activation status of the FGFR4 in FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and FGFR4 
Arg/Arg385 MEFs. The Western Blot Analsyis in Figure 24A displays neither an 
overexpression nor a hyperactivation of the FGFR4 Arg385 in MEFs. 
Next, we wanted to investigate the involvement of the FGFR4 Arg385 on several 
physiological processes that could be responsible for the facilitated and accelerated 
transformation rate in FGFR4 Arg385 carrying MEFs. To exclude the dependence of an 
enhanced transformation rate from a higher proliferative potential or a prolonged life span of 
FGFR4 Arg385 carrying MEFs, we compared the population doubling rate of FGFR4 
Gly/Gly385, FGFR4 Gly/Arg385 and FGFR4 Arg/Arg385 MEFs. Here, FGFR4 Arg385 
carrying MEFs display no increased proliferative capacity compared to FGFR4 Gly/Gly385 
carrying MEFs as seen in Figure 24B. Further, we investigated the impact of the FGFR4 
Arg385 allele on senescence to determine if the FGFR4 Arg385 extends the life span of the 
cell and thereby facilitates  neoplastic transformation (Collado et al., 2007). To do that, we 
stained MEFs, subcultured for 30 days, for the expression of β-galactosidase to visualize 
senescent cells. As shown in Figure 24C FGFR4 Arg385 carrying MEFs do not display a 
prolonged life span or an obvious difference in the initiation of senescence neither by 
microscopic anaylsis nor by the quantification of the percentage of senescent cells between 
the FGFR4Gly385 and FGFR4 Arg385 alleles (Figure 24C).  
Migration of cancer cells contributes to accelerated tumor progression. As a motility 
enhancing effect of the FGFR4 Arg388 had already been shown by Bange and colleagues 
with the MDA-MB-231 human mammary carcinoma cell line model (Bange et al., 2002) we 
further investigated the influence of the FGFR4 Arg385 allele on the migratory capacity of 
normal MEFs. Therefore, we analyzed the migration in Boyden Chamber assays 
microscopically and quantified these results via ELISA analysis. In contrast to the results by 
Bange et al., no difference was observed when FGFR4 Gly/Gly385 were compared to 
FGFR4Arg/Arg385 MEFs in their migratory behaviour (Figure 24D).  
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Figure 24: The FGFR4 Arg385 allele does not promote a prolonged life span or migration in MEFs; A) 
Expression analysis of the FGFR4 in FGFR4 Gly/Gly385 (n=3), FGFR4 Gly/Arg385 (n=3) and FGFR4 
Arg/Arg385 (n=3) MEFs: expression and activation of the immunoprecipitated FGFR4 was detected via 
western blotting; MEFs carrying the FGFR4 Arg385 allele show no altered expression or activity of the 
FGFR4.  
B) Proliferation and life span in FGFR4 Gly/Gly385 (n=3), FGFR4 Gly/Arg385 (n=3) and FGFR4 
Arg/Arg385 (n=3) MEFs: cell number of seeded MEFs was monitored over time to calculate the population 
doubling rate; MEFs display no altered proliferation or a prolonged life span in the presence of the 
FGFR4 Arg385 allele;  
C) Senescence Assay in FGFR4 Gly/Gly385 (n=3) and FGFR4 Arg/Arg385 (n=3) MEFs: apparently 
senescent MEFs were stained for β-galactosidase expression and the amount of senescent cells were 
calculated and quantified microscopically (20x); MEFs display no altered occurrence of senescence in the 
presence of the FGFR4 Arg385 allele; 
D) Migration Assay in FGFR4 Gly/Gly385 (n=3) and FGFR4 Arg/Arg385 (n=3) MEFs; migratory capacity 
of MEFs to 4% FCS was analyzed in Boyden Chamber assays after 16 hours microscopically (20x) and 
quantified via ELISA analysis; MEFs display no altered migratory capacity in the presence of the FGFR4 
Arg385 allele;  
All data are shown as mean ± SDM. 
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The neoplastic transformation of cells can further be induced via mutations that accumulate 
within an unstable genome. Generally, primary cells undergo apoptosis due to mitotic crisis 
that is induced by genomic instability. If the cells overcome this mitotic crisis the aquired 
mutations can contribute to cancerous transformation (Hanahan and Weinberg, 2000; Jeggo, 
2005). Therefore, we analyzed the response of FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 MEFs to treatment with chemotherapeutic drugs that intercalate with 
DNA. In response to doxorubicin MEFs display a significantly reduced extent of apoptosis  
over 48 hours when they express the FGFR4 Arg385 allele as homo- or hetrocygotes 
(Gly/Arg-p=0.000008, Arg/Arg-p=0.000000001) (Figure 25A). These data suggest that the 
FGFR4 Arg385 protects the cell from through DNA-damage-induced apoptosis. Furthermore, 
we aimed to investigate the underlying mechanism of this effect. It is known, that oncogenic 
receptor tyrosine kinases can overcome apoptosis by more efficient DNA-repair (Skorski, 
2002). This accelerated repair results in a delay of the cell cycle phase G2 in response to 
DNA-damaging drugs. Therefore, we analyzed the cell cycle distribution of FGFR4 
Gly/Gly385, FGFR4 Gly/Arg385 and FGFR4 Arg/Arg385 MEFs upon treatment with 
doxorubicin for 24 hours. As shown in Figure 25B, MEFs homozygous for the FGFR4 
Arg385 allele display a significant increase in the percentage of cells in G2 after 24 hours of 
doxorubicin treatment compared to MEFs homozygous for the FGFR4 Gly385 allele 
(p=0.019). These data suggest that an accelerated DNA-repair mechanism keeps the cells in 
G2 to repair the occurred DNA-damage resulting in a lower percentage of apoptotic cells after 
48 hours. To analyze the effect of G2 delay and anti-apoptosis on the molecular level we 
determined the expression of several target genes involved in DNA-damage, apoptosis and 
survival after doxorubicin treatment over time in FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 
MEFs. As seen in Figure 25C, γH2AX, an indicator of DNA- damage and apoptosis is highly 
upregulated in FGFR4 Gly385 MEFs, indicating  more intense downstream signalling towards 
apoptosis as a result of  extended DNA-damage (Tanaka et al., 2006). Caspase-3 cleavage and 
the phosphorylation of the pro-apoptotic protein Bad do not differ between the FGFR4 
isotypes. The tumor suppressor Rb is upregulated in FGFR4 Gly385 expressing MEFs 
whereas the tumor suppressor p53 is downregulated. This may lead to a higher DNA repair 
response and to the observed G2 delay in FGFR4 Arg385 expressing MEFs. As the pro-
apoptotic proteins Caspase3 and Bad do not differ between the FGFR4 genotypes we 
analyzed typical pro-survival genes that may switch the balance towards survival in FGFR4 
Arg385 MEFs. The protein p-Akt that is known as a potent pro-survival signal is clearly 
upregulated in FGFR4 Arg385 expressing MEFs after doxorubicin treatment compared to 
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FGFR4 Gly385 expressing MEFs (Wang et al., 2008). In contrast, p-Erk is equally expressed 
between the isotypes. Further, the expression of the pro-survival genes BCL2 and BCLX are 
clearly upregulated in FGFR4 Arg385 MEFs, a further hint for increased cell survival, as 
these proteins are linked to the inhibition of anticancer-drug induced apoptosis via Akt (Lin et 
al., 2008; Woo et al., 2005). 
Similarly, the apoptotic response of FGFR4 Arg/Arg385 MEFs towards cisplatin, that also 
induces DNA-damage, is significantly reduced compared to FGFR4 Gly/Gly385 MEFs 
(p=0.0002).  In contrast, after 48 hours of treatment with taxol, which interferes with the 
organization of the mitotic spindle, MEFs do not alter their apoptotic response in the presence 
of the Arg385 allele (Figure 25D). 
In conclusion, the FGFR4 Arg385 allele seems to promote cell survival in response to DNA-
damage via two mechanisms. Firstly, FGFR4 Arg385 seems to support accelerated DNA-
repair and secondly contributes to the upregulation of typical pro-survival genes as a 
counterbalance of apoptotic downstream signaling (Skorski, 2002).  
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Figure 25: The FGFR4 Arg385 allele promotes cellular survival in MEFs; A) Cellular survival in FGFR4 
Gly/Gly385 (n=8), FGFR4 Gly/Arg385 (n=8) and FGFR4 Arg/Arg385 (n=8) carrying MEFs: MEFs were 
treated with 0.5 µM doxorubicin for 48 hours to induce cellular stress by DNA-damage; apoptosis was 
measured via FACS Analysis; MEFs display a significantly reduced number of apoptotic cells in the 
presence of the FGFR4 Arg385 allele in response to the treatment with doxorubicin (Gly/Arg-
p=0.0000008, Arg/Arg-p=0.000000001); 
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B) Cell cycle distribution in FGFR4 Gly/Gly385 (n=3), FGFR4 Gly/Arg385 (n=3) and FGFR4 Arg/Arg385 
(n=3) carrying MEFs: MEFs were treated with 0.5 µM doxorubicin for 24 hours to induce cellular stress 
by DNA-damage; cell cycle distribution was measured via FACS Analysis; MEFs homozygous for the 
FGFR4 Arg385 display a significantly increased number of cells in G2-phase in response to the treatment 
with doxorubicin; (Arg/Arg-p=0.019); 
C) Molecular mechanisms of the FGFR4 Gly/Gly385 (n=3) and FGFR4 Arg/Arg385 (n=3) carrying MEFs 
in response to doxorubicin treatment monitored over time: Expression of analyzed proteins was detected 
by Western Blotting. Actin served as a loading control and normalization value. MEFs homozygous for 
the FGFR4 Arg385 allele display an increased upregulation of pro-survival genes like p-Akt, BCL-XL and 
BCL-2 
D) Cellular survival in FGFR4 Gly/Gly385 (n=5) and FGFR4 Arg/Arg385 (n=5) carrying MEFs: MEFs 
were treated with 3 µM cisplatin and 0.5 µM taxol for 48 hours to induce cellular stress by DNA-damage; 
apoptosis was measured via FACS Analysis; MEFs display a significantly reduced number of apoptotic 
cells in the presence of the FGFR4 Arg385 allele in response to cisplatin treatment but not towards taxol; 
(Arg/Arg-p=0.0002);  
All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant 
 
4.2.2.3 Impact of FGFR4 Arg385 on proliferation, migration, invasion and 
apoptosis in transformed MEFs 
As the transformation of FGFR4 Arg385 MEFs with EGFR displays a unusally high 
efficiency in the focus formation assay compared to FGFR4 Gly/Gly385 MEFs we wanted to 
investigate the involvement of the FGFR4 Arg385 allele on several physiological processes 
after stable transformation with EGFR. As the migratory capacity of MEFs does not alter in 
the presence of the FGFR4 Arg385 allele in non-transformed MEFs, we further wanted to 
analyze if these processes are possibly influenced by the FGFR4 Arg385 allele in transformed 
cells. Therefore, we stably transformed FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 MEFs 
by the overexpression of EGFR. As a positive control we stably transformed MEFs through 
the overexpression of the oncogene v-src. As a negative control we stably expressed the 
pLXSN vector to calculate spontaneous transformation of MEFs. After selection with G418, 
EGFR and v-src were analyzed via western blotting and quantification to ensure equal 
expression in the infected MEFs. As shown in Figure 26A, EGFR and v-src are equally 
expressed. Additionally, FGFR4 expression was analyzed in transformed cells to investigate if 
the overexpression of EGFR or v-src has any impact on  FGFR4 expression. Interestingly, 
FGFR4 is upregulated in EGFR transformed cells and  in FGFR4 Arg/Arg385 MEFs. Above 
that, the phosphorylation status of the FGFR4 Arg385 MEFs is enhanced in MEFs 
transformed with EGFR indicating a higher activity of FGFR4 Arg385 compared to the 
Gly385 isotype. This finding could be an explanation for the unusually strong transformation 
rate in the focus formation assay of FGFR4 Arg/Arg385 MEFs infected with EGFR. 
Moreover, the upregulation of the FGFR4 is a further indication of a so far unknown crosstalk 
between these two receptors. We further investigated if this upregulation of the FGFR4 
Arg/Arg385 compared to FGFR4 Gly/Gly385 in MEFs transformed with EGFR influences 
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cellular processes including proliferation, migration, invasion or survival. Furthermore, we 
aimed to show if these processes are possibly not influenced by the FGFR4 Arg/Arg385 in v-
src transformed cells as there was no upregulation of the FGFR4 expression detectable in the 
Western Blot compared to MEFs transformed with EGFR.  First, we analyzed the influence 
on proliferation by monitoring the cell number over time and calculating the population 
doubling rate of MEFs. As shown in Figure 26B MEFs transformed with EGFR display no 
proliferative advantage in the presence of the FGFR4 Arg385 allele. Likewise, MEFs 
transformed with v-scr are not altered in their proliferation rate depending on their FGFR4 
genotype. Similarily, the non-transformed MEFs stably expressing the empty pLXSN also do 
not display changes in proliferation behaviour. As primary MEFs display an anti-apoptotic 
effect in response to the DNA-damaging agents doxorubicin and cisplatin in the presence of 
the FGFR4 Arg385 allele, we wanted to reproduce these results in MEFs transformed by 
EGFR or v-src. Figure 26C displays the percentage of apoptotic cells determined by FACS 
analysis after treatment with 0.5µM doxorubicin, 3µM cisplatin and 0.5µM taxol after 48 
hours. MEFs transformed with EGFR display a significant decrease in apoptosis in the 
presense of the FGFR4 Arg385 allele in response to the DNA-damaging agents doxorubicin 
and cisplatin (cisplatin-p=0.021; doxorubicin-p=0.0000046). No difference was apparent for 
the response to taxol. In MEFs transformed with v-src neither the chemotherapeutic drugs nor 
the FGFR4 isotypes result in an alteration of the anti-apoptotic response. The non-
transformed MEFs expressing the empty pLXSN displayed the same significant results as the 
primary MEFs in their response to doxorubicin, cisplatin and taxol after 48 hours (cisplatin-
p=0.0000039; doxorubicin-p=0.016).  
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Figure 26: A) Western blot analysis of transformed FGFR4 Gly/Gly385 (n=3) and FGFR4 Arg/Arg385 
(n=3) MEFs: EGFR and v-src are not upregulated in control MEFs infected with empty pLXSN; v-src is 
overexpressed in MEFs infected with pLXSN-vsrc; EGFR is overexpressed in MEFs infected with 
pLXSN-EGFR; actin served as a loading control and normalization value for quantification; FGFR4 
Arg385 expression and activation is upregulated in MEFs transformed with EGFR. 
B) Proliferation Assay of transformed FGFR4 Gly/Gly385 (n=5) and FGFR4 Arg/Arg385 (n=5) MEFs: cell 
number of seeded MEFs was monitored over time to calculate the population doubling rate; the presence 
of the FGFR4 Arg385 allele does not influence the proliferation neither in control MEFs (empty pLXSN) 
nor in MEFs transformed with v-src or EGFR; 
C) Apoptosis in transformed FGFR4 Gly/Gly385 (n=5) and FGFR4 Arg/Arg385 (n=5) MEFs: MEFs were 
treated with 0.5 µM doxorubicin, 3µM Cisplatin or 0.5 µM Taxol for 48 hours; amount of apoptotic cells 
was calculated via FACS analysis; MEFs transformed with EGFR and homozygous for the FGFR4 
Arg/Arg385 allele display a significantly decreased number of apoptotic cells compared to FGFR4 
Gly/Gly385 MEFs in response to doxorubicin or cisplatin treatment (cisplatin-p=0.021, doxorubicin-
p=0.0000046); in response to taxol treatment the presence of the FGFR4 Arg/Arg385 allele does not 
influence the apoptotic response in MEFs transformed with EGFR; MEFs transformed with v-src and 
homozygous for the FGFR4 Arg/Arg385 allele do not display a decreased number of apoptotic cells in 
response to doxorubicin, cisplatin or taxol treatment compared to FGFR4 Gly/Gly385 MEFs; control 
MEFs expressing the empty pLXSN and homozygous for the FGFR4 Arg/Arg385 allele display a 
significantly decreased number of apoptotic cells compared to FGFR4 Gly/Gly385 MEFs in response to 
doxorubicin or cisplatin treatment (cisplatin-p=0.0000039, doxorubicin-p=0.016) but not towards taxol; 
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All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant 
 
Next we analyzed the differences in cell motility in dependence of FGFR4 genotype. 
Therefore we analyzed the migration of FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 MEFs 
transformed with EGFR and v-src or stably expressing the empty pLXSN vector in a Boyden 
chamber assay to 4% FCS for 16 hours. Migration was analyzed microscopically after crystal 
violet staining and quantified via ELISA analysis. In contrast to non-transformed MEFs, 
FGFR4 Arg/Arg385 (n=3) MEFs transformed with EGFR display a significantly (p=0.005) 
increased migratory capacity compared to FGFR4 Gly/Gly385 MEFs (Figure 27A). This 
significant difference was not apparent in MEFs transformed with v-src or non-transformed 
MEFs stably expressing the pLXSN vector. These data indicate, that FGFR4 Arg/Arg385 
influences migration only in transformed cells and that the involvement of the FGFR4 seems 
to be dependent on the oncogenetic background. This increased motility of FGFR4 
Arg/Arg385 expressing MEFs transformed with EGFR seems to be one of the contributing 
factors of accelerated focus formation. Next to migration and the loss of contact inhibition that 
contributes to tumor progression, cancer cells aquire the ability to survive without anchorage. 
This anchorage independent ability to grow in combination with enhanced motility and 
invasivity allows cancer cells to metastasize thereby making tumors more aggressive. To 
analyze if MEFs transformed with EGFR or v-src display a more aggressive phenotype in the 
presence of the FGFR4 Arg385 allele we performed a soft agar assay to investigate the impact 
of the FGFR4 Arg385 on anchorage independent growth in FGFR4 Gly/Gly385 and FGFR4 
Arg/Arg385 MEFs transformed with EGFR or v-src. Soft Agar colony formation was 
analyzed and quantified by counting formed colonies. As shown in Figure 27B MEFs 
transformed with EGFR display a significantly enhanced anchorage independent growth after 
24 and 96 hours if they express the FGFR4 Arg/Arg385 (24h-p:0.00004; 48h-p:0.00003). In 
contrast, no alterations were apparent between FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 
MEFs after 96 hours transformed by v-src. The negative control of non-transformed MEFs 
expressing the empty pLXSN vector was not able to grow anchorage independently. These 
data demonstrate that the FGFR4 Arg/Arg385 is implicated in the process of anchorage 
independent growth and likewise with migration dependent on the oncogenic background.  
For successful metastasis, cancer cells aquire the ability to degrade the extracellular matrix 
surrounding them to spread and invade the surrounding tissue. To determine this activity and 
the influence of FGFR4 isotypes on oncogene-primed MEFs we performed a Matrigel assay 
to analyze invasivity and branching of FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 MEFs 
transformed by EGFR or v-src. As shown in Figure 27C MEFs transformed with EGFR 
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display  significantly enhanced branching in Matrigel after 24 and 96 hours if they express the 
FGFR4 Arg/Arg385 isotype (96h-p:0.0009). In contrast, no alterations were apparent between 
FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 MEFs after 96 hours transformed by v-src. The 
negative control of non-transformed MEFs expressing the empty pLXSN vector was not able 
to branch in Matrigel. These data demonstrate that the FGFR4 Arg/Arg385 is clearly 
implicated in the invasive process of branching in Matrigel and likewise in cell motility and 
soft agar colony formation dependent on the oncogenic background.  
These results demonstrate that in MEFs, FGFR4 Arg385 significantly influences 
physiological processes including motility, invasivity and survival that all contribute to tumor 
progression. These processes are distinct from those affected by FGFR4 Gly385 and, 
furthermore, the impact of the FGFR4 Arg385 is in dependence on the genetic background 
that confers cell transformation in vitro. 
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Figure 27: The FGFR4 Arg385 allele promotes migration, soft agar colony formation and invasion in 
EGFR-transformed MEFs; A) Migration assay of stably transformed FGFR4 Gly/Gly385 (n=3), and 
FGFR4 Arg/Arg385 (n=3) MEFs: Migratory capacity was analyzed microscopically after crystal violet 
staining (20x) and quantified via ELISA analyis. MEFs transformed with EGFR and  homozygous for the 
FGFR4 Arg385 allele display a significantly (p=0.0005) increased migratory capacity to 4% FCS in a 
boyden chamber assay after 16h compared to MEFs homozygous for the FGFR4 Gly385 allele; MEFs 
transformed with v-src displayed no difference in their migratory capacity regarding their FGFR4 allele. 
MEFs stably expressing the empty pLXSN-vector served as a negative control. 
B) Soft Agar Assay of stably transformed FGFR4 Gly/Gly385 (n=3), and FGFR4 Arg/Arg385 (n=3) MEFs: 
Anchorage independent growth was analyzed and quantified microscopically (20x) after the indicated 
time points. MEFs transformed with EGFR and  homozygous for the FGFR4 Arg385 allele display a 
significantly increased capacity of anchorage independent growth in Soft Agar after 24-96h compared to 
MEFs homozygous for the FGFR4 Gly385 allele (24h-p=0.00004; 96h-p=0.00003); MEFs stably expressing 
the empty pLXSN-vector served as a negative control. MEFs transformed with v-src displayed no 
difference in their capacity to proliferate anchorage independent regarding their FGFR4 allele. 
C) Invasion Assay in Matrigel of stably transformed FGFR4 Gly/Gly385 (n=3) and FGFR4 Arg/Arg385 
(n=3) MEFs: branching in Matrigel was analyzed and quantified microscopically (20x) after the indicated 
time points; MEFs transformed with EGFR and homozygous for the FGFR4 Arg385 display a 
significantly increased invasion in Matrigel after 96h compared to MEFs homozygous for the FGFR4 
Gly385 allele (p=0.00009); MEFs stably expressing the empty pLXSN-vector served as a negative control. 
MEFs transformed with v-src displayed no difference in their capacity to branch in Matrigel regarding 
their FGFR4 allele. 
All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant 
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To further analyze the underlying mechanism of accelerated MEF migration, soft agar colony 
formation and invasion, the expression of several genes associated with tumor progression, 
aggressiveness and invasiveness of transformed cells was investigated.  For that purpose, the 
mRNA levels of these proteins were measured in MEFs transformed with EGFR carrying the 
FGFR4 Gly385 or Arg385 allele. As seen in Figure 28 the cluster of tumor suppressors 
displays no dectectable difference in regard of the FGFR4 isotypes. Regarding cell cycle and 
proliferation markers, the expression of the cell cycle dependent kinases (CDK) 1, 2 and 4 
were measured. As the FGFR4 is known to have weak mitogenic activity, no diffenrence 
between FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 expressing MEFs was expected. In 
contrast, there was a significantly higher expression of CDK1 in FGFR4 Arg/Arg385 
expressing MEFs transformed with EGFR (p=0.0091). As CDK1 is strongly associated with 
migration, this significant overexpression seems to promote the increased migration of the 
transformed MEFs resulting in a more aggressive phenotype of FGFR4 Arg/Arg385 carrying 
MEFs transformed with EGFR (Manes et al., 2003). In the cluster of proteins that are 
associated with invasion,  MMP13 as well as MMP14 were found to be overexpressed in 
FGFR4 Arg/Arg385 carrying MEFs transformed with EGFR, likely contributing to a higher 
metastatic potential (MMP13-p=0.002;MMP14-p=0.004)(Ellsworth et al., 2008; Jiang et al., 
2006; Rizki et al., 2008). Next to MMPs, N-cadherin was highly overexpressed in MEFs 
carrying the FGFR4 Arg385 isotype indicating a higher potential of migration and invasion 
(Lafleur et al., 2005; Nagi et al., 2005; Su et al., 2008). This data reflect the results derived 
from the physiological experiments presented in Figure 27 and suggests a more aggressive 
and invasive phenotype of MEFs carrying the FGFR4 Arg385 allele when transformed with 
the EGFR oncogene. 
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Figure 28: Expression Analysis of MEFs carrying the FGFR4 Gly385 (n=3) or Arg385 (n=3) allele 
transformed with EGFR: target gene expression was analyzed via semiquantitative RT-PCR; GAPDH 
served as housekeeping gene for normalization; expression values of FGFR4 Arg/Arg385 MEFs are blotted 
relatively to the expression values of FGFR4 Gly/Gly385 MEFs and grouped regarding their physiological 
function; N-cadherin (p=0.001), MMP13 (p=0.002) and MMP14 (p=0.004) are significantly upregulated in 
the presence of the FGFR4 Arg/Arg385 allele suggesting a more aggressive phenotype; all data are shown 
as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 0.03 were considered 
statistically significant 
 
4.2.3 The impact of the FGFR4 and its variant Arg385 on tumor 
progression in vivo 
4.2.3.1 The FGFR4 Arg385 allele promotes tumor mass and size of WAP-TGFα 
but not MMTV -PymT derived tumors 
The in vitro experiments with primary and transformed MEFs demonstrate the impact of the 
FGFR4 Arg385 on cell biological properties that are relevant to tumor progression  namely 
survival, motility, anchorage independence and invasivity in Matrigel. Furthermore, the 
impact of the FGFR4 Arg385 allele seems to be dependent on the oncogenic background. To 
ultimately clarify the influence of the FGFR4 Arg385 on accelerated tumor progression and 
aggressiveness we investigated the impact of the Arg385 isotype on tumor progression in a 
mouse breast cancer model in vivo. As the FGFR4 is known to be upregulated in breast cancer 
and furthermore the FGFR4 Arg385 allele is known to promote progression of mammary 
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carcinoma in humans we wanted to investigate the impact of this allele on mammary cancer 
progression in a clean background-free cancer model system. Similar to the experiments in 
vitro we wanted to analyze the involvement of the FGFR4 Arg385 on tumor progression in 
combination with the well established WAP-TGFα and the MMTV-PyMT transgenes. In the 
WAP-TGFα mouse tumor model, mammary carcinoma is induced by the overexpression of 
TGFα resulting in the hyperactivation of the EGFR (Sandgren et al., 1995). In the MMTV-
PyMT mouse mammary carcinoma model, neoplastic transformation of the mammary gland is 
initiated by the overexpression of the Polyoma Middle T resulting in hyperactive, oncogenic 
src (Guy et al., 1992).  
Therefore, we crossed the FGFR4 Arg385 KI mice to oncomice either transgenic for WAP-
TGFα or MMTV-PymT in the C57BL/6 background. To ensure normal lactation of female 
mice, the transgene was only inherited by males. To distinguish the different FGFR4 alleles, 
the genotyping was done by PCR-RFLP by the aforementioned restriction site (Figure 29A). 
To confirm the presence of the transgenes in the progeny we performed genotyping with 
specific primers for TGFα or PymT (Figure 29B). 
 
 
Figure 29: A) Genotyping of FGFR4 Arg385 KI mice: amplification product was cut by MvaI to obtain 
specific banding to distinguish the FGFR4 alleles 
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B) Conformation of the WAP-TGFα and MMTV-PymT transgen and crossing scheme of FGFR4 Arg385 
KI mice and oncomice transgenic for WAP-TGFα or MMTV-PyMT: the WAP-TGFα and the MMTV-
PyMT transgen were only inherited by males to ensure normal lactation of the females. 
 
To investigate the impact of the FGFR4 Arg385 on tumor progression in the WAP-TGFα 
model we analyzed the tumors of 6 month old female FGFR4 Gly/Gly385, FGFR4 
Gly/Arg385 and FGFR4 Arg/Arg385 mice. The analyzed criteria for tumor progression are the 
mass, area and the percentage of mass and area of the analyzed tumors. As shown in Figure 
30A the tumor mass is significantly increased in mice homozygous for the FGFR4 Arg385 
allele and transgenic for WAP-TGFα  when compared to FGFR4 Gly385 controls (Arg/Arg-
p=0.01). Figure 30B shows the percentage of tumor mass that is significantly increased in 
FGFR4 Arg385 carrying mice transgenic for WAP-TGFα (Gly/Arg-p=0.004; Arg/Arg-
p=0.0004). Furthermore, the tumor area is significantly increased in WAP-TGFα transgenic 
mice in the presence of the FGFR4 Arg385 allele when compared to FGFR4 Gly385 control 
mice (Figure 30C)(Gly/Arg-p=0.006; Arg/Arg-p=0.0005). Just as the percentage of tumor 
mass, the percentage of tumor area is significantly increased in FGFR4 Arg385 carrying mice 
transgenic for WAP-TGFα (Gly/Arg-p=0.000000006; Arg/Arg-p=0.000000001) (Figure 
30D). These results indicate that the FGFR4 Arg385 allele is a potent enhancer of WAP-
TGFα−induced mammary tumors in mass and area. Furthermore, the higher significance in 
the percentages of tumors and the area of tumors suggest that the FGFR4 Arg385 is not an 
enhancer of cancer cell proliferation, but seems to accelerate processes like migration 
resulting in the increase of the invaded area in the mammary gland. Moreover, the more 
significant increase in tumor area may result from a facilitated neoplastic transformation rate 
in FGFR4 Arg385 carrying mice transgenic for WAP-TGFα. These results are in line with the 
in vitro experiments with transformed MEFs.  
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Figure 30: The FGFR4 Arg385 allele significantly progresses WAP-TGFα induced tumors; In Figure 3 (A-
D) every data point represents the values of one female mouse transgenic for WAP-TGFα carrying the 
FGFR4 Gly/Gly385 (n=8) FGFR4 Gly/Arg385 (n=8) or FGFR4 Arg/Arg385 (n=8) allele: Mice were 
sacrificed after 6 month of tumor progression. The values of the investigated tumors were normalized on 
body weight and plotted against the different investigated FGFR4 genotypes; all data are shown as mean ± 
SDM; all p-values were calculated using the students T-test and values ≤ 0.03 were considered statistically 
significant. 
(A) Analysis of the normalized tumor mass of the sacrificed mice transgenic for WAP-TGFα regarding 
their FGFR4 genotype: Mice homozygous for the FGFR4 Arg385 allele display a significantly increased 
tumor mass after 6 month of tumor progression compared to mice homozygous for the FGFR4 Gly385 
allele (Arg/Arg-p=0.01). 
(B) Analysis of the percentage of tumor mass proportional to mammary gland tissue of the sacrificed mice 
transgenic for WAP-TGFα regarding their FGFR4 genotype: Mice display a significantly increased 
percentage of tumor mass after 6 month of tumor progression in the presence of the FGFR4 Arg385 allele 
compared to mice homozygous for the FGFR4 Gly385 allele (Gly/Arg-p=0.004; Arg/Arg-p=0.0001) 
(C) Analysis of the normalized tumor area of the sacrificed mice transgenic for WAP-TGFα regarding 
their FGFR4 genotype: Mice display a significantly increased tumor mass after 6 month of tumor 
progression in the presence of the FGFR4 Arg385 allele compared to mice homozygous for the FGFR4 
Gly385 allele (Gly/Arg-p=0.006, Arg/Arg-p=0.00005). 
(D)  Analysis of the percentage of tumor area proportional to mammary gland tissue of the sacrificed mice 
transgenic for WAP-TGFα regarding their FGFR4 genotype: Mice display a significantly increased 
percentage of tumor mass after 6 month of tumor progression in the presence of the FGFR4 Arg385 allele 
compared to mice homozygous for the FGFR4 Gly385 allele (Gly/Arg-p=0.000000006, Arg/Arg-
p=0.000000001). 
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Furthermore, the potent tumor enhancing impact of the FGFR4 Arg385 allele is apparent 
when comparing an FGFR4 Arg/Arg385 carrying mouse to a Gly/Gly385 control transgenic 
for WAP-TGFα sacrificed after 8 month of tumor progression (Figure 31). Mice transgenic for 
WAP-TGFα display more as well as larger tumors in the presence of the FGFR4 Arg385 
allele as indicated by the white arrows. 
 
 
Figure 31: Tumor progression in mice transgenic for WAP-TGFα sacrificed after 8 month: As indicated 
by the white arrows, mice homozygous for the FGFR4 Arg385 allele display a visibly increased tumor 
progression after 8 month compared to mice homozygous for the FGFR4 Gly385 allele 
 
In addition to the WAP-TGFα mouse model, we also investigated the tumor promoting 
impact of the FGFR4 Arg385 allele in the MMTV-PymT mouse mammary carcinoma model. 
Because of the in vitro results in MEFs transformed with v-src we investigated whether in this 
model the tumor promoting action of the FGFR4 Arg385 allele is just like in vitro not 
apparent in vivo, to further confirm that the tumor enhancing effect of the FGFR4 Arg385 is 
dependent on the oncogene background. 
We analyzed the tumors of 3 month old female FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 mice. The measured criteria for tumor progression are the mass and area 
of the analyzed tumors. As seen in Figure 32A and B there is neither a significant difference 
in tumor mass nor in tumor size between FGFR4 Gly/ Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 mice transgenic for MMTV-PymT. Thus, the tumor promoting effect of 
the FGFR4 Arg385 allele is dependent on the genetic background, which triggers 
oncogenesis. 
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Figure 32: The FGFR4 Arg385 allele does not promote MMTV-PymT induced mammary tumors: A) 
Analysis of tumor size in 3 month old FGFR4 Gly/Gly385 (n=8), FGFR4 Gly/Arg385 (n=13) and FGFR4 
Arg/Arg385 (n=11) mice transgenic for MMTV-PyMT: Mice carrying the FGFR4 Arg385 allele display no 
difference in the size of tumors compared to mice homozygous for the FGFR4 Gly385 allele; B) Analysis of 
tumor mass in 3 month old FGFR4 Gly/Gly385 (n=8), FGFR4 Gly/Arg385 (n=13) and FGFR4 Arg/Arg385 
(n=11) mice transgenic for MMTV-PyMT: Mice carrying the FGFR4 Arg385 allele display no difference in 
the mass of tumors compared to mice homozygous for the FGFR4 Gly385 allele; all data are shown as 
mean ± SDM; all p-values were calculated using the students T-test and values ≤ 0.03 were considered 
statistically significant. 
 
The analyzed control mammary glands of FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 mice without an oncogenic background do not alter in their mass, size or 
pathology as seen in Figure 33A and B. These data demonstrate that the FGFR4 Arg385 KI 
has no influence on the pathohistology of a non-malignant mammary gland. 
 
Figure 33: The FGFR4 Arg385 allele has no influence on non-malignant mammary glands; (A) Analysis of 
mammary gland mass in FGFR4 Gly/Gly385 (n=12), FGFR4 Gly/Arg385 (n=17) and FGFR4 Arg/Arg385 
(n=13) mice. Mice carrying the FGFR4 Arg385 allele display no difference in the mass of mammary glands 
compared to mice homozygous for the FGFR4 Gly385 allele. 
(B) Analysis of mammary gland size in FGFR4 Gly/Gly385 (n=12), FGFR4 Gly/Arg385 (n=16) and FGFR4 
Arg/Arg385 (n=12). Mice carrying the FGFR4 Arg385 allele display no difference in the mass of mammary 
glands compared to mice homozygous for the FGFR4 Gly385 allele; all data are shown as mean ± SDM. 
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4.2.3.2 The impact of FGFR4 Arg385 on tumor mass and size of WAP-
TGFα derived tumors over time 
To further analyze the tumor promoting effect of FGFR4 Arg385 in the WAP-TGFα model 
we followed tumor progression of WAP-TGFα induced mammary carcinoma over time by 
sacrificing the female mice at defined periods during tumor progression.  
We first checked the visible time point of tumor incidence to investigate if the FGFR4 Arg385 
allele facilitates the onset of neoplastic transformation and thereby decreases the time point of 
tumor incidence. Therefore, we monitored and analyzed the visible time point of tumor 
incidence in FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and FGFR4 Arg/Arg385 mice 
transgenic for WAP-TGFα. As shown in Figure 34A the visible time point of tumor incidence 
is significantly decreased in mice carrying the FGFR4 Arg385 allele (p=0.001). To ensure that 
these data are independent of the genetic background, we backcrossed the WAP-TGFα 
oncomice and the FGFR4 Arg385 KI mice at least five times to the FVB background. Here, 
we also analyzed the visible tumor incidence in FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 mice transgenic for WAP-TGFα. Like in the C57BL/6 background, the 
visible tumor incidence is significantly decreased in mice carrying the FGFR4 Arg385 allele 
(p=0.002) (Figure 34B). 
 
Figure 34: FGFR4 Arg385 decreases visble time point of tumor onset: (A) Time point of visible tumor 
incidence in FGFR4 Gly385 (n=10) and FGFR4 Arg385 (n=10) mice transgenic for WAP-TGFα:  in the 
C57BL/6 background tumors occurr significantly earlier in the presence of the FGFR4 Arg385 allele 
(p=0.001). 
B) Time point of visible tumor incidence in FGFR4 Gly385 (n=8) and FGFR4 Arg385 (n=8) mice 
transgenic for WAP-TGFα in the FVB background: tumors occur significantly earlier in the presence of 
the FGFR4 Arg385 allele (p=0.002). 
All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant. 
 
 
Results 
 90 
 
In the C57BL/6 background we further investigated the tumor progression over time. 
Therefore, we analyzed the tumors at the indicated time points in FGFR4 Gly/Gly385, FGFR4 
Gly/Arg385 and FGFR4 Arg/Arg385 mice transgenic for WAP-TGFα. The analyzed criteria 
for tumor progression were the number of tumors, the mass, area and the percentage of mass 
and area of the dissected tumors. Figure 35A displays the increasing amount of tumors 
induced by WAP-TGFα. Here, mice homozygous for the FGFR4 Arg385 allele just partly 
establish a significant larger amount of tumors at very late points of tumor progression (8 
month Arg/Arg-p=0.0002). However, FGFR4 Arg385 carrying mice seem to induce a larger 
amount of tumors simultaneously, but importantly, increase their number of tumors over time 
faster than FGFR4 Gly/Gly385 mice transgenic for WAP-TGFα . In Figure 35B the 
progression of tumor mass is shown. Here, mice homozygous for the FGFR4 Arg385 allele 
just partly establish a significant higher tumor mass at very early time points (4 month 
Arg/Arg-p=0.00002). Nevertheless, the FGFR4 Arg385 allele seems to clearly progress tumor 
mass over time. In contrast, the percentage of tumor mass is significantly increased in FGFR4 
Arg/Arg385 mice (4 month Arg/Arg-p=0.0008; 5 month Arg/Arg-p=0.005; 6 month Arg/Arg-
p=0.003) (Figure 35C). Contrarily to the tumor mass, the tumor area, as shown in Figure 35D, 
is mostly significantly increased in FGFR4 Arg/Arg385 mice (4 month Arg/Arg-p=0.000005; 
5 month Arg/Arg-p=0.009; 6 month Arg/Arg-p=0.007). The most significant difference 
between FGFR4 Arg385 and FGFR4 Gly385 carrying mice is shown in the percentage of 
tumor area (Figure 35E). Here, mice heterozygous for the FGFR4 Arg385 allele partly display 
a significant increase (5month Gly/Arg-p=0.0004) and mice homozygous for the FGFR4 
Arg385 display a significant increase in the percentage of tumor mass at all analyzed time 
points (4 month Arg/Arg-p=0.00008; 5 month Arg/Arg-p=0.003; 6 month Arg/Arg-
p=0.00000003; 8 month Arg/Arg-p=0.0003)  
These data further indicate the earlier onset of neoplastic transformation by the FGFR4 
Arg385 allele. The highly significant differences in tumor area and the percentage of tumor 
area further suggest once again, that the impact of the FGFR4 Arg385 is not on proliferation 
but rather the motility of cancer cells and their invasion of the surrounding tissue. In 
summary, the FGFR4 Arg385 allele promotes breast tumor progression over time in number, 
mass and size of the occurring tumors and seems to facilitate the initiation of oncogenesis and 
thereby advances the time point of tumor onset.  
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Figure 35: The FGFR4 Arg385 allele promotes WAP-TGFα induced mammary tumors over time; A) 
Progression of tumor number in FGFR4 Gly/Gly385 (n≥3), FGFR4 Gly/Arg385 (n≥3) and FGFR4 
Arg/Arg385 (n≥3) mice transgenic for WAP-TGFα: Mice homozygous for FGFR4 Arg385 partly establish a 
significantly higher number of tumors over time ( 8month Arg/Arg-p=0.0002). 
B) Progression of tumor mass in FGFR4 Gly/Gly385 (n≥3), FGFR4 Gly/Arg385 (n≥3) and FGFR4 
Arg/Arg385 (n≥3) mice transgenic for WAP-TGFα: mice homozygous for FGFR4 Arg385 partly display a 
significant increase of tumor mass over time (4month Arg/Arg-p=0.00002). 
C) Progression of percentage of tumor mass in FGFR4 Gly/Gly385 (n≥3), FGFR4 Gly/Arg385 (n≥3) and 
FGFR4 Arg/Arg385 (n≥3) mice transgenic for WAP-TGFα proportional to mammary gland tissue: mice 
homozygous for FGFR4 Arg385 partly display a significant increase in the percentage of tumor mass over 
time (4month Arg/Arg-p=0.0008, 5month Arg/Arg-p=0.005, 6month Arg/Arg-p=0.003).  
D) Progression of tumor area in FGFR4 Gly/Gly385 (n≥3), FGFR4 Gly/Arg385 (n≥3) and FGFR4 
Arg/Arg385 (n≥3) mice transgenic for WAP-TGFα: mice homozygous for FGFR4 Arg385 partly display a 
significantly increase in the tumor area over time (4month Arg/Arg-p=0.000005, 5month Arg/Arg-
p=0.009, 6month Arg/Arg-p=0.007).  
E) Progression of percentage of tumor area in FGFR4 Gly/Gly385 (n≥3), FGFR4 Gly/Arg385 (n≥3) and 
FGFR4 Arg/Arg385 (n≥3) mice transgenic for WAP-TGFα proportional to mammary gland tissue: mice 
homozygous and heterozygous for FGFR4 Arg385 partly display a significant increase in the percentage of 
tumor area over time (5month Gly/Arg-p=0.0004, 4month Arg/Arg-p=0.00008, 5month Arg/Arg-p=0.003, 
6month Arg/Arg-p=0.00000003, 8month Arg/Arg-p=0.0003).  
All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant. 
 
4.2.3.3 Molecular characterisation of WAP-TGFα derived tumors with different 
FGFR4 genotypes 
To further investigate the underlying mechanism of the tumor promoting effect of the FGFR4 
Arg385 allele, we studied molecular differences of the FGFR4 alleles. In many human cancers 
overexpression of the FGFR4 is a commonly observed feature of tumors (Ezzat et al., 2002; 
Gowardhan et al., 2005; Jaakkola et al., 1993; Jeffers et al., 2002). Therefore, we examined 
FGFR4 expression in WAP-TGFα-derived 6 month old tumors from FGFR4 Gly/Gly385, 
FGFR4 Gly/Arg385 and FGFR4 Arg/Arg385 mice by immunoprecipitation and quantified the 
expression. Here, the FGFR4 protein is clearly overexpressed in tumors compared to 
mammary gland without an oncogenic background; however, there was no detectable 
difference in FGFR4Arg385 expressing tissue  (Figure 36A).  
Furthermore, we analyzed the constitutive phosphorylation status of WAP-TGFα-derived 
tumors from 6 month old FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and FGFR4 Arg/Arg385 
mice by immunoprecipitation. As shown in Figure 36B, FGFR4 Arg/Arg385 displays a 
significantly enhanced phosphorylation and thereby a higher activation state than FGFR4 
Gly/Gly385 or FGFR4 Gly/Arg385 (p=0.012). This result indicates a possible hint for the 
tumor promoting potential of the FGFR4 Arg385 allele to influence the kinase activity and 
thereby leading to a tumor promoting effect. Because of the higher phosphorylation of the 
FGFR4 Arg/Arg385, we determined the expression and activation of p-Erk and p-Akt to 
analyze if the higher phosphorylation of the FGFR4 Arg/Arg385 results in a higher activation 
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of typical downstream molecules. However, the quantification of p-Erk and p-Akt of WAP-
TGFα-derived 6 month old tumors from FGFR4 Gly/Gly385, FGFR4 Gly/Arg385 and 
FGFR4 Arg/Arg385 mice does not display significant differences with respect to different 
FGFR4 genotypes (Figure 36B). We further checked the expression levels of the FGFR4 of 
WAP-TGFα-derived 3 month old hyperplasic mammary glands and 6 month old 
adenocarcinomas from FGFR4 Gly/Gly385 and FGFR4 Arg/Arg385 mice 
immunohistochemically. Interestingly, the expression of the FGFR4 in Arg/Arg385 
hyperplasias is clearly increased compared to hyperplasias in FGFR4 Gly/Gly385 mice 
transgenic for WAP-TGFα (Figure 36C). Similar to the Western Blot analysis the expression 
of the FGFR4 in adenocarcinomas does not alter in the presence of the FGFR4 Arg385 
(Figure 36D). This result indicates that the expression of the FGFR4 Arg/Arg385 in mammary 
oncogenesis is accelerated with an earlier onset that could result in enhanced tumor 
progression.  
Next to the analysis of the FGFR4 expression in primary tumors, we wanted to investigate the 
expression of genes associated with aggressive breast cancer. We primarily analyzed genes 
that are involved in migration, invasion and angiogenesis in 6 month old tumors from FGFR4 
Gly/Gly385 and FGFR4 Arg/Arg385 mice transgenic for WAP-TGFα. As seen in Figure 36 E 
genes related to tumor suppression, cell cycle, angiogenesis and Matrix-Metalloproteases 
(MMPs) were investigated. Here, the expression in FGFR4 Gly/Gly385 expressing WAP-
TGFα-induced tumors was set on 100% and the expression in FGFR4 Arg/Arg385 expressing 
WAP-TGFα-induced tumors was determined relative to this expression. 
First, we analyzed the expression of the FGFR4 and EGFR to exclude that the tumor 
progressive impact is a result of the overexpression of the FGFR4 Arg385 or the EGFR and to 
ensure, that these two proteins are equally expressed among the investigated mice. As seen in 
Figure 36E both, the FGFR4 and the EGFR display no overexpression in the presence of the 
FGFR4 Arg385 allele on the mRNA level. In the set of analyzed tumor suppressors, the only 
significant alteration was measured for p21, which is significantly downregulated in FGFR4 
Arg/Arg385 expressing WAP-TGFα-induced tumors (p=0.03). This tumor suppressor is 
known to predict the poorest prognosis if its downregulated together with high EGFR 
expression (Somlo et al., 2008). Regarding cell cycle and proliferation markers, the 
expression of the cell cycle dependent kinases (CDK) 1, 2 and 4 and Cyclin B was measured. 
As FGFR4 is known to have a weak mitogenic activity, no diffenrence between FGFR4 
Gly/Gly385 or FGFR4 Arg/Arg385 expressing tumours was expected. In contrast, there was a 
significantly higher expression of CDK1 in FGFR4 Arg/Arg385 expressing tumours 
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(p=0.0091). As CDK1 is strongly associated with migration, this significant overexpression 
seems to not promote higher proliferation but an increase in migratory action of the tumor 
cells resulting in a more aggressive phenotype of FGFR4 Arg/Arg385 carrying tumours 
(Manes et al., 2003). In the group of invasion, the expression of proteins associated with 
metastasis and angiogenesis were analyzed. Here, CD44 and flk-1 are significantly 
overexpressed in FGFR4 Arg/Arg385 tumors (CD44-p=0.02; flk-1-p=0.02). The impact of 
CD44 on invasion is still controversial, however, its metastasis-promoting impact is widely 
accepted (Godar et al., 2008; Mylona et al., 2008; Sheridan et al., 2006). Next to CD44 also 
flk-1 is significanctly overexpressed in FGFR4 Arg/Arg385 expressing tumors. This indicates 
a more aggressive potential of FGFR4 Arg/Arg385 tumours as flk-1 promotos angiogenesis 
leading to a more aggressive behaviour of the tumor and its metastatic capacity (Liang and 
Hyder, 2005). In the cluster of MMPs, MMP13 as well as MMP14 are overexpressed in 
FGFR4 Arg/Arg385 contributing to a higher metastatic potential (MMP13-p=0.021;MMP14-
p=0.02)(Ellsworth et al., 2008; Jiang et al., 2006; Rizki et al., 2008).  
These data are in line with the data obtained from expression analysis in EGFR-transformed 
MEFs and strongly suggest a more aggressive behaviour of WAP-TGFα induced tumors 
expressing the FGFR4 Arg/Arg385 resulting in increased tumor progression.  
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Figure 36: Molecular characterisation of WAP-TGFα derived tumors regarding the FGFR4 isotypes A) 
Analysis of FGFR4 expression in FGFR4 Gly/Gly385 (n=3), FGFR4 Gly/Arg385 (n=3) or FGFR4 
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Arg/Arg385 (n=3) mammary glands compared to mammary tumors of FGFR4 Gly/Gly385 (n=8), FGFR4 
Gly/Arg385 (n=8) or FGFR4 Arg/Arg385 (n=8) mice transgenic for WAP-TGFα  after 6 month of tumor 
progression: FGFR4 expression was analyzed via immunoprecipitation and Western Blotting. Tubulin 
served as a loading control and normalization value for the quantification of the FGFR4 expression; 
FGFR4 is overexpressed in WAP-TGFα derived tumors compared to normal mammary gland; there is no 
difference detectable in mice carrying the FGFR4 Arg385 allele compared to mice homozygous for the 
FGFR4 Gly385 allele; 
B) Analysis of the activation status of the FGFR4 in mammary tumors of FGFR4 Gly/Gly385 (n=8), 
FGFR4 Gly/Arg385 (n=8) or FGFR4 Arg/Arg385 (n=8) mice transgenic for WAP-TGFα after 6 month of 
tumor progression: Mice homozygous for the FGFR4 Arg/Arg385 allele display a significantly increased 
phosphorylation of the FGFR4 compared to mice homozygous for the FGFR4 Gly/Gly385 allele in WAP-
TGFα derived tumors; FGFR4 expression served as a loading control and for the quantification of the 
phosphorylation levels (Arg/Arg-p=0.012); phosphorylation of downstream signaling molecules p-Erk and 
p-Akt display no difference regarding the FGFR4 genotype; 
C) FGFR4 expression in hyperplasic mammary glands of FGFR4 Gly/Gly385 (n=10) or FGFR4 
Arg/Arg385 (n=10) mice transgenic for WAP-TGFα; FGFR4 expression was detected 
immunohistochemically and analyzed microscopically (20x) after 3 month of tumor progression: The 
higher magnification displays a clear overexpression of the FGFR4 Arg/Arg385 compared to the FGFR4 
Gly/Gly385 in hyperplasic mammary glands derived from mice transgenic for WAP-TGFα; hyperplasic 
mammary glands derived from mice transgenic for WAP-TGFα display no pathohistological differences 
regarding their FGFR4 alleles. 
D) FGFR4 expression in mammary adenocarcinoma of FGFR4 Gly/Gly385 (n=10) or FGFR4 Arg/Arg385 
(n=10) mice transgenic for WAP-TGFα after 8 month of tumor progression: FGFR4 expression was 
detected immunohistochemically and analyzed microscopically (20x); FGFR4 is overexpressed in WAP-
TGFa derived mammary adenocarcinomas but no difference is detectable in the expression level of the 
FGFR4 Arg/Arg385 compared to the FGFR4 Gly/Gly385; mammary adenocarcinoma derived from mice 
transgenic for WAP-TGFα display no pathohistological differences regarding their FGFR4 alleles. 
E) Expression analysis of tumors derived from FGFR4 Gly/Gly385 (n=10) or FGFR4 Arg/Arg385 (n=10) 
mice transgenic for WAP-TGFα after 6 month of tumor progression: target gene expression was analyzed 
via semiquantitative RT-PCR; GAPDH served as housekeeping gene for normalization; expression values 
of FGFR4 Arg/Arg385 tumors are blotted relatively to the expression values of FGFR4 Gly/Gly385 tumors 
and grouped regarding their physiological function; mRNA expression level of FGFR4 or EGFR does not 
differ between the different genotypes; Tumors significantly overexpress genes involved in migration, 
invasion, vascularization in the presence of the FGFR4 Arg/Arg385 allele; p21 is significantly 
downregulated in the presence of the FGFR4 Arg/Arg385 allele (MMP14-p=0.02, MMP13-p=0.021, 
MMP9-p=0.019, flk-1-p=0.02, CD44-p=0.02, CDK1-p=0.0091, p21-p=0.03); 
All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant. 
 
4.2.3.4 The impact of the FGFR4 Arg385 allele on lung metastasis of WAP-TGFα 
derived tumors 
Cancer cells can aquire the ability to circulate in the blood or lymphatic stream in the 
organism to establish distant metastases. As clinical outcome of cancer is strongly dependent 
on the invasive stage of the primary tumor it is essential to investigate the impact of the 
FGFR4 Arg385 allele on aggressiveness and invasiveness of WAP-TGFα-derived tumors. 
Importantly, the expression of genes involved in cell invasivity and metastasis are 
significantly upregulated in WAP-TGFα derived tumors homozygous for the FGFR4 Arg385, 
suggesting that these tumors may develop a more aggressive and invasive phenotyope.  
Therefore, we investigated distant metastases in the lungs of FGFR4 Gly/Gly385, FGFR4 
Gly/Arg385 and FGFR4 Arg/Arg385 mice transgenic for WAP-TGFα . First we calculated the 
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incidence of lung metastases in FGFR4 Gly385 and FGFR4 Arg385 mice transgenic for WAP-
TGFα. Strikingly, FGFR4 Arg385 display a significant earlier incidence of lung metastases 
when compared to Gly385 mice (Figure 37A)(p=0.007). Yet again, this result indicates a 
faster progression of tumors expressing the FGFR4 Arg385 as their ability to invade distant 
organs is aquired earlier. However, as seen in Figure 37B, mice display no patho-histological 
alterations of lung metastases in the presence of the FGFR4 Arg385 allele when compared 
with FGFR4 Gly/Gly385 mice transgenic for WAP-TGFα. Furthermore, we investigated the 
number and size of metastases in the invaded lungs of FGFR4 Gly/Gly385, FGFR4 
Gly/Arg385 and FGFR4 Arg/Arg385 mice transgenic for WAP-TGFα after 8 month of tumor 
progression. As shown in Figure 37C mice expressing the FGFR4 Arg385 allele partly display 
a significant increase in the number of metastases in the investigated lungs. Mice 
heterozygous for the FGFR4 Arg385 allele show significantly more metastases, that are 
bigger than 320µM (320µM Gly/Arg-p=0.007). Mice homozygous for the FGFR4 Arg385 
allele show significantly more metastases that are smaller than 80µM or bigger than 320µM 
(80µMArg/Arg-p=0.004; 320µM Arg/Arg-p=0.009). The significant increase in metastases 
bigger than 320µm indicates that tumor cells expressing the FGFR4 Arg/Arg385 are able to 
invade the lung at an earlier time point. The significant increase in metastases smaller than 
80µm indicates, that more tumor cells aquire the ability to invade distant organs in the 
presence of the FGFR4 Arg/Arg385 allele resulting in a higher number of metastases. These 
data go in line with the significant upregulation of genes involved in metastasis in the 
expression analysis in WAP-TGFα-derived tumors homozygous for the FGFR4 Arg385. 
Furthermore, these results suggest that the FGFR4 Arg385 allele contributes to accelerated 
tumor cell invasion as well as an earlier incidence and faster growth of metastases. 
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Figure 37: The FGFR4 Arg385 promotes lung metastasis in WAP-TGFα induced mammary carcinoma: 
(A) Incidence of cancer cell metastasis in the lung of FGFR4 Gly/Gly385 (n=10) and FGFR4 Arg/Arg385 
(n=10) mice transgenic for WAP-TGFα: mice transgenic for WAP-TGFα display a significantly decreased 
incidence of metastasis to the lung in the presence of the FGFR4 Arg385 allele (p=0.007).  
(B) HE-staining of lung metastases in 6 month old FGFR4 Gly/Gly385 (n=3), and FGFR4 Arg/Arg385 
(n=3) mice transgenic for WAP-TGFα: black arrows indicate metastases; no obvious pathohistological 
changes were found to be induced by the different FGFR4 genotypes. 
(C) Analysis of occurred metastases of 8 month old FGFR4 Gly/Gly385 (n=5), FGFR4 Gly/Arg385 (n=5) 
and FGFR4 Arg/Arg385 (n=5) mice transgenic for WAP-TGFα: size of metastases is plotted against 
number of metastases; mice hetero- or homozygous for FGFR4 Arg385 partly display a significantly 
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accelerated number of metastases (>320µM Gly/Arg-p=0.007, <80µM Arg/Arg-p=0.004, >320µM 
Arg/Arg-p=0.009).  
All data are shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 
0.03 were considered statistically significant. 
 
4.3 Investigation of new FGFR4 interaction partners  
The most prominent influence of FGFR4 and its Arg388 variant is its implication in cancer 
correlating with a poor clinical outcome. Furthermore, FGFR4 is involved in the maintainance 
of liver homeostasis. However, the distinct mechanisms by which the FGFR4 supports 
oncogenesis or liver metabolism have yet to be elucidated. For that purpose, we performed a 
proteomic analysis of FGFR4 interaction partners by SILAC-based mass spectrometry in vitro 
and in vivo. 
4.3.1 Investigation of new FGFR4 binding partners in MDA-MB-231 cells 
As the FGFR4 is expressed at rather low levels compared to e.g. HER-family receptors and 
the scientific tools like antibodies represent a limitation in the investigation of this receptor, 
we chose MDA-MB-231 breast tumor-derived cells modified by Bange et al. (2002) as  model 
system. Here, FGFR4 is overexpressed either in its Gly388 or Arg388 variant and excerts its 
cancer progression accelerating effects (Bange et al. 2002). FGFR4 overexpression, 
extensively simplifies the detection of the FGFR4 protein via mass spectrometry and the 
differences between the FGFR4 alleles can be analyzed in the same model system. 
To perform  quantitative mass spectrometry analysis of FGFR4 interaction partners we used 
the SILAC Technology do achieve  differerential  metabolic labelling of the cells (Ong and 
Mann, 2006). To verify the obtained interaction partners we performed a so called “label 
switch”. Quantitative mass spectrometry was performed on MDA-MB-231 cells 
overexpressing either the Gly388 or Arg388 variant by Arg0/Lys0 as well as Arg10/Lys8 labels. 
Parental MDA-MB-231 cells expressing the empty pLXSN vector served as a negative 
control and were labeled Arg4/Lys6. Labelling of cells and sample preparation was done as 
previously described (Andersen et al., 2005; Shevchenko et al., 1996) (Figure 38 ). 
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Figure 38: Simplified scheme of the experimental setup to analyze FGFR4 interaction partners in MDA-
MB-231 cells expressing either empty pLXSN vector, pLXSN-FGFR4 Gly388 or pLXSN-FGFR Arg388; 
cell lines were subcultured in media containing modified amino acids for SILAC labelling; between MDA-
MB-231 cells expressing FGFR4 Gly388 and Arg388 a lable switch was performed to verify the results. 
After cell lysis, lysates were pooled 1:1; FGFR4 and its interactors were immunoprecipitated and 
subjected for in-gel digest with Trypsin and LysC followed by quantitative LC-MS/MS analysis. 
 
Table 9 displays all proteins that are potential interaction partners of the FGFR4. Identified 
proteins were normalized to their detection value in MDA-MB-231 cells expressing the empty 
pLXSN. Therefrom, all proteins with a 5-fold upregulation compared to the negative control 
are putative interaction partners of the FGFR4. Table 9 further displays the intensity of 
interaction indicated by the upregulation compared to the negative control and the differences 
between the FGFR4 Gly388 and Arg388 variant at which the value 1 means no difference in 
interaction.  
The FGFR4 Gly388 and Arg388 themselfes were found to be highly upregulated as a result of 
the overexpression in MDA-MB-231 cells. These results indicate that the experimental setup 
as well as the overexpresion system worked properly. Further, the protein tyrosine 
phosphatase, receptor type F (PTPRF, LAR), the neurogenic locus notch homolog protein 2 
(NOTCH2), the Ephrin type-A receptor 2 (EPHA2) and most interestingly the Epidermal 
Growth Factor (EGFR) were found to be highly upregulated. LAR is a transmembrane 
phosphatase and is known to regulate the function of various receptor tyrosine kinases. Its 
activity is known to be negatively regulated by the EGFR (Ruhe et al., 2006). Loss of LAR is 
associated with increased hepatocyte cell proliferation by c-MET, insulin resistance and 
increased tumor cell metastasis (Machide et al., 2006; Mander et al., 2005; McArdle et al., 
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2005). Overexpression of LAR induces apoptosis in mammalian cells (Weng et al., 1998). 
Above that, LAR is implicated in the regulation of FGF-induced signalling by interacting with 
FRS2 (Wang et al., 2000). EPHA2 is a transmembrane receptor tyrosine kinase that is 
upregulated on many human aggressive cancer cells. Unlike other receptors, it displays kinase 
activity without ligand binding (EphrinA1) that causes tumor progression. In breast cancer 
cells, including MDA-MB-231, EPHA2 negatively regulates malignant cancer cell behavior 
upon ligand or antibody binding that induces cell adherence (Carles-Kinch et al., 2002; 
Noblitt et al., 2004).  
EGFR overexpression in MDA-MB-231 cells is associated with several key features of cancer 
development and progression and represents a valid target in various cancers. In MDA-MB-
231 cells, the stimulation of the EGFR via multiple mechanisms results in an increase of their 
malignant behavior (Wang et al., 2009; Zheng et al., 2009). These data indicate that MDA-
MB-231 cells overexpressing the FGFR4 Gly388 or Arg388 variant present a useful model to 
study potential interaction partners of the FGFR4 in breast cancer cells. Furthermore, FGFR4 
seems to interact with a variety of receptor tyrosine kinases. However, all potential interaction 
partners displayed no difference between the different FGFR4 isotypes. 
 
 
Table 9: Summary of possible new interaction partners of the FGFR4 in MDA-MB-231 cells; potential 
interaction partners were verified by the “lable switch”; evaluation criteria of identified proteins were 
upregulation ≥ 5-fold, Razor Peptides (=RPs) > 2, PEP < 0.03; The table further displays fold of 
upregulation and fold difference between the FGFR4 isotypes; value 1 implies equal interaction between 
the FGFR4 isotypes 
 
4.3.2 Validation of the EGFR/FGFR4 interaction 
Interestingly, the data obtained from the mass spectrometry analysis in MDA-MB-231 cells, 
displayed the EGFR amongst others as an interaction partner of the FGFR4. The EGFR is a 
key regulator of various processes in cancers, approved therapeutic target and the main 
component of tumor progression in the WAP-TGFα mouse mammary carcinoma model used 
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in our experiments. Therefore, the validation of the potential interaction between the EGFR 
and the FGFR4 preceded the validation of the other analyzed interaction partners. 
First we aimed to show, that the FGFR4 gets co-immunoprecipitated with the EGFR in MDA-
MB-231 cells overexpressing either the empty pLXSN, pLXSN-Gly388 or –Arg388 (Figure 
39A). These data indicate a first hint for the interaction of these two receptors. In contrast to 
the mass spectrometry analysis, the Western Blot Analysis displayed an increased content of 
co-immunoprecipitated FGFR4 Arg388 compared to FGFR4 Gly388. As expected, the 
negative control displayed no co-immunoprecipitated FGFR4 as FGFR4 is barely expressed 
in MDA-MB-231 cells. Nevertheless, as proteins are mostly localized in clusters on the 
membrane, co-immunoprecipitation is no final evidence for an interaction of two receptors. 
Therefore, we investigated the EGFR-FGFR4 interaction upon EGF stimulation. As shown in 
Figure 39B, the EGFR displays increased phosphorylation in the presence of the 
overexpressed FGFR4. Furthermore, the EGFR in MDA-MB-231 cells overexpressing the 
FGFR4 Arg388 is even more activated than in the presence of the FGFR4 Gly388. 
Interestingly, the co-immunoprecipitated FGFR4-Arg388 is more active than the FGFR4-
Gly388. Above that, phosphorylation of the FGFR4 increases over time upon EGF 
stimulation. These data are confirmed by the quantification of the Western Blot Analysis 
(Figure 39C) Furthermore, the activation of the downstream signalling protein Akt is 
increased in MDA-MB-231 cells overexpressing the FGFR4 Arg388 upon EGF stimulation. 
The activation of Erk did not differ between the different FGFR4 isotypes (data not shown). 
This result indicates a physiological interaction of the FGFR4 and EGFR upon EGF 
stimulation. Similarily, the EGFR-FGFR4 interaction is hardly seen in unstimulated cells. In 
summary, the FGFR4 and the EGFR are direct interaction partners. Here, FGFR4 seems to 
support EGFR induced signalling by receptor phosphorylation upon EGF stimulation, 
whereas the FGFR4 Arg388 enhances the signal.  
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Figure 39: Validation of the EGFR/FGFR4 interaction; A) Co-Immunoprecipitation of EGFR and FGFR4 
in MDA-MB-231 cells overexpressing the empty pLXSN, pLXSN-Gly388 and –Arg388: Interaction of 
EGFR and FGFR4 Arg388 seems to be stronger than EGFR and FGFR4 Gly388; B) EGFR-FGFR4 
interaction upon EGF-stimulation: increased phosphorylation of the EGFR and accelerated FGFR4 
interaction and activation in MDA-MB-231 cells expressing the FGFR4 Arg388; C) Quantification of 
Western Blot Analysis of EGF stimulated MDA-MB-231 cells: MDA-MB-231 cells expressing the FGFR4 
Ag388 display an accelerated EGFR and Akt activation, total EGFR and tubulin served as normalization 
value for quantification, respectively; the co-immunoprecipitated FGFR4 Arg388 displays a accelerated 
binding to the EGFR and increased activation comparetd to the co-immunoprecipitated FGFR4 Gly388 
 
To further confirm the data obtained in MDA-MB-231 cells we investigated the signalling 
upon EGF and TGFα stimulation in MEFs derived from the FGFR4 Arg385 KI mice 
transformed with EGFR. MEFs transformed with EGFR displayed an accelerated and 
prolonged activation of Akt in the presence of the FGFR4 Arg385 allele upon EGF and TGFα 
stimulation (Figure 40A). The activation of Erk shows no difference between the different 
FGFR4 isotypes (data not shown). Similar to the MDA-MB-231 cells overexpressing the 
FGFR4 Arg388, MEFs transformed with EGFR and expressing the FGFR4 Arg385 display a 
significant increase in pEGFR levels compared to FGFR4 Gly385 MEFs (EGF5’-p=0.000073, 
EGF10’-p=0.0025, TGFα5’-p=0.07, TGFα10’-p=0.01) (Figure 40B). Above that, MEFs 
transformed with EGFR display an activation of the FGFR4 upon EGF and TGFα stimulation 
(Figure 40C). Similar to MDA-MB-231 cells, MEFs expressing the FGFR4 Arg385 allele 
display an increased activation of the FGFR4. These data confirm the results obtained in 
MDA-MB-231 cells. The FGFR4 Arg385 clearly supports the activation and following 
downstream signaling of the EGFR. 
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Figure 40: Western Blot analysis of MEFs derived from FGFR4 Gly385 or Arg385 homozygous mice 
transformed with EGFR upon EGF and TGFα stimulation; A) MEFs transformed with EGFR display an 
increased and prolonged activation of Akt upon EGF and TGFα stimulation when expressing the FGFR4 
Arg385 allele; B) MEFs transformed with EGFR display an significantly increased activation of the EGFR 
upon EGF and TGFα stimulation when expressing the FGFR4 Arg385 allele (EGF5’-p=0.000073, EGF10’-
p=0.0025, TGFα5’-p=0.07, TGFα10’-p=0.01); actin served as a normalization value for quantification C) 
In MEFs, transformed with EGFR, FGFR4 gets activated upon EGF and TGFα stimulation whereas the 
FGFR4 Arg385 displays an increased phosphorylation compared to the FGFR4 Gly385; All data are 
shown as mean ± SDM; all p-values were calculated using the students T-test and values ≤ 0.03 were 
considered statistically significant. 
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4.3.3 The FGFR4 Arg385 influences the migratory behavior and the 
sensitivity towards Gefitinib in MDA-MB-231 cells 
To further investigate the interaction between the EGFR and the FGFR4, we analyzed the 
influence of the FGFR4 Arg385 on the biological properties of MDA-MB-231 cells. We 
firstly analyzed the proliferation of MDA-MB-231 cells overexpressing the empty pLXSN, 
pLXSN-Gly385 and –Arg385. As shown in Figure 41A the overexpressed FGFR4 had no 
influence on the proliferation of MDA-MB-231 cells under normal conditions. As shown in 
Figure 41B overexpression of the FGFR4 results in a tremendous increase in migration 
indicating the immense capacity of the FGFR4 to promote the migratory behavior of cells 
(Gly388-p=0.001, Arg388-p=0.001). Above that, MDA-MB-231 cells overexpressing the 
FGFR4 Arg388 display accelerated migratory behavior compared to MDA-MB-231 cells 
overexpressing the FGFR4 Gly388. In contrast to the data of Bange et al., FGFR4 Gly388 did 
not suppress the migration of MDA-MB-231 cells. This may be due to the scratch assay of 
Bange et al. (2002) that possibly resulted in a different response compared to a Boyden 
Chamber Assay that monitors changes in chemotactic migration rather than cell-cell contact. 
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Figure 41: Biological properties of MDA-MB-231 cells expressing empty pLXSN, pLXSN-Gly388 or 
pLXSN-Arg388; A) MDA-MB-231 cells do not alter their proliferative capacity by overexpressing the 
FGFR4; B) MDA-MB-231 cells display a partly significantly increased migratory capacity by 
overexpressing the FGFR4 (FGFR4 Arg388-p=0.001); MDA-MB-231 cells overexpressing the FGFR4 
Arg388 allele display a significantly accelerated migration compared to MDA-MB-231 cells expressing the 
FGFR4 Gly388 allele (FGFR4 Arg388-p=0.001); All data are shown as mean ± SDM; all p-values were 
calculated using the students T-test and values ≤ 0.03 were considered statistically significant. 
 
 
To further analyze the physiological connection between the EGFR and the FGFR4 we 
investigated the differences between the different FGFR4 alleles in MDA-MB-231 
overexpressing cells upon exposure to Gefitinib. This small molecule tyrosine kinase inhibitor 
blocks EGFR phosphorylation by competing with ATP and thereby inhibits EGFR-mediated 
downstream signalling (Herbst et al., 2004). Therefore, physiological processes that require 
the dimerization of the EGFR and the FGFR4 should lead to different results in the presence 
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of Gefitinib compared to those obtained without an EGFR inhibitor. We first determined the 
response of MDA-MB-231 cells either overexpressing the empty pLXSN vector or FGFR4 
Gly388 or FGFR4 Arg388 towards increasing concentrations of Gefitinib (0.025-20µM) in a 
MTT-proliferation assay (Figure 42A). Interestingly, FGFR4 Arg388 expressing cells display 
a typical dose resonse curve whereas FGFR4 Gly388 and empty pLXSN vector expressing 
cells display no response up to 20µM of Gefitinib. The analyzed IC50 was estimated to be 
18.72 µM for both, MDA-MB-231 cells expressing the empty pLXSN or FGFR4 Gly388. In 
contrast, the calculated IC50 for MDA-MB-231 cells overexpressing the FGFR4 Arg388 allele 
was 9.53µM. These results indicate a higher sensitivity of MDA-MB-231-FGFR4Arg388 
cells towards Gefitinib and suggest a higher EGFR-dependence of these cells. Further, we 
wanted to determine if the decreased proliferation results from a proliferative stop or 
apoptosis induced by Gefitinib. Therefore, we investigated the impact of FGFR4 Arg388 
overexpression on apoptosis in response to Gefitinib treatment in MDA-MB-231 cells. As 
shown in Figure 42B FGFR4 Arg388 expressing MDA-MB-231 cells display a significantly 
increased apoptotic response towards Gefitinib after 96 hours compared to MDA-MB-231 
cells expressing the FGFR4 Gly388 (20µM-p=0.012; 10µM-p=0.0022). These data indicate 
that MDA-MB-231 cells expressing the FGFR4 Arg388 allele display an increased sensitivity 
towards Gefitinib regarding cellular survival. As MDA-MB-231 cells aquired a significantly 
accelerated migratory capacity by overexpressing the FGFR4 Arg388 allele we determined 
the migratory behavior of MDA-MB-231 cells in the presence of Gefitinib (2.5µM) (Figure 
42C). After 15 hours of migration in Boyden Chamber Assays, MDA-MB-231 cells 
expressing the FGFR4 Arg388 allele display 22.28% inhibition of migration compared to the 
DMSO treated control cells. In contrast, MDA-MB-231 cells overexpressing the FGFR4 
Gly388 allele displayed only 6.28% of inhibition. This result indicates that the mirgratoy 
capacity of MDA-MB-231 cells overexpressing the FGFR4 Arg388 is dependent on the 
molecular action of the EGFR and furthermore displays an increased response towards 
Gefitinib treatment. 
In conclusion, the treatment of MDA-MB-231 cells with Gefitinib suggests a strong 
physiological connection between FGFR4 and EGFR regarding cellular survival and 
migration. Above that, the dependence of the molecular interaction between FGFR4 and 
EGFR is increased in the presence of the FGFR4 Arg388 allele.  
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Figure 42: Impact of Gefitinib in MDA-MB-231 cells expressing empty pLXSN, pLXSN-Gly388 or 
pLXSN-Arg388 on proliferation, apoptosis and migration; A) MDA-MB-231 cells overexpressing the 
FGFR4 Arg388 allele display a increased sensitivity (IC50=9.53) towards Gefitinib compared to FGFR4 
Gly388 or control cells (IC50=18.72); B) MDA-MB-231 cells display a significant increase in apoptosis in 
the presence of the FGFR4 Arg388 allele compared to the FGFR4 Gly388 towards Gefitinib (20µM-
p=0.012;10µM-p=0.0022); C) MDA-MB-231 cells display a decrease in migration in the presence of the 
FGFR4 Arg388 allele compared to the FGFR4 Gly388 in response to Gefitinib; All data are shown as mean 
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± SDM; all p-values were calculated using the students T-test and values ≤ 0.03 were considered 
statistically significant. 
 
4.3.4 Investigation of new interaction partners of the hepatic FGFR4 in 
vivo 
Stable isotype labelling in cell culture (SILAC) has become a versatile tool for quantitative, 
mass spectrometry (MS)-based proteomics. In order to investigate global interactions and 
connections tissue-specifically and with the impact of an whole organism Kruger et al. 
established an in vivo SILAC by feeding mice with a diet containing either the natural or the 
13C6-substituted version of lysine (Figure 43). 
 
 
 
 
Figure 43: In Vivo labelling of C57BL/6 mice: mice were fed with a diet containing either the natural or   
13C6-substituted version of lysine; The efficiacy of labeling is dependent on the cell proliferation rate of the 
specific tissue; the F2 generation is labeled completely (Kruger et al., 2008) 
 
The FGFR4 is involved in various metabolic processes in the liver including lipid-, glucose- 
and bile acid metabolism as well as in liver carcinogenesis (Huang et al., 2008; Huang et al., 
2007). Also recent publications provide some evidence for the molecular action of the FGFR4 
and its Arg388 variant the distinct mechanism including interaction partners is still unknown 
(Stadler et al., 2006; Wang et al., 2006; Wang et al., 2008).  
 
4.3.5 Quantitative analysis of hepatic FGFR4 binding partners and their 
differences regarding the FGFR4 isotypes 
In order to investigate novel interaction partners of the hepatic FGFR4, a mass spectrometry 
analysis was performed to identify all proteins co-immunoprecipitated with the FGFR4. To 
allow a quantifiable analysis of the interaction partners the labelled SILAC-mouse was used 
as an internal standard (Kruger et al., 2008). To exclude unspecific binding partners the first 
expermimental step was to establish FGFR4 blocking peptides to selectively block the 
antibody-FGFR4 interaction to identify all unselective binders. As seen in Figure 44A a 
FGFR4 overexpressing construct that was used to generate the homemade α-FGFR4ex 
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antibody (C. Stadler, 2005) was transfected in HEK293 cells. The recombinant FGFR4 
protein was purified and digested with either Trypsin or LysC. The obtained blocking peptides 
were tested in a FGFR4 immunoprecipitation for their blocking efficacy. As shown in Figure 
44A especially the tryptic digest of the FGFR4 blocking peptides clearly diminished the 
antibody-FGFR4 interaction. Therefore, the synthesized blocking peptides were applicable for 
the following mass spectrometry analysis of novel FGFR4 interaction partners in the liver. 
Figure 44B displays the experimental setup regarding the investigation of novel FGFR4 
interaction partners via in vivo SILAC. The SILAC mouse was used as an internal standard to 
achieve quantifiable results. The hepatic FGFR4 of the unlabelled mouse was 
immunoprecipitated in the presence of the blocking peptides to detect unspecific binding 
partners. In the quantitative LC-MS/MS analysis FGFR4 and its specific interaction partners 
should be highly upregulated in the labelled fraction. Unspecific interaction partners should 
display a 1:1 ratio compared to the unlabelled fration incubated with the blocking peptides. 
Although the blocking peptides displayed a high efficacy in the Western Blot analysis, mass 
spectrometry analysis detected ~ 300 proteins as specific binding partners of the FGFR4 (data 
not shown). Such a high number of binding partners can not be a result of physiologically 
relevant interactions. Therefore, quantitative mass spectrometry analysis of hepatic FGFR4 
interaction partners can not be performed with the blocking peptides employed in these 
experiments. In order to improve the specificity of the blocking reaction, we sequenced the 
obtained blocking peptide mixture to synthesize specific blocking peptides (Figure 44C). In 
contrast to the blocking peptide mix obtained from the tryptic digest, all of the synthesized 
blocking peptides were inactive in the Western Blot analysis (data not shown). For that 
reason, the investigation of hepatic FGFR4 interaction partners was done with the liver of 
FGFR4 KO mice (Yu et al., 2000) that were kindly provided by Wallace L. McKeehan, PhD, 
Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas, 
Houston, USA. Figure 44 D and E shows the experimental setup to identify interaction 
partners of the hepatic FGFR4 and their differences between the FGFR4 isotypes. 
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Figure 44: Investigation of hepatic interaction partners of the FGFR4 via in vivo SILAC: A) Synthesis of 
blocking peptides; HEK293 were used to transiently transfect a vector containing the extracellular domain 
of the FGFR4 tagged with GST. Via specific signal petides, the recombinant protein can be delivered to 
the cell media; after digestion with either Trypsin or Lysin the efficiacy of the blocking peptides were 
tested in an immunoprecipitation experiment with FGFR4. 
B) Experimental scheme to analyze interaction partners of hepatic FGFR4 via blocking peptides; to 
enable a quantifiable analyis, the labelled SILAC mouse was used as an internal standard; livers of 
labelled and unlabelled mice were dissected and lysed; with unlabelled liver-lysates FGFR4 was 
immunoprecipitated in the presence of the blocking peptides preventing the binding of FGFR4 with the 
antibody for the detection of unspecific binding partners; in labelled liver-lysates, FGFR4 was 
immunoprecipitated without blocking peptides to analyze FGFR4 binding partners. 
C) Sequence analysis for the generation of specific blocking pepetides.  
D) Experimental scheme to analyze interaction partners of hepatic FGFR4 via FGFR4 KO mice; to enable 
a quantifiable analyis, the labelled SILAC mouse was used as an internal standard; livers of labelled and 
unlabelled mice were dissected, lysed and mixed together for FGFR4 immunoprecipitation. 
E) Experimental scheme to analyze interaction partners of hepatic FGFR4 Arg385; to enable a 
quantifiable analyis, the labelled SILAC mouse was used as an internal standard; livers of labelled and 
unlabelled mice were dissected, lysed and mixed together for FGFR4 immunoprecipitation. 
 
Table 10 displays all identified FGFR4 isotype interaction partners. Here, significance 
(PEP<0.03), amount of razor peptides (RPs, > 1) and an upregulation of at least 3 fold in 
FGFR4 KO experiments identified potential FGFR4 interaction partner. FGFR4 is highly 
upregulated in SILAC mice compared to FGFR4 KO mice. Therefore, the experimental 
workflow displays proper settings for the investigation of hepatic interaction partners of the 
FGFR4. Furthermore, the FGFR4 is not differentially expressed between the FGFR4 isotypes, 
a fact that was already shown by the characterization of the FGFR4 Arg385 KI mice. ΒKlotho 
is a known high affinity interaction partner of the FGFR4. This single-transmembrane protein 
is the essential co-receptor for the activation of downstream signaling events upon FGF19/15 
stimulation of the FGFR4 (Kurosu and Kuro, 2009; Wu et al., 2007). Therefore, the 
identification of βKlotho as a strong interaction partner was the “positive control” in the MS-
analysis. As seen in Table 10 βKlotho is highly upregulated in SILAC mice compared to 
FGFR4 KO mice indicating yet again proper experimental settings. Besides that, the in vivo 
SILAC analysis of our mice yilded so far unknown interaction partners that could contribute 
to the elucidation of the molecular action of the FGFR4 and its Arg385/388 variant. 
Hydroxyacid-oxidase 1 (Hao1) is a mainly peroxisomal protein that oxidizes glycolate and 
glyoxycolate with a subsequent production of H2O2 and is primarily expressed in the liver 
and pancreas. Downregulation of Hao1 in rats results amongst others in the upregulation of 
proteins associated with oxidative stress (Recalcati et al., 2003). Propanoyl-CoA C-
acetyltransferase (Scp2) plays an important role in the intracellular movement of cholesterol 
and possibly other lipids. Its deficiency results in multiple phenotypes in humans 
(Ferdinandusse et al., 2006). In mice loss of Scp2 induces alterations in the biliary lipid 
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secretion and hepatic cholesterol metabolism (Fuchs et al., 2001). Formididoyl-transferase-
cyclodeaminase (Ftcd) is suggested to control folic acid liver metabolism (Bashour and 
Bloom, 1998). Furthermore, Ftcd is recognized as a liver specifc antigen that is detected in 
sera of patients with autoimmune hepatitis (Lapierre et al., 1999). Above that, Ftcd is 
overexpressed in hepatocellular carcinoma (HCC) and is therefore suggested to contribute to 
the diagnosis of early stage HCC (Fuchs et al., 2001). Hydroxymethylglutaryl-CoA-synthase 
(Hmgcs2) is a key regulator of keton body production and is highly expressed in liver and 
colon. It is known that Hmgcs2 is transcriptionally regulated by c-myc and FKHRL1, a 
member of the forkhead in rhabdomysarcoma family that represses the transcription of 
Hmgcs2 in HepG2 cells upon insulin stimulation. Furthermore, Hmgcs2 is implicated in colon 
cancer via its downregulation (Camarero et al., 2006; Nadal et al., 2002). Among these 
potential interactors Hao1 and Scp2 display stronger interaction with the FGFR4 Arg385 
variant indicated by a higher ratio compared to the FGFR4 Gly385.  All afore mentioned 
potential interaction partners are not yet implicated in tyrosine kinase signalling or known to 
interact with RTKs. Therefore, fundamental follow-up experiments are necessary to first put 
these proteins into the context of the molecular action of receptor tyrosine kinases. Next to 
these potential new interactors the most interesting target is the epidermal growth factor 
receptor (EGFR). The EGFR was found to significantly interact with the FGFR4 and 
furthermore has a higher affinity to the FGFR4 Arg385 isotype. Besides others, the EGFR-
RAS-MAPKK axis is one of the most important pathways for cell proliferation in liver 
(Llovet and Bruix, 2008). These data show various new interaction partners of hepatic 
FGFR4. The direct interaction with the FGFR4 and their involvement in FGFR4-mediated 
signalling should be the subject of further investigations.  
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Table 10: Listing of identified interaction partners of hepatic FGFR4 and their differences between the 
FGFR4 isotypes; List displays razor peptides of identified protein (RPs), protein and gene names, protein 
IDs and their significance (PEP< 0.03); furthermore, the list displays the intensity of the interaction 
partners and their differences between the FGFR4 alleles 
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5 Discussion 
5.1 Loss of p53 and Rb in human primary cells as a model of oncogenesis in 
vitro 
In vitro systems are necessary tools to investigate and understand the distinct steps of the 
processes that govern cells into a malignant phenotype. The advantages of in vitro models are 
lower costs as well as a simplification and acceleration of experimental approaches. The 
disadvantage of in vitro models is the absent influence of a whole organism that has a distinct 
impact on physiological processes via metabolism, release of hormones or the immunesystem 
(van Staveren et al., 2009).  
Therefore, manipulated cell culture models should mimic the in vivo situation as close as 
possible. So far, transformation models manipulate the cell via oncogenes, viral proteins or re-
expression of telomerase. These manipulations occur barely and take place as late events in 
human carcinogenesis. Above that, except the re-expression of telomerase, most models 
directly transform primary cells without any further necessary cellular alteration. Because of 
that, these in vitro transformation systems disable the investigation of early steps of 
tumorigenesis as well as the analysis of necessary alterations towards a neoplastic phenotype 
(Hahn et al., 1999; Kyo et al., 2003; MacKenzie et al., 2002; Mondello et al., 2003; Zongaro 
et al., 2005).  
Therefore, there is a big need in investigating natural in vitro transformation models to 
establish a proper alternative to in vivo models. In this study, a model was established in 
primary human cells by the stable reduction of p53 and Rb. Both, p53 and Rb are lost or 
mutated in many human cancers and, together with other tumor suppressors, the inactivation 
of p53 and Rb takes place as one of the earliest events in tumorigenesis (Diehl, 2002; 
Hollstein et al., 1999; Malumbres and Barbacid, 2001; Palmero and Peters, 1996; Sherr, 2000; 
Sherr and McCormick, 2002). Furthermore, the successful transformation after a double loss 
of these two tumor suppressors was already shown as a very elegant model of non-small-cell-
lung-cancer in vivo (Meuwissen et al., 2003). Thus, the reduction of p53-and Rb expression 
would possibly enable the transformation of primary cells and, furthermore, provide an insight 
into the multiple steps towards malignant transformation of human cells.  
As a highly efficient knockdown displays the basis of a proper oncogenesis model, the first 
step was the establishment of a competent knockdown approach. Here, the knockdown via 
siRNA-constructs was analyzed compared to miRNA-constructs (P2Magic)(Paddison et al., 
2004). The miRNA-constructs displayed a more efficient knockdown than the pRETROSuper 
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constructs of both p53 and Rb. The siRNA-sequence seemed to be improper for the stable 
expression after cloning into the pRETROSuper vector. But the main reason is possibly the 
fact, that the P2Magic constructs express the shRNA as a mir-30 transcript. This expression 
strategy displays following advantages regarding the knockdown efficacy. First, adding the 
miR30 loop and 125nt of miR30 flanking sequence on either side of the hairpin is known to 
result in >10-fold increase in Drosha and Dicer processing of the expressed hairpins when 
compared to older designs.  Increased Drosha and Dicer processing translates into greater 
siRNA production and greater potency for expressed haripins. Second, by using the miR30 
the 5’ end of antisense strand gets unstabilized which results in strand specific incorporation 
of miRNAs into RISC (Miyagishi and Taira, 2002; Paddison et al., 2004). 
After the establishment of an appropriate knockdown-approach, Rb and p53 were stably 
knocked down by the specific shRNAs in the non-cancerous cell lines HEK293, HaCat and 
MCF10A. As p53 and Rb are key regulators of the cell cycle and genomic integrity, the loss 
of these two tumor suppressors should result in an accelerated cell cycle and a decrease in 
apoptosis (Bennett et al., 1998). Therefore, the proliferation of double knockdown cells was 
monitored and the cell cycle distribution upon a weak doxorubicin treatment was investigated 
with the expected results. Because of that, this knockdown seems to be not only sufficient for 
a distinct reduction of the protein level, but also to achieve expected physiological outputs, 
which makes this knockdown strategy a proper approach to establish an in vitro 
transformation model (Naidu et al., 2007).  
Routinely used non-cancerous cell lines are artificially immortalized and thereby released 
from senescence and primed for the establishment of a neoplastic phenotype. Further, the 
perpetual subculturing of these cells enables the accumulation of mutations that maybe alter 
the physiology of these cells. Therefore, typical non-cancerous cell lines do not reflect the 
status of real primary cells. For that reason, the double knockdown of p53 and Rb was 
efficiently established in normal human dermal fibroblasts (NHDF, further referred as 
NHDFdk). As a negative control, NHDF cells were stably infected with a non-silencing 
shRNA construct (further referred as NHDFscr). Similar to the knockdown in non-cancerous 
cell lines, the reduction of p53 and Rb should result in several physiological outputs. The first 
advantage that most pre-cancerous cells achieve is the increased ability to proliferate. 
According to that, NHDFdk cells display increased proliferation doubling rates (PDR) 
indicating the loss of an accurate cell cycle control by the reduction of p53 and Rb. This 
phenotype is confirmed moleculary in the upregulation of the cell cyle promoter Cyclin D. 
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The step of uncontrolled cell growth is necessary for the primary cell to aquire further 
necessary properties.  
 Morphological changes are also typical for pre-cancerous cells. In the case of fibroblasts the 
typical morphology gets replaced by the irregular size of pre-malignant cells. This was also 
seen in NHDFdk cells that became smaller, rounder and even seemed to be barely attached. 
The first stage of cellular transformation is represented by the achievement of an unlimited 
proliferation capacity, called immortalization. Primary cells are characterized by a permament 
growth arrest after a defined number of population doublings induced by several mechanisms 
like telomere shortening. The cellular senescence is suggested to be a protective mechanism to 
circumvent instability of the genome and  possible neoplastic transformation (Ha et al., 2008; 
Prieur and Peeper, 2008). In contrast, pre-cancerous cells avoid cellular senescence. A 
prolonged life span contributes in turn to an immortalized phenotype. As NHDFdk cells 
doubled the stated proliferation rate of NDHF (15 PDRs), the cells can be described as 
immortal (Gray-Schopfer et al., 2006). This could also be verified by a β-galactosidase assay 
that marks senescent cells, which were absent in NHDFdk even after 15 PDs. To confirm 
these data on the molecular level, the mRNA level of the tumor suppressors p16, p21 and p27 
were analyzed over time. Especially p16 and p21 are potent promoters of cellular senescence 
(Dulic et al., 2000). Whereas NHDFdk cells suppress the expression of these tumor 
suppressors or maintain their expression, NHDFscr cells clearly upregulate the expression of 
p16, p21 and p27 that results in permament growth arrest.  
For complete malignant transformation it is essential for the cell to expand its relevant 
biological properties. These abilities include the loss of contact inhibition that allows tumor 
formation. Here, the cells overcome the proliferative stop when the space allotted to them is 
filled and a dense monolayer is formed (Herrlich et al., 2000). As NHDFdk did not stop 
proliferating in subconfluent culture and their cell-layer diplayed a disordered appearance, 
these cells seemed to achieve the ability to partly overcome this proliferative stop by contact 
to other cells.  
The loss of cell-cell or cell-matrix contacts in primary cells usually activates “anoikis”. 
Anoikis is a form of apoptosis that occurs in cells that are detached from their surrounding 
tissue. By this mechanism the organism is able to get cells out of a cell layer if its position 
there is incorrect (Chiarugi and Giannoni, 2008; Simpson et al., 2008). Cancer cells are able 
to survive without cell-cell contacts. The anchorage indepence enables the invasion of the 
organism by entering the blood or lymphatic stream. In contrast to NHDFscr cells, NHDFdk 
cells were able to grow in suspension in non-coated culture dishes indicating the acquisition 
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of anchorage independent growth. Next to anchorage independence, NHDFdk cells were able 
to form foci in Matrigel and displayed a slight branching. Malignant cells are often capable in 
degrading the extracellular matrix (ECM) for the invasion of surrounding and distant tissues. 
Hence, the slight branching of NHDFdk cells in Matrigel indicates a slight invasive behaviour 
of these cells. To comfirm the loss of contact inhibition, anchorage independence and the 
slight branching in Matrigel on the molecular level, the expression of oncogenes were 
monitored over time. In NHDFdk cells SRC gets clearly upregulated over time. In all 
probability, the overexpression of SRC causes the malignant phenotype as SRC is one of the 
most potent oncogenes and is involved in a broad variety of cellular processes including 
proliferation, migration or cell-cell adhesion (Frame, 2002; Irby and Yeatman, 2000; 
Sakamoto et al., 2001; Warmuth et al., 2003). Its overexpression is frequent in many cancers 
as its activation can be achieved via diverse mechanisms and src signalling  can thereby lead 
to even more cellular phenomena (Martin, 2001). In contrast H-Ras is not upregulated. 
Although H-Ras is also considered a strong oncogene and its upregulation is frequent in 
various cancers and transformed cells, its tumorigenicity seems to be dependent on a distinct 
cellular context and cooperative events (Bahk et al., 2008) that may be not present in the 
p53/Rb knockdown model. Further studies show, that its overexpression is also involved in 
oncogene-induced senescence resulting in  permanent growth inhibition of normal cells 
caused by DNA-damage (Di Micco et al., 2006).  
Further, the expression of Matrix-Metallo-Proteases (MMPs) was monitored over time. 
MMPs are essential for degrading the ECM for invasion and are often overexpressed in cancer 
cells (Stahtea et al., 2008). Compared to NHDFscr cells that were not capable to form foci or 
branch in Matrigel, NHDFdk cells clearly overexpress MMP9 and slightly MMP 2 that might 
be the molecular explanation for the observed growth and slight branching in matrigel. In 
summary, NHDFdk cells seem to develop a transformed phenotype over time that is indicated 
by the acquisition of typical properties that cancer cells exihibt. Furthermore, these properties 
could be explained be the overexpression or suppression of genes that are associated with the 
observed phenotypes. To analyze the expression pattern of NHDFdk cells in more detail a 
micro array analysis or a proteomic analysis should be done in further experiments. Results 
obtained from these expression analyses potentially help in the understanding of distinct 
expression pattern or their alterations in oncogenesis. In addition, further target genes of the 
p53 or Rb pathway could be identified. 
Genomic instability is critical in the accumulation of mutations that in turn cause the 
development of a neoplastic phenotype. Therefore, genomic instability is one of the most 
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important events in tumorigenesis. To get a first insight of a potential DNA-damage in 
NHDFdk cells, the expression of γH2AX was analyzed. Upon DNA-damage, H2AX gets 
phosphorylated and amongst others activates the DNA-damage signaling by p53 or Rb 
(Fillingham et al., 2006; Halicka et al., 2005). The obtained accelerated activation of γH2AX 
in NHDFdk cells indicates an increase in DNA damage over time. The activation of H2AX is 
associated with early precursor lesions (but not normal tissues) of the bladder, breast, lung, 
and colon (Bartkova et al., 2005). In advanced breast and lung carcinomas, the DNA damage 
response is constitutively activated (Lukas et al., 2003). Furthermore, γH2AX is suggested to 
be a prognostic marker in melanoma (Wasco et al., 2008). Next to active H2AX, the 
expression of Mad (mitotic- arrest-deficient-like) 1 was abolished in NHDFdk cells over time. 
The cell cycle checkpoint protein Mad 1 prevents the entry of the cells in anaphase if the 
chromosomes are not properly organized for cell division. Several studies display that the loss 
of Mad1 in cancer cells results in chromosomal instability. The overexpression of Mad1 
results in suppression of proliferation or the malignant phenotype of cancer cells (Chen et al., 
1995; Vastrik et al., 1995; Zou et al., 2006). Hence, the activation of H2AX and the loss of 
expression of Mad1 indicate genomic instability and DNA-damgage caused by an 
uncontrolled cell division in NHDFdk cells. According to this, the karyotype analysis of mock 
tranfected and double knockdown-cells displayed an accelerated aneuploidy in form of loss or 
gain of chromosomes in NHDFdk cells that increases over time. Although this form of 
aneuploidy is often thought to be rather a consequence than a cause of oncogenesis this 
genomic instability seems to contribute to the oncogenic progress in these cells. These data 
highlight, that NHDFdk cells display an excellent in vitro model to investigate the 
contribution of genomic instability to oncogenesis. Therefore a karyotypic analysis should be 
done by spectral karyotyping analysis (SKY) to determine the loss or gain of specific 
chromosmes over time in detail or the occurrence of chromosomal abnormalities by 
translocation, deletions or fusions of chromosomes (Padilla-Nash et al., 2007). Furthermore, 
the sequencing of specific genes could give insight in the genetic alterations of these cells. 
Hence, NHDFdk cells could contribute to the creation of a possible “mutational timetable” of 
oncogenesis that could give a deep insight in the development and behaviour of cancerous 
cells.  
A further subject of the genomic constitution of NHDFdk cells was the analysis of telomere 
length. Telomere shortening not only induces cellular senescence, but short telomeres often 
lead to genomic instability that governs cells into a mitotic crisis and apoptosis as a tumor-
protective mechanism (Kim et al., 1994; Shay and Bacchetti, 1997; Wright and Shay, 2001). 
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If cells overcome this mitotic crisis by the reactivation of telomerase or alternative telomere 
lengthening (ALT), the cells usually get cancerous (Cesare and Reddel, 2008; Shay and 
Wright, 2005). As NHDFdk cells did not reactivate the expression of telomerase and these 
cells neither enter a permanent growth arrest nor apoptosis, the extended telomere shortening 
seems to be tolerated by the cells. Furthermore, the telomeres should be stabilized via 
alternative telomere lengthening (ALT). Otherwise, telomere dysfunction would result in 
permanent growth arrest or cell death (Campisi, 2005; d'Adda di Fagagna et al., 2003). 
Interestingly, so called ALT-cells or ALT-tumors often do not exhibit p53 expression and 
often display a profound genomic instability according to the established model (Chen et al., 
2006; Scheel et al., 2001).  
In recent years it has become accepted, that genomic alterations and changes in expression 
patterns can support the cells in “reaquiring“a so called “stemness”. Several publications 
report of the existence of a subpopulation of cancer cells in routinely used cancer cell lines 
that display a more aggressive phenotype after selection from the parental cell line (Ho et al., 
2007; Huang et al., 2008; Sung et al., 2008). Therefore, the NHDFdk cells were investigated 
for a stem cell like subpopulation to analyze if the p53/Rb doubleknockdown could serve as in 
vitro model for the establishment of a stem cell like cancer cell subpopulation. However, 
NHDFdk cells did not display any stem cell like subpopulation analyzed by several stem cell 
markers. 
The ultimative evidence of the successful transformation of NHDF cells deficient for p53 and 
Rb is the tumor formation in vivo. Fully transformed cells overcome even the cancer-
preventive influences of a mammalian organism. Therefore, NHDFdk cells were injected into 
BalbC; Nu/Nu mice to monitor tumor growth. Even after 9 month NHDFdk cells were not 
able to form a visible tumor. These data suggest that the knockdown of p53 and Rb just 
partially transforms NHDF cells with the lack of the necessary lack of malignancy to promote 
tumor growth in vivo. Furthermore, the used Balb/C nude mice just partially lack an 
immunesystem that potentially turns these mice into an unusable system to monitor tumor 
growth of less aggressive cell lines. The use of other nude mice strains possibly could result in 
tumor growth of the NHDFdk cells.  
In summary, the loss of p53 and Rb promotes several physiological mechanisms towards a 
neoplastic phenotype of cells. NHDF cells with reduced levels of p53 and Rb overcome 
permanent growth arrest and lost contact inhibition as well as anchorage dependence. These 
processes seem to be promoted by the occurred genomic instability. Nevertheless, the 
transformation by the loss of p53 and Rb is not potent enough to induce tumor growth in vivo. 
Discussion 
 
 123 
 
Therefore, this in vitro model develops just partially transformed cells. For all that, the 
modelling of oncogenesis in fibroblasts can not stand for the tumorigenesis of all tissues. 
Fibroblasts are basically easier transformable than any other cell type. To prove if this 
approach is really appropriate for studying cancer development, it is essential to establish the 
double knockdown of p53 and Rb in other primary cells, for example epithelial cells. 
However, the loss of p53 and Rb displays a natural model of partial in vitro oncogenesis and 
provides the possibility of investigating the distinct steps of tumorigenesis with a special 
focus on the loss of genomic integrity.  
 
5.2 FGFR4 Arg385 promotes MEF transformation in vitro and accelerates 
tumor growth and metastasis in the WAP-TGFα mouse mammary tumor 
model  
Breast Cancer is the most frequently diagnosed cancer in women in the United States and 
Europe and the fifth leading cause of cancer death. Breast cancers have a huge 
histopathological and genetic diversity that all results in a variety of clinical outcomes. This 
diversity is confronted by just a few prognostic markers that turn breast cancer into a complex 
and difficult disease to be cured. Therefore, the investigation of new prognostic markers and 
their impact on tumor progression and clinical outcome is of highest priority. 
Receptor tyrosine kinases (RTKs) are often implicated in the progression of breast cancer via 
a dysregulated signaling leading to uncontrolled cell growth. The family of Fibroblast Growth 
Factor Receptors (FGFR) are implicated either by overexpression like in pancreatic- or 
prostate carcinoma (Eswarakumar et al., 2005; Gowardhan et al., 2005; Morrison et al., 1994) 
or by activating mutations leading to abnormal fusion proteins or nucleotide substitutions 
(Cappellen et al., 1999; Fioretos et al., 2001; Jang et al., 2001; Macdonald et al., 1995). The 
fourth family member of the FGFRs, the FGFR4, was often associated with tumor progression 
(Ho et al., 2009). Furthermore, its inactivation or the inhibition of its ligand FGF19 results in 
impaired tumor growth (Desnoyers et al., 2008; Ho et al., 2009). A single nucleotide 
polymorphism in the FGFR4 that substitutes a Glycine (Gly) to an Arginine (Arg) is 
correlated with accelerated tumor progression of various cancers and is suggested to be 
involved in resistances to certain therapies in breast cancer (Bange et al., 2002; Desnoyers et 
al., 2008; Ho et al., 2009; Jaakkola et al., 1993; Jezequel et al., 2004; Morimoto et al., 2003; 
Morrison et al., 1994; Shah et al., 2002; Spinola et al., 2005; Spinola et al., 2005; Streit et al., 
2004; Streit et al., 2006; Thussbas et al., 2006; Wang et al., 2004). However, the correlative 
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studies on clinical data also resulted in controversial results due to the genetic heterogeneity 
of patient cohorts (Jezequel et al., 2004). In this study the impact of the change of a single 
nucleotide in the mouse genome, in the gene encoding the receptor tyrosine kinase FGFR4, 
was investigated for the first time on the initiation and progression of breast cancer in vivo. 
First, the mouse model was characterized to ensure an accurate modelling of the human 
situation. As the FGFR4 Arg385 KI is inherited in a Mendelian ratio, the KI does not seem to 
interfere with embryonic development of Arg385-carrying mice. Like humans, who carry the 
Arg388 allele mice carrying the FGFR4 Arg385 display no obvious phenotype that 
distinguishes them from Gly388-carriers (Bange et al., 2002). In FGFR4 expression, 
localization and distribution, the KI model also matches its human counterpart. The 
expression of the FGFR4 Arg388/385 allele does not differ from the Gly 388/385 allele in 
humans as well as in the FGFR4 Arg385 KI mice (Bange et al., 2002).  
To investigate the impact of the FGFR4 Arg385 on physiological processes we first analyzed 
the differences of the FGFR4 alleles in mouse embryonic fibroblasts (MEFs). MEFs display a 
typical and easy available in vitro system to investigate an altered physiology of genetically 
modified mice. As the most prominent impact of the FGFR4 Arg385 allele is the disease 
progression once the cancer has been initiated, we aimed to investigate the impact of the 
FGFR4 Arg385 on the transformation rate of MEFs (Bange et al., 2002; Morimoto et al., 
2003; Spinola et al., 2005; Streit et al., 2004; Streit et al., 2006). Accordingly, MEFs carrying 
the Arg385 allele showed a significant higher transformation rate than control fibroblasts 
when infected with different oncogenes in a Focus Formation Assay. Furthermore, FGFR4 
Arg385 MEFs not only display a higher number of foci but remarkebly transform with an 
earlier onset and an accelerated growth once the foci are established.  
In search of the molecular mechanism underlying this effect, we interestingly could show that 
FGFR4 Arg385 MEFs display a significant increased survival in response to DNA-damaging 
agents. Upon doxorubicin treatment, the FGFR4 Arg385 seems to support a more efficient 
DNA-repair that is shown by a significantly delayed G2-Arrest and the upregulation of p53 at 
early time points of response. Moreover, the FGFR4 Arg385 seems to significantly decrease 
apoptosis by the distinct upregulation of genes that are involved in pro-survival signalling like 
p-Akt, BCL-2 and BCL-XL (Masumoto et al., 1999; Pietras et al., 1994). The support of 
DNA-repair as well as pro-survival signalling is a common feature by receptor tyrosine 
kinases (Lin et al., 2008; Wang et al., 2008; Woo et al., 2005). Furthermore, the upregulated 
target genes are known to be integrators of damage signals and get upregulated by the 
downstream signalling of several receptor tyrosine kinases like EGFR, HER2 or kit (Blume-
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Jensen et al., 1998; Carson et al., 1994; Kumar et al., 1996; Wang et al., 1999). The 
accelerated upregulation of anti-apoptotic genes is possibly caused by an accelerated crosstalk 
of the FGFR4 Arg385 to other proteins. Contrarily, apoptotic markers like Caspase 3 clevage 
or phosphorylation of Bad did not differ between the genotypes. These data indicate that 
FGFR4 Arg385 does not inhibit apoptotic signalling but rather upregulates pro-survival genes 
as counterbalance to the apoptotic downstream signalling. These two mechanisms seem to 
enable the cell to manage DNA-damage without entering apoptosis. In turn, this advantage 
potentially contributes to an extended tolerance towards genomic instability that in turn 
displays the prerequisite of a malignant cellular transformation (Jeggo, 2005; Skorski, 2002). 
Interestingly, taxol that does not initiate DNA damage did not cause the anti-apoptotic 
response of the FGFR4 Arg385, indicating, that the FGFR4 Arg385 just contributes to 
survival towards DNA-damaging agents.  
As the focus formation via the overexpression of EGFR resulted in an unusal high number of 
foci we wanted to investigate if the FGFR4 Arg385 allele contributes to EGFR driven 
transformation. Therefore, we stably transformed the MEFs with EGFR. Interestingly, FGFR4 
was upregulated in EGFR transformed MEFs and the FGFR4 Arg385 was detected to be 
hyperactive in MEFs transformed with EGFR compared to FGFR4 Gly385. These results 
indicate a possible crosstalk between these two receptors as it is already known between the 
Her2 and FGFR4 (Koziczak and Hynes, 2004). Furthermore, the anti-apoptotic response to 
DNA-damage of FGFR4 Arg385 could be reproduced in MEFs transformed with EGFR. 
Moreover, the FGFR4 Arg385 isotype was strongly associated with significantly increased 
migration, a significantly higher potential in soft agar colony formation and accelerated 
branching in Matrigel. These data indicate that the FGFR4 Arg385 progresses the aggressive 
phenotype of cells via processes connected to migration and invasion (Bange et al., 2002). 
Furthermore, as a migratory effect is not detectable in non-transformed MEFs, these data 
clearly indicate that the FGFR4 Arg385 is not an oncogene per se, but rather supports 
oncogenes by the promotion of several physiological processes. Contrarily, FGFR4 Arg385 
had no impact on the proliferation of EGFR transformed MEFs.  
Interestingly, no impact of the FGFR4 Arg385 could be detected when MEFs were 
transformed with v-src neither in anti-apoptosis nor in soft agar colony formation or 
branching in Matrigel. These results suggest that the impact of FGFR4 Arg385 is clearly 
dependent on the oncogenic background that triggers the neoplastic transformation and 
indicates once more a rather supportive than independent action of the FGFR4 Arg385.  
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To further characterize these physiological outputs the expression of various genes related to 
migration, invasion and proliferation were analyzed. The equal expression of cell cycle 
dependent kinases (CDK) thereby reflects the equal proliferative behaviour of Gly385- and 
Arg385-carrying MEFs. Especially MMPs and N-cadherin, powerful indicators of highly 
invasive cells, are strongly overexpressed in Arg385-carrying MEFs (Lafleur et al., 2005; 
Nagi et al., 2005; Su et al., 2008). These data confirm the impact of the FGFR4 Arg385 allele 
on processes like migration and invasion. 
After this clear implication of the FGFR4 and its variant Arg385 in defined physiological 
processes that are involved in tumor progression and aggressiveness we aimed to show for the 
first time the influence of the FGFR4 Arg385 on tumor progression and accelerated 
aggressiveness. Above all, the impact of the FGFR4 Arg385 allele yielded at times marginal 
results due to the highly complex and heterogeneous genetic background of the patients 
leading to controversial results (Jezequel et al., 2004; Spinola et al., 2005). Because of that the 
FGFR4 SNP is not yet established as a progression marker for clinical outcome or as basis for 
individual patient treatment decisions. The FGFR4 Arg385 KI mouse overcomes the problem 
of heterogenetic patient cohorts to clarify the possible impact of the FGFR4 Arg385 in tumor 
progression. 
The FGFR4 is known to be upregulated in diverse cancers including breast cancer (Ezzat et 
al., 2002; Gowardhan et al., 2005; Jaakkola et al., 1993; Jeffers et al., 2002). Furthermore, the 
FGFR4 Arg385 allele is known to promote mammary carcinoma in humans. Therefore, we 
investigated the impact of this SNP on mammary cancer progression (Bange et al., 2002). 
Similar, to the experiments in vitro we wanted to analyze the involvement of the FGFR4 
Arg385 on tumor progression in combination with the well established WAP-TGFα and the 
MMTV-PyMT transgenes (Pittius et al., 1988; Sandgren et al., 1995). The WAP-TGFa model 
induces mammary carcinoma by the overexpression of TGFα that results in hyperactive 
EGFR. The MMTV-PymT model elicit mammary tumors by the constitutive activation of src 
by PymT (Pittius et al., 1988; Sandgren et al., 1995). The WAP-TGFα induced oncogenesis 
closely models human mammary carcinogenesis. First, the onset of tumors is moderate 
indicating that just a few cells overcome the anti-cancer barriers to form neoplasias. Second, 
working in the C57BL/6 background requires pregnancy of the mice, which is consistent with 
the human situation, where pregnancy can contribute to mammary hyperplasias as the human 
breast epithelial cells starts proliferation in pregnancy to ensure nursing. Last, the 
hyperactivated EGFR in the WAP-TGFα model display an oncogenic force that is more 
common in human breast cancer in comparison to models that trigger mammary oncogenesis 
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via viral oncoproteins as in the MMTV-PymT model. In addition, expression studies displayed, 
that the FGFR4 was upregulated in the MMTV-PymT and WAP-TGFα mouse mammary 
carcinoma model (S. Streit, 2004). These facts qualified these models for the investigation of 
the FGFR4 Arg385 allele on tumor progression. For that reason, the FGFR4 Arg385 KI mice 
were crossed to mice transgenic for WAP-TGFα and mice transgenic for MMTV-PymT.   
We show that the FGFR4 Arg385 allele directly promotes TGFα-induced mammary tumors in 
mass and area significantly. In addition, these tumors display a faster progression with a partly 
significant increase over time depending on the different FGFR4 genotypes. Furthermore, 
FGFR4 Arg385 decreases the visible time point of tumor incidence. Therefore, the 
involvement of the FGFR4 Arg385 allele is no longer limited on tumor progression but also 
includes the facilitation of tumor initiation. A correlation between the tumor initiating ability 
of the FGFR4 Arg388 allele is already shown on clinical prostate cancer data (Wang et al., 
2004). Moreover, the analysis of the criteria of tumor progression displayed a more significant 
difference in the area and the percentage of tumor area. These data indicate, that the impact of 
the FGFR4 Arg385 is rather migratory than proliferative. This goes in line with the results of 
MEFs transformed with EGFR that were promoted in migration and invasion via the FGFR4 
Arg385 allele. As transgenic mouse models so far do no completely mimic the situation in 
human breast cancers several disadvantages of the WAP-TGFα model must be considered. As 
the WAP-promoter is regulated by hormones, the expression of TGFα is also active in the 
developing virgin mammary gland and potentially in the embryonic mammary bud 
influencing the mammary gland in very early development. Second, although the WAP-
promotor is mammary gland specific, this promoter is active at very low levels in variety of 
tissues including the brain. Next, the expression of a ligand does not exclude the influence of 
other systemic processes on tumor progression, or the fact, that the FGFR4 Arg385 allele 
influences tumor progression not directly in the mammary epithelial cells. These effects could 
be excluded via mammary gland transplantation.   
Furthermore, we analyzed the molecular action of the FGFR4 Arg385 in tumors to investigate 
the underlying mechanism of the accelerated tumor progression. Although FGFR4 Arg385 is 
not overexpressed in primary tumors compared to FGFR4 Gly385 its activity is significantly 
upregulated. The amino acid substitution in the FGFR4 results in the change to a hydrophilic 
amino acid. Therefrom, the structure of the FGFR4 Arg385 possible disables an accurate 
binding of negative regulators to the kinase domain or vice versa enables an accelerated 
binding of activators. In turn, the varying regulation of the receptor possibly leads to a 
differing downstream signalling and target gene expression. So far, two studies display an 
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altered target gene expression in the presence of the FGFR4 Arg385. Here, the FGFR4 
Arg385 expression  results in the upregulation of the metastasis-associated gene Ehm2 in 
prostate cancer and the pro-migratory gene EDG-2 in MDA-MB-231 cells overexpressing the 
Arg388 allele that is suppressed by the overexpression of the FGFR4 Gly385 (Stadler et al., 
2006; Wang et al., 2006). Furthermore, Wang and colleagues showed an increased stability of 
the FGFR4 Arg385 receptor in prostate cancer cell lines (Wang et al., 2008). The delayed 
internalization of the FGFR4 Arg385 allele potentially results from an altered structure 
leading to a relatively higher phosphorylation status of the FGFR4 Arg385. However, the 
distinct differences of the molecular mechanism of the FGFR4 Arg385 compared to the 
FGFR4 Gly385 have to be elucidated. As Stadler et al. and Wang et al. could show different 
expression of target genes in the presence of the FGFR4 Arg385, micro array analysis of 
WAP-TGFα derived tumors possibly helps to investigate differences between the FGFR4 
allele regarding their target gene expression. Further, a mass spectrometry analysis of co-
immunoprecipitated interaction partners of the FGFR4 Gly385 and FGFR4 Arg385 in tumors 
could show, if the interaction partners or the binding of the interaction partners differ between 
the FGFR4 isotypes. Furthermore, a phosphoproteomic analyis could define differences in the 
activated FGFR4 phosphosites or a difference of downstream signalling between the FGFR4 
alleles. Differences in the structure of the FGFR4 Arg385 and its position in the cellular 
membrane induced by the change to a hydrophilic amino acid could be elucidated by 
crystallography or electron microscopy.   
Furthermore, we analyzed several target genes involved in tumor progression, invasion and 
vascularization of WAP-TGFα derived tumors to further specify the impact of the FGFR4 
Arg385 on tumor aggressiveness. Here, the expression analysis clearly displays a more 
aggressive phenotype of WAP-TGFα derived tumors expressing the FGFR4 Arg385. The 
signifincant downregulation of the tumor suppressor p21 is known to predict the poorest 
prognosis together with high EGFR expression (Somlo et al., 2008). The significant 
upregulation of the cell cycle dependent kinase (CDK) 1 once more involves the FGFR4 
Arg385 in an accelerated migratory capacity of cancer cells (Manes et al., 2003). Contrarily, 
all of the other ananlyzed cell cycle proteins do not differ regarding the FGFR4 isotypes. This 
result confirms molecularily the exclusion of the FGFR4 Arg385 from a proliferative impact. 
Moreover, genes associated with invasion were significantly upregulated in FGFR4 Arg385 
expressing tumors. CD44 that is significantly overexpressed, promotes metastases (Godar et 
al., 2008; Mylona et al., 2008; Sheridan et al., 2006), likewise flk-1, by promoting 
angiogenesis leading to a more aggressive behaviour of the tumor (Liang and Hyder, 2005). 
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Accordingly, MMP13 as well as MMP14 are significantly overexpressed in FGFR4 
Arg/Arg385 carrying tumors contributing to a higher metastatic potential (Ellsworth et al., 
2008; Jiang et al., 2006; Rizki et al., 2008).  
Due to the differences in the expression pattern of FGFR4 Arg385 carrying tumors towards a 
more aggressive phenotype, it was essential to investigate the impact of the FGFR4 Arg385 
on metastasis. Above that, the clinical outcome of cancer is dependent on the invasive stage of 
the primary tumor. If the FGFR4 Arg385 is involved in the onset of metastasis, the allele all 
the more could serve as a prognostic marker in breast cancer patients. Next to invading the 
bone or the liver, breast cancer cells mostly establish pulmonary metastases (Lee, 1983). 
Therefore, the lungs of the different FGFR4 genotypes transgenic for WAP-TGFα were 
analyzed. Remarkably, the FGFR4 Arg385 allele not only promotes aggressiveness but also 
supports invasion of the lung. Metastasis formation sets in earlier and the lungs of FGFR4 
Arg385 carrying mice are more intensely invaded. Therefore, the significantly altered 
expression in genes involved in invasion is reflected by the fact that cancer cells expressing 
the FGFR4 Arg385 allele display a significantly accelerated potential in invading the lung to 
form distant metastases in vivo. These data strongly associate the FGFR4 Arg388 allele with 
poor prognosis and thereby highlight the receptor as a marker of breast cancer progression. 
In contrast, FGFR4 Arg385 was not able to promote mammary cancer progression in mice 
transgenic for MMTV-PyMT neither in tumor mass or area. However, the negative results in 
the MMTV-PyMT-model display an indirect evidence of a cancer cell specific action of the 
FGFR4. If the cancer promoting effect would be caused apart the cancer cell, the FGFR4 
Arg385 should promote mammary tumor progression induced by MMTV-PyMT.  This goes in 
line with the results derived from MEFs stably transformed with v-src. Here, FGFR4 Arg385 
could not promote any of the analyzed physiological mechanism including migration or 
invasion. These findings underline the dependency of the FGFR4 Arg385 allele on the 
oncogenic background of neoplastic transformation. Above that, TGFα induced tumors 
include a hyperactive EGFR; the PyMT activates src leading to tumor formation. As a 
receptor tyrosine kinase, EGFR possibly crosstalk to FGFR4 and this crosstalk differs in 
cancer cells expressing the FGFR4 Arg385 allele. Contrarily, src is a downstream molecule. 
Here, the FGFR4 and its FGFR4 Arg385 allele are possibly unable to significantly influence 
the activity of src that is strongly activated by PymT. This fact further confirms the supportive 
role of the FGFR4 and its Arg385 allele on tumor progression. Besides that, the malignant 
transformation of src takes place so rapidly and intensively that possible impacts of the 
FGFR4 Arg385 may not be detectable.  
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Our data demonstrate that the FGFR4 Arg385 allele is a potent enhancer of breast tumor 
development, progression and metastasis formation in vivo. The development of an antibody 
blocking the FGFR4 or its ligands could possibly be used in combination with classical cancer 
therapies like chemotherapeutic drugs as already shown in several studies (Ho et al., 2009; Pai 
et al., 2008).  The strong impact of the FGFR4 on disease outcome is further underlined by 
Roidl and colleagues who could show that breast cancer cell lines with a aquired 
chemoresistance upregulate the FGFR4 (Roidl et al., 2009). Further, the FGFR4 predicts 
failure in tamoxifen treatment of breast cancer patients (Meijer et al., 2008). Above that, the 
FGFR4 could not only be targeted, but the allelic identity of this receptor may conceivably be 
included as a diagnostic parameter in the individual determination of therapy decisions. This 
notion is strongly supported by our previous findings, that the time of mammary cancer 
relapse after different drug-treatments is associated with different FGFR4 alleles (Thussbas et 
al., 2006). These data suggest the further use of the FGFR4 Arg385 KI model also for the 
investigation of cancer treatment and mechanism of resistance with respect to the FGFR4 
alleles. 
As recent publications correlate the FGFR4 Arg388 allele with various types of cancer our KI 
model could indicate the impact of the SNP on their progression and outcome. In particular, 
diseases related to the liver should be investigated as several recent publications implicate the 
FGFR4 in liver function and homeostasis (Desnoyers et al., 2008; Huang et al., 2007). 
Moreover, our data clearly postulate the generation of similar KI models to causally determine 
the impact of SNPs, which could be connected to various diseases and physiological 
processes. 
In summary, our KI model clearly demonstrates an important role of the FGFR4 and 
especially the Arg388 allele in mammary tumor progression. Our findings strongly support a 
role of the FGFR4 Arg388 allele as a marker for poor clinical outcome in breast cancer 
progression and metastasis. On this account, these data further validate the FGFR4 and its 
isotypes as a target for the development of prototypical drugs. Above all, our findings 
highlight the impact of germline alterations including SNPs in receptor tyrosine kinase genes 
for the clinical progression of cancer and generally pinpoint the importance of individualized 
therapy regimens for cancer patients and emphasize the individual nature of this disease.  
5.3 Investigation of new FGFR4 binding partners in vitro and in vivo 
 The FGFR4 is implicated in the development and progression of various cancers and the 
clinical outcome of patients. The FGFR4 further mediates chemoresistance and was shown to 
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be a potential target in cancer therapy (Ho et al., 2009; Roidl et al., 2009; Streit et al., 2004). 
Furthermore, its Arg388 variant is associated with enhanced tumor progression and above that 
with a poor clinical outcome of cancer patients (Bange et al., 2002; Streit et al., 2006). 
However, the distinct mechanisms that trigger FGFR4 driven oncogenesis and, importantly, 
the accelerated progression by the FGFR4 Arg388 are still uncertain.  
The FGFR4 is a receptor tyrosine kinase that mediates cellular signaling upon ligand 
stimulation, dimerization with other receptors and binding of downstream effectors 
(Eswarakumar et al., 2005). Therefore, we emphasized the investigation of new FGFR4 
interaction partners. Furthermore, the FGFR4 Arg388 variant substitutes a Glycin to an 
Arginin in the juxtamembrane domain indicating that the hydrophilic Arginin possibly alters 
the structure of the receptor resulting in an altered binding behavior compared to the FGFR4 
Gly388.  
For that purpose, we performed a proteomic analysis of FGFR4 interaction partners by SILAC 
based mass spectrometry. SILAC based proteomics displays a powerful tool to investigate 
global interactions on a quantifiable level. To analyze interaction partners of the FGFR4 in 
vitro, we decided to use MDA-MB-231 breast cancer cells, modified by Bange et al. (2002), 
as a model system. Here, FGFR4 is overexpressed either in its Gly388 or Arg388 variant 
enabling the analysis of the different FGFR4 isotypes in the same model system. Above that, 
the overexpression-system in MDA-MB-231 cells enables extensively simplified protein 
detection via mass spectrometry and the analysis of potential interaction partners of the 
FGFR4.  
The identified proteins displayed the FGFR4 as the mostly upregulated protein indicating a 
proper experimental setup that reflects the overexpression system in MDA-MB-231 cells. 
Furthermore, FGFR4 Arg388 is not upregulated compared to Gly388 demonstrating an equal 
overexpression among the variants. Mass spectrometry analysis of FGFR4 co-
immunoprecipitated proteins detected several interesting potential interaction partners. To 
verify these identified proteins, we performed a lable switch and excluded proteins that were 
upregulated in just one setup. To further strengthen the specifity of interaction partners we 
listed only proteins that were upregulated at least 5-fold.  
The identified potential interaction partners were LAR, EPHA2 and the EGFR. LAR is a 
transmembranous phosphatase and is known to be negatively regulated by the EGFR (Ruhe et 
al., 2006). Depletion of LAR accelererates hepatocyte cell proliferation by c-MET, insulin 
resistance and increased metastasis (Machide et al., 2006; Mander et al., 2005; McArdle et al., 
2005). Furthermore, LAR is implicated in the regulation of FGF-induced signalling by 
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interacting with FRS2 (Wang et al., 2000). Therefore, an interaction of LAR and FGFR4 is 
conceivably possible. Since LAR is a tyrosine phosphatase the interaction with FGFR4 
potentially display a novel negative regulation of the FGFR4. Here, LAR co-
immunoprecipitation and FGFR4 dephosphorylation upon ligand stimulation would give a 
deeper insight in the interaction and the regulatory function of LAR regarding FGFR4 
signalling. EPHA2 and EGFR are known transmembraneous receptors that are linked to the 
promotion of malignant phenotypes in MDA-MB-231 cells as well as various cancer types 
(Carles-Kinch et al., 2002; Noblitt et al., 2004; O'Neill et al., 2007; Wang et al., 2009; Zheng 
et al., 2009). However, the interaction with FGFR family members or the contribution to 
FGF-mediated signalling is not described so far. Therefore, the distinct mechanism and the 
impact of the interaction of these proteins with the FGFR4 should be the subject of further 
investigations. The results obtained from the mass spectrometry analysis indicate that MDA-
MB-231 cells overexpressing the FGFR4 Gly388 or Arg388 variant present a useful model to 
study potential interaction partners of the FGFR4 in breast cancer cells and the differences 
regarding the FGFR4 isotypes. Here, FGFR4 seems to interact with different receptor tyrosine 
kinases. However, one should keep in mind that overexpression systems do not reflect the 
situation of proteins that are expressed endogenously. The interaction of the FGFR4 with the 
detected proteins has to be investigated precisely as overexpression systems can lead to results 
that are irrelevant for the endogenous or in vivo situation. Therefore, the interaction partners 
must be followed up in systems with endogenous FGFR4 expression with a special focus on 
in vivo studies, and the impact of the interaction should be determined by the depletion or 
blocking of the novel interactor. Furthermore, expression studys on clinical samples could 
help to elucidate a potential co-expression and its prognostic value on the outcome of cancer 
patients. 
Nevertheless, the MDA-MB-231 cells display a powerful system to get a first insight on the 
FGFR4 signalling complex. However, all potential interaction partners displayed no 
differences between the different FGFR4 isotypes. Besides that, interactors that specifically 
bind the FGFR4 Gly388 or Arg388 variant could not be detected. To detect potential 
differences in the binding of the interactors a mass spectrometry analyses upon ligand 
stimulation possible enables a deeper insight in the interaction profiles regarding the FGFR4 
alleles. 
The most interesting interaction partner that was identified is the EGFR. The EGFR is 
associated with several key features of cancer development and growth. Next to non-small 
cell lung cancer the EGFR displays a promising target in various cancers. In MDA-MB-231 
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cells, the stimulation of the EGFR via multiple mechanisms results in an increase of their 
malignant behavior (Wang et al., 2009; Zheng et al., 2009). Furthermore, the in vivo studies 
that determined the promoting impact of the FGFR4 Arg385 on breast cancer were done on 
the basis of an EGFR-dependent mammary carcinoma model. Therefore, we decided to have a 
closer look on the interaction of the EGFR and the FGFR4. Here, we could show that the 
FGFR4 in MDA-MB-231 cells gets co-immuoprecipitated with the EGFR and gets 
phosphorylated upon EGF stimulation in a time dependent manner. Above that, the interaction 
and activation with the FGFR4 Arg388 variant was accelerated compared to the FGFR4 
Gly388. Furthermore, downstream Akt gets more phosphorylated upon EGF stimulation in 
the presence of the FGFR4 Arg388 allele. These data verify the interaction of the EGFR and 
FGFR4 and furthermore display a physiological connection upon ligand stimulation. The 
accelerated phosphorylation of the EGFR and downstream Akt upon EGF and TGFα 
stimulation is also present in EGFR-transformed MEFs expressing the FGFR4 Arg385. 
Additionally, immunoprecipitated FGFR4 Arg385 displays an accelerated phosphorylation 
upon EGF and TGFα stimulation than the FGFR4 Gly385. These data confirm the interaction 
of the EGFR and FGFR4 also in an ex vivo system. Above all, the interaction of these two 
receptors and the accelerated activation in the presence of the FGFR4 Arg385 is consequently 
suggested to be the molecular explanation for the accelerated tumor progression in the WAP-
TGFa mouse mammary carcinoma model. Here, clinical data from human patient samples 
could potentially confirm this interaction by co-expression of these two receptors. 
Furthermore, the human patient samples could possibly then correlate the worse clinical 
outcome of FGFR4 Arg388 carriers together with high EGFR expression. In this case, the 
FGFR4 Arg388 and EGFR would achieve a high impact in their prognostic value of the 
outcome of cancer patients. 
Moreover, we could show the MDA-MB-231 cells expressing the FGFR4 Arg388 display an 
increased sensitivity towards Gefitinib treatment in proliferation, apoptosis and migration. 
The accelerated response towards Gefitinib treatment potentially results from the elevated 
interaction and downstream signaling of the EGFR and FGFR4 Arg388. These data conclude 
that several physiological mechanisms are dependent on the EGFR-FGFR4 interaction and 
further indicate that the FGFR4 and especially the Arg388 variant induces certain EGFR 
dependence, as MDA-MB-231 cells are usually referred as rather insensitive towards 
Gefitinib treatment. To ultimately verify these results, specific inhibition of the EGFR by a 
blocking antibody would finally determine this effect as the level of Gefitinib response is 
dependent on the expression of several other proteins (Ferrer-Soler et al., 2007). Here, for 
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example Akt, that is hyperactivated in MDA-MB-231 cells expressing the FGFR4 Arg388, 
predicts sensitivity to gefitinib. Therefore, the obtained reduction in cellular survival and 
migration could also result from decreased Akt activity. Furthermore, these data should be 
confirmed in cancer cell lines from various tissue origins and above that, with an endogenous 
expression of the FGFR4 and its FGFR4 Arg388 allele. Further, the treatment of our FGFR4 
Arg385 KI mice crossed to WAP-TGFα mice with EGFR-inhibitors could evidence the in vivo 
significance of the accelerated sensitivity of EGFR-driven breast cancer in the presence of the 
FGFR4 Arg388 allele. Besides that, clinical data from human tumor samples treated with 
Gefitinib could clarify if the response gets significantly increased by the presence of the 
FGFR4 Arg388 allele in human conditions. This would expand the prognostic value of the 
FGFR4 Arg388 allele on response to cancer therapy as it is already known in response to 
tamoxifen (Thussbas et al., 2006). Taken together, the interaction between the EGFR and 
FGFR4 in MDA-MB-231 cells is the first reported direct interaction between the HER and 
FGFR family. Above that, this interaction opens up the possibility of new prognostic and 
therapeutic interventions and gives a deeper insight in the mechanism of breast cancer 
progression driven by EGFR and FGFR4.  
In 2008, Kruger et al. presented the first study based on in vivo SILAC by feeding mice with a 
diet containing heavy lysine (Kruger et al., 2008). Therefore, the limitations posed by in vitro 
studies are now circumvented by SILAC-based in vivo proteomics that provides the actual 
“global view” on the proteome of a certain tissue. Here, organs derived from SILAC mice 
serve as an internal standard for a large number of subsequent experiments. Furthermore, 
investigation of cell types that are difficult to study ex vivo, are effortlessly approachable. 
Besides that, in vivo SILAC is independent from a biological scale ranging from the analysis 
of whole organs down to interacellular compartments or single proteins (Kruger et al., 2008). 
In this study, we investigated the interactom of the FGFR4 in murine liver to get a deeper 
insight in the molecular action of the FGFR4 in the regulation of liver homeostasis and 
hepatocellular carcinogenesis. Moreover, we aimed to analyze the interaction differences 
between the FGFR4 Gly385 and FGFR4 Arg385 by the use of our generated FGFR4 Arg385 
KI mouse.  
One major function of the liver is the production of bile acids (Chiang, 2004; Russell, 2003). 
The regulation of bile acid synthesis is tightly regulated by a negative feedback loop to 
prevent the damage of the enterohepatic tissue. Here, the cholesterol 7α-hydrolase, the 
catalyzer of bile acid expression, is repressed by circulating bile acids itself (Jelinek et al., 
1990). Responsible for this feedback loop is the regulation of the FGFR4/FGF15 pathway by 
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bile acids (Inagaki et al., 2005). In maintaining homeostatsis, FGFR4 and the FGF19 
subfamily members additionally play an important role in systemic lipid and glucose 
homeostasis. Here, the hepatic activity of the FGFR4 serves to prevent systemic 
hyperlipidemia and-cholesterolemia. In summary, the hepatic FGFR4 seems to be a potential 
target for intervention in systemic cholesterol/bile acid, lipid and glucose metabolism (Huang 
et al., 2007; Ishikawa and Fidge, 1979; Yu et al., 2002; Yu et al., 2000). Besides that, the 
FGFR4 seems to be implicated in the progression of hepatocellular carcinoma. Surprisingly, 
previous data implicate the FGFR4 as a tumor suppressor as well as a tumor promoting factor 
(Desnoyers et al., 2008; Hu et al., 1995; Huang et al., 2008; Nicholes et al., 2002). To further 
analyze the underlying mechanism by which the FGFR4 regulates bile acid homeostasis and 
liver carcinogenesis we aimed to investigate the interaction partners of the murine FGFR4 in 
liver. In order to address this question we first investigated the optimal conditions to study the 
liver interactome of the FGFR4. In the course of that, we specifically focused on the 
minimization of unspecific binders. As liver tissue exhibits high protein content, a so called 
“beads-only control” was not sufficient to exclude all false positive results. For that reason, 
we generated blocking peptides derived from tryptic digestion of the expressed FGFR4Ex-
GST construct in HEK293 cells. Although the Western Blot analysis displayed a high efficacy 
of blocking the antibody–FGFR4 interaction, subsequent mass spectrometry analysis 
exhibited an unphysiological high number of interactors. That may be due to the fact that an 
insufficient purification of the homemade FGFR4Ex-GST antibody resulted in remaining anti-
GST antibody that was additionally established by the immunisized rabbit (C. Stadler, 2005). 
This remaining GST-antibody in turn gets also blocked by the peptides as we used a mixture 
derived from tryptic digest. Compared to the internal SILAC standard these proteins 
subsequently appear to be upregulated although they are not interacting with the FGFR4. To 
circumvent that problem we sequenced the obtained blocking peptides and synthezised over 
20 blocking peptides to specifically block the antibody-FGFR4 interactions. However, 
successsive Western Blot Analysis only displayed a low or no blocking efficacy of the 
synthesized petides. As these tools were not powerful enough to maximize the exclusion of 
unspecific binders we decided to use FGFR4 KO livers as a negative control to finally 
determine the murine hepatic FGFR4 interactome (kindly provided by Wallace L. McKeehan, 
PhD, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, 
Texas, Houston, USA). By the use of the FGFR4 KO liver lysates we tremendously decreased 
the amount of regulated potential FGFR4 interaction partners. Here, the enormous 
upregulation of the FGFR4 and its co-receptor βKlotho demonstrated a proper experimental 
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setup. Further, we identified a variety of so far unknown potential interaction partners. 
Unfortunately, except the EGFR none of these interaction partners was connected to tyrosine 
kinase signaling or interaction with receptor tyrosine kinases so far. Interestingly, all these 
potential interaction partners are involved in liver homeostasis in the cholesterol- and lipid 
metabolism. Hao1 oxidizes glycolate and glyoxycolate (Recalcati et al., 2003). Scp2 plays an 
important role in the intracellular movement of cholesterol. In mice loss of Scp2 induces 
alterations in the biliary lipid secretion and hepatic cholesterol metabolism (Fuchs et al., 
2001). Ftcd is suggested to control folic acid liver metabolism (Bashour and Bloom, 1998). 
Above that, Ftcd is overexpressed in hepatocellular carcinoma (HCC) and is therefore 
suggested to contribute to the diagnosis of early stage HCC (Fuchs et al., 2001). Hmgcs2 is a 
key regulator of keton body production in the liver. It is known that Hmgcs2 is 
transcriptionally regulated by c-myc and FKHRL1 (Camarero et al., 2006; Nadal et al., 2002). 
Among these potential interactors Hao1 and Scp2 display a stronger interaction to the FGFR4 
Arg385 variant indicated by a higher ratio compared to the FGFR4 Gly385. As the FGFR4 is 
known to be a critical modulator of these processes, the intracellular interaction of these 
identified proteins with the FGFR4 is theoretically imaginable. Nevertheless, fundamental 
follow-up experiments are necessary to firstly put these proteins in context to the molecular 
action of receptor tyrosine kinases. Further, the interaction of these proteins with the FGFR4 
and their involvement in FGFR4-mediated signalling has to be precisely elucidated. Co-
immunoprecipitation studies would provide first insights in the interaction with the FGFR4. 
Furthermore, interaction upon various stimuli including FGFR4 ligands and metabolic stimuli 
would offer the possibility to investigate the physiology of these potential interaction partners 
with the FGFR4. These experiments could be repeated by the use of FGFR4 KO mice to 
investigate the same physiological interactions in an in vivo context. 
Next to these potential new interactors the most interesting and promising target is the 
epidermal growth factor receptor itself. The EGFR was found to significantly interact with the 
hepatic FGFR4 and furthermore displays a higher interaction to the FGFR4 Arg385. 
Furthermore, several publications show that the EGFR as well as the FGFR4 are highly 
implicated in liver physiology. Regarding liver cell proliferation, published data present only 
conflictive data so far. Here, the EGFR-RAS-MAPKK axis is one of the most important 
pathways for cell proliferation in liver (Llovet and Bruix, 2008). Furthermore, although liver 
specific EGFR KO induces no further phenotypes, mice lacking the hepatic EGFR display an 
increased mortality after partial hepatectomy indicating that the EGFR is indispensable for 
proper liver regeneration (Natarajan et al., 2007). In contrast, the FGFR4 was not suggested to 
Discussion 
 
 137 
 
regulate cellularity of normal or regenerating liver or cell proliferation during response to liver 
injury (Hu et al., 1995; Yu et al., 2000). That is maybe due to the fact that the FGFR4 plays a 
rather supportive role by interacting with the EGFR. Contrarily, after injection of Carbon-
tetrachloride, FGFR4-deficieny accelerates liver injury and liver fibrosis suggesting that the 
FGFR4 may have a role in liver injury-induced regeneration (Yu et al., 2002). Interestingly, 
liver injury induced by Carbon-Thetrachloride can be reduced by the systemic administration 
of EGF (Berlanga et al., 1998). These data implicate both the EGFR as well as the FGFR4 in 
the protection of liver injury. A double knockout of both EGFR and FGFR4 could give first 
insights in their interplay regarding liver cell proliferation after a partial hepatectomy or liver 
injury. In regulating liver metabolism the conditional loss of EGFR in prenatal murine livers 
is known to result in decreased body weight. Interestingly, mice lacking FGFR4 displayed 
decreased glucose and insulin tolerance (Huang et al., 2007; Ishikawa and Fidge, 1979; Yu et 
al., 2002; Yu et al., 2000). In hepatocellular carcinoma (HCC), EGFR signalling is highly 
implicated in the progression of HCC and the subject of many ongoing clinical trials that 
specifically target EGFR signalling (Llovet and Bruix, 2008). Interestingly, mice ectopically 
overexpressing FGF19, display hepatoma-like lesions and the inhibition of FGF19 by specific 
antibodies is reported to contribute to tumor reduction (Desnoyers et al., 2008; Nicholes et al., 
2002). In contrast, mice deficient for FGFR4 display an accelerated DEN-induced 
carcinogenesis and the restoration of FGFR4 increases apoptosis in tumor cells suggesting a 
tumor suppressive function in HCC (Huang et al., 2008).  Therefore, the impact of EGFR-
FGFR4 interaction on liver physiology, liver injury, regeneration and cancer has to be further 
elucidated. 
In conclusion, the SILAC based MS-screen shows various new interaction partners of the 
hepatic FGFR4. Besides that, these results indicate that in vivo SILAC is a powerful tool to 
get first insights into the interactom of a certain protein; however, the data obtained with in 
vivo SILAC based mass-spectrometry has to be critically optimized with a special focus on 
false positive interaction partners and has to be further critically confirmed by decisive 
follow-up experiments.  
In the pool of identified potential interaction partners, the EGFR displays the most interesting 
and promising target in the elucidation of the molecular action of the FGFR4 and furthermore 
it’s Arg385/388 variant. This potential interaction should be the subject of further 
investigation in both liver homeostasis and cancer as previous publications present antithetic 
data. Furthermore, one should keep in mind that all aforementioned studies had no focus on 
the FGFR4 Ag385 allele, that possibly lead to another physiological output compared to the 
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FGFR4 Gly385 variant. Therefore, in vivo studys with our FGFR4 Arg385 KI mice together 
with EGFR knockout (Sibilia and Wagner, 1995) or the mig-6 knockout mice (Ferby et al., 
2006), that lead to hyperactivated EGFR, could finally determine the impact of the FGFR4 
Arg385 allele on the interplay with the EGFR and their combinded impact on liver 
physiology.  
Summary 
 
 139 
 
6 Summary 
 
In the first project, an in vitro transformation model should be established by the stable 
reduction of p53 and Rb. So far, human in vitro transformation systems include the expression 
of oncogenes, viral proteins or telomerase. These manipulations display mostly inartificial 
ways of oncogenesis. The stable knockdown of p53 and Rb mimics the frequent and early loss 
of these proteins in human cancer and should therefore be a natural model of carcinogenesis. 
In primary human fibroblasts the loss of these tumor suppressors induces characteristic 
changes in their expression pattern based on the genomic instability that occurs. These 
changes result in an accelerated cell cycle, unlimited life span, loss of contact inhibition and 
adherence independence. However, the neoplastic transformation of NHDF was not malignant 
enough to induce tumor growth in nude mice. Nevertheless, this study suggests that the loss of 
p53 and Rb in normal human primary cells can serve as an accurate model of oncogenesis 
with a special focus on genomic instability. 
In the second project, the impact of the FGFR4 Arg388 allele on tumor progression in vivo 
was investigated. The FGFR4 Arg388 occurs frequently in the human population and has 
been implicated in the progression of various cancers. In this study, generated FGFR4 Arg385 
KI (corresponding to human codon 388) mice were crossed to WAP-TGFα transgenics. The 
development and progression of mammary tumors and pulmonary metastases were 
significantly increased in WAP-TGFα  mice carrying the FGFR4 Arg385 allele. These data 
were supported by accelerated cell survival and increased in vitro transformation of FGFR4 
Arg385 carrying MEFs. In transformed MEFs, the FGFR4 Arg385 promotes cancer cell 
survival, migration and invasion. These results demonstrate that the FGFR4 Arg388 allele 
qualifies as a prognostic marker for breast cancer patients and represents a prototypical drug 
target for individualized cancer therapy development.  
In the last project, we aimed to investigate the interactome of the FGFR4 in vitro and in vivo 
and the differences regarding the FGFR4 isotypes. Therefore, we performed SILAC based 
mass spectrometry analysis on the MDA-MB-231 breast cancer cell line model established by 
Bange et al. and on murine liver of our FGFR4 Arg385 KI mice. In vitro and in vivo we could 
interestingly show that the EGFR is a strong interaction partner of the FGFR4 with a higher 
affinity towards the FGFR4 Arg385/388 allele and subsequent increased downstream 
signalling. Furthermore, MDA-MB-231 cells expressing the FGFR4 Arg388 allele are more 
sensitive to the EGFR inhibitor Gefitinib. Our data suggest that the FGFR4 Arg385/388-
EGFR signaling complex might account for the observed accelerated tumor progression in 
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WAP-TGFα transgenic mice and highlights the prognostic value of these two receptor 
tyrosine kinases in breast cancer. 
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7 Zusammenfassung 
 
Im ersten Teil dieser Arbeit war es das Ziel ein zelluläres System zu etablieren in dem die 
Karzinogenese primärer Zellen verfolgt werden kann. Hierbei sollte ein Model entwickelt 
werden, dass sich so nah wie möglich der in vivo Situation angleicht. Da bis heute keine 
derartigen Modelle zur Verfügung stehen, sollte die Transformation primärer humaner 
Fibroblasten durch den stabilen Knockdown der beiden Tumor Suppressoren p53 und Rb 
erreicht werden. Die maligne Veränderung der manipulierten Fibroblasten wurde über die Zeit 
mit Hilfe verschiedenster Experimente überprüft. Diese Fibroblasten zeigten genomische 
Instabilität, die zu einer Veränderung in ihrem Genexpressionsmuster führte. Dies wiederum 
führte zu zellulären Eigenschaften, die charakteristisch für Krebszellen sind. Dazu zählt der 
Verlust der Kontaktinhibition wie auch die Fähigkeit ohne Adherenz zu wachsen. Obwohl 
kein Tumorwachstum dieser Fibroblasten in Nacktmäusen beobachtete werden konnte, zeigt 
dieses Model, dass es möglich ist, primäre Zellen durch den Verlust von p53 und Rb teilweise 
zu transformieren. Daher kann die Veränderung einer Primärzelle zur Krebszelle in einem 
derartigen Modell vor allem bezüglich genomischer Instabilität untersucht werden. 
Im zweiten Projekt sollte der Einfluss des FGFR4 Arg388 Alleles auf die Progression von 
Brustkrebs in vivo untersucht werden. Dieser single nucleotide polymorphism (SNP) ist häufig 
im menschlichen Genom zu finden wurde bereits zahlreich mit der Progression und einer 
schlechten Prognose korreliert. In diesem Projekt wurden FGFR4 Arg385 KI Mäuse 
(entsprechend codon 388 im menschlichen Genom) in das WAP-TGFα Brustkrebsmodell 
eingekreuzt. Sowohl die Progression des Primärtumors als auch die Metastasierung in die 
Lunge waren signifikant erhöht wenn die Mäuse das FGFR4 Arg385 Allele trugen. Diese 
Ergebnisse konnten durch in vitro Experimente unterstützt werden. In MEFs erhöht der 
FGFR4 Arg/Arg385 die Transformationsrate und das Überleben der Zellen nach 
chemotherapeutischer Behandlung. Stabil transformierte FGFR4 Arg/Arg385 MEFs zeigen 
außerdem eine erhöhte Migration und Invasion. Diese Daten zeigen, dass das FGFR4 Arg385 
Allel zum einen ein geeigneter Marker für die Prognose von Brustkrebspatienten ist und zum 
anderen auch ein Zielprotein für die Entwicklung spezifischer Therapien darstellt. 
Im letzten Teil der Arbeit sollte das Interaktom des FGFR4 mittels SILAC basierender 
Massenspektrometrie in vitro und in vivo untersucht werden. In vitro wurde das von Bange et 
al. etablierte MDA-MB-231 Brustkrebsmodell verwendet, in vivo die Lebern der generierten 
FGFR4 Arg385 KI Mäuse. In beiden Fällen konnte unter anderem der EGFR als 
Interaktionspartner identifiziert werden. In MDA-MB-231 Zellen konnte weiterhin gezeigt 
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werden, dass der EGFR eine höhere Affinität zum FGFR4 Arg388 aufweißt und dadurch die 
EGFR vermittelte Signaltransduktion erhöht wird. Außerdem zeigen MDA-MB-231 Zellen, 
die FGFR4 Arg388 exprimieren, eine höhere Sensitivität gegenüber Gefitinib. Unsere Daten 
deuten darauf hin, dass der FGFR4 Arg385-EGFR Signalkomplex die molekulare Erklärung 
der erhöhten Tumorprogression in WAP-TGFα  transgenen Mäuse zu sein scheint.  
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8 Appendix 
8.1 Abbreviations 
 
°C  degree celsius 
A  Ampère 
ALT alternative mechanism of telomere lenghtening 
Amp  Ampicillin 
APS  Ammoniumperoxodisulfat 
APS  amonium peroxodisulfat 
Arg Arginine 
ATCC American type culture collection  
ATM for ataxia telangiectasia mutated 
ATP adenosin triphosphat 
ATR ataxia telangiectasia related 
bp  base pair 
BSA  bovine serum albumin  
CDK cyclin-dependent kinase 
cDNA  complementary DNA  
Chk2 checkpoint kinase 2 
c-jun  Cellular homologue to v-jun (avian sarcoma virus 
CYP7A Cholesterol-7alpha-hydroxylase 
Da  Dalton  
DEN Diethyl-nitrosamine 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  Dimethylsulfoxid 
DNA  desoxyribonucleic acid  
dNTP  Desoxyribonukleosidtriphosphat 
DTT  Dithiorethiol 
E embryos on day 
E.coli  Escherichia coli 
e.g. for example 
E2F elongation factor 2 
ECL  Enhanced Chemical Luminescence 
EDTA  Ethylendiamin–N, N, N`, N`-tetraacetat 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor 
ELISA  Enzyme linked Immunosorben Assay 
Erk extracellular signal-regulated kinase 
ES-cells embryonic stem cells 
et al. et alterum 
FACS fluorescence associated cell sorting 
FBS  foetal bovine serum  
FGF  fibroblast growth factor 
FGFR  fibroblast growth factor receptor 
FITC fluorescein isothiocyanate 
FRS2  FGF receptor substrate 2 
FXR farnesoid x receptor 
G Glycine 
g  gramm 
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Gab1  Grb2-associated binder-1 
GFP  green fluorescence protein 
Gly Glycine 
Grb2  Growth factor receptor binding protein 2 
GSH  Glutathion 
GST  Glutathion-S-Transferase 
h  hour 
H2AX H2A histone family member X 
HCC human hepatocellualr carcinoma 
HE Hemalaun-Eosin 
HEPES  N-(2-Hydroxyethyl)-piperazin-N‘-2-ethansulfonsäure 
HER  humane EGFR 
HPV human papilloma virus 
HRP horese radish peroxidase 
hTERT active subdomain of telomerase 
ICH immunohistochemistry 
Ig  Immunoglobulin 
IP  immunoprecipitation 
JAK janus kinase 
JNK c-jun N-terminal kinase 
kb  Kilobasen 
kd double-knockout 
kDa  Kilodalton 
KI knock in 
KO knockout 
LB  „Luria Bertani“ media 
LC-MS/MS liquid chromatography based mass spectrometry 
M  Molar 
mAb monoclonal antibody  
MAP mitogen activated protein 
MAPK mitogen activated protein kinase 
MDM2 mouse double minute 2 
MEFs mouse embryonic fibroblasts 
min minute 
miRNA microRNA 
MMP Matrix-Metalloproteinase 
MMTV mouse mammary tumor viras 
mRNA  messenger RNA (Boten-RNA) 
MW  molecular weight  
n  nano 
neo neomycin 
NHDF normal human dermal fibroblasts 
ON over night 
p  pico 
p53 Tumor protein 53 
PAGE  Polyacrylamid-gelelectrophoresis 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PD  population doubling 
PDGF  platelet-derived growth factor 
pH  negative decade logarithm of H+ concentration 
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PH-Domäne  Pleckstrin homology doamin 
PI propidium iodid 
PI 3-Kinase  Phosphatidylinositol 3-Kinase 
PLCγ Phospholipase C-γ 
PMSF  Phenylmethylsulfonyl-Fluorid 
PTB  phosphotyrosine binding  
PTP(n)  Proteintyrosinphosphatases 
PY  Phosphotyrosin 
PymT Polyoma middle T 
R Arginine 
Raf Homologue to v-raf (murine sarcoma viral) 
Ras Homologue to v-ras (rat sarcoma viral oncogene) 
Rb retinoblastoma gene product 
RFLP restriction lenght polymorphism 
RNA ribonucleic acid  
RNase  Ribonuklease 
rpm  rounds per minute  
RT  Raumtemperatur 
RTK(n)  receotor tyrosine kinases 
RXR retinoid X receptor 
scr scrambled/mock transfected cells 
SDS  sodium dodecyl sulfate  
SDS-PAGE  SDS Polyacrylamid Gelelektrophorese 
sec  second 
SH2 3-Domain Src Homology 2, 3 Domain 
SHC  SH2-domain containing 
SHP-2  SH2-Domäne containing Phosphatase 2 
shRNA shot hairpin RNA 
SILAC stable isotype labelling by amino acids in cells 
siRNA small interfering RNA 
SNP single nucleotide polymorphism 
Sos son of sevenless 
src Homologue to v-src (sarcoma viral oncogene) 
ss  single stranded  
Stat Signal transducer and activator of transcription 
SV40 LT papilloma simian virous 40 arge T antigen  
TA  annealing temperature  
TAE  Tris-Acetat-EDTA 
Taq  Thermus aquaticus 
TEMED  N, N, N‘, N‘-Tetramethylethylendiamin 
TGFα  tranforming growth factor alpha 
TM  melting temperature  
Tris  Tris(hydroxymethyl)aminomethan 
Triton X-100  4-(2`, 2`, 4`, 4`-Tetramethylbutyl)-phenyldecaethylenglycoether 
Tween 20  Polyoxyethylensorbitanmonolaureat 
U  Units 
UV  Ultraviolett 
V Volt 
VEGFR vascular endothelial growth factor receptor 
w/v weight/volume 
WAP whey acidic protein 
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WB  Western-Blot 
WT  Wildtype 
α  anti 
µ  micro 
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